IQVIA (IQV) 10-K 11 Feb 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Feb. 04, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Trading Symbol	Q
Entity Registrant Name	Quintiles Transnational Holdings Inc.
Entity Central Index Key	1,478,242
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		119,384,993
Entity Public Float			$ 5,835,192,138

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Service revenues	$ 4,326,419,000	$ 4,165,822,000	$ 3,808,340,000
Reimbursed expenses	1,411,200,000	1,294,176,000	1,291,205,000
Total revenues	5,737,619,000	5,459,998,000	5,099,545,000
Costs of revenue, service costs	2,725,586,000	2,684,106,000	2,471,426,000
Costs of revenue, reimbursed expenses	1,411,200,000	1,294,176,000	1,291,205,000
Selling, general and administrative	920,985,000	882,338,000	860,510,000
Restructuring costs	30,752,000	8,988,000	14,071,000
Impairment charges	2,484,000	0	0
Income from operations	646,612,000	590,390,000	462,333,000
Interest income	(4,317,000)	(3,410,000)	(3,937,000)
Interest expense	101,792,000	100,589,000	123,508,000
Loss on extinguishment of debt	7,780,000		19,831,000
Other expense (income), net	2,362,000	(8,978,000)	(185,000)
Income before income taxes and equity in earnings (losses) of unconsolidated affiliates	538,995,000	502,189,000	323,116,000
Income tax expense	158,989,000	150,056,000	95,965,000
Income before equity in earnings (losses) of unconsolidated affiliates	380,006,000	352,133,000	227,151,000
Equity in earnings (losses) of unconsolidated affiliates	8,298,000	4,368,000	(1,124,000)
Net income	388,304,000	356,501,000	226,027,000
Net (income) loss attributable to noncontrolling interests	(1,099,000)	(118,000)	564,000
Net income attributable to Quintiles Transnational Holdings Inc.	$ 387,205,000	$ 356,383,000	$ 226,591,000
Earnings per share attributable to common shareholders:
Basic	$ 3.15	$ 2.78	$ 1.83
Diluted	$ 3.08	$ 2.72	$ 1.77
Weighted average common shares outstanding:
Basic	123,038	127,994	124,147
Diluted	125,630	131,083	127,862

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 388,304	$ 356,501	$ 226,027
Comprehensive income adjustments:
Unrealized (losses) gains on marketable securities, net of income taxes of ($168), ($376) and $2,016	(268)	(600)	3,225
Unrealized (losses) gains on derivative instruments, net of income taxes of ($3,679), ($1,767) and ($751)	(9,523)	(5,067)	358
Defined benefit plan adjustments, net of income taxes of $318, ($2,981) and ($131)	(36)	(7,237)	2,278
Foreign currency translation, net of income taxes of ($5,581), ($2,101) and ($2,465)	(60,024)	(47,807)	(22,663)
Reclassification adjustments:
Gains on marketable securities included in net income, net of income taxes of ($1,927)		(3,077)
Losses on derivative instruments included in net income, net of income taxes of $5,826, $4,022 and $4,991	12,443	4,608	8,089
Amortization of prior service costs and losses included in net income, net of income taxes of $355, $275 and $389	618	468	655
Comprehensive income	331,514	297,789	217,969
Comprehensive loss (income) attributable to noncontrolling interests	3,416	(121)	551
Comprehensive income attributable to Quintiles Transnational Holdings Inc.	$ 334,930	$ 297,668	$ 218,520

CONSOLIDATED STATEMENTS OF COM4

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement Of Income And Comprehensive Income [Abstract]
Unrealized (losses) gains on marketable securities, income taxes	$ (168)	$ (376)	$ 2,016
Unrealized (losses) gains on derivative instruments, income taxes	(3,679)	(1,767)	(751)
Defined benefit plan adjustment, income taxes	318	(2,981)	(131)
Foreign currency translation, income taxes	(5,581)	(2,101)	(2,465)
Gains on marketable securities included in net income, income taxes		(1,927)
Losses on derivative instruments included in net income, income taxes	5,826	4,022	4,991
Amortization of prior service costs and losses included in net income, income taxes	$ 355	$ 275	$ 389

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 977,151	$ 867,358
Restricted cash	2,478	2,882
Trade accounts receivable and unbilled services, net	1,165,749	975,255
Prepaid expenses	50,624	44,628
Deferred income taxes	100,978	118,515
Income taxes receivable	34,089	45,357
Other current assets and receivables	80,916	92,088
Total current assets	2,411,985	2,146,083
Property and equipment, net	188,393	190,297
Investments in debt, equity and other securities	32,911	34,503
Investments in and advances to unconsolidated affiliates	52,382	31,508
Goodwill	719,740	464,434
Other identifiable intangibles, net	368,106	280,243
Deferred income taxes	42,684	35,972
Deposits and other assets	110,115	112,913
Total assets	3,926,316	3,295,953
Current liabilities:
Accounts payable	145,484	108,743
Accrued expenses	760,757	733,644
Unearned income	584,646	543,305
Income taxes payable	35,173	55,694
Current portion of long-term debt and obligations held under capital leases	48,513	826
Other current liabilities	19,603	29,688
Total current liabilities	1,594,176	1,471,900
Long-term debt and obligations held under capital leases, less current portion	2,419,293	2,282,612
Deferred income taxes	65,702	61,797
Other liabilities	182,826	183,656
Total liabilities	$ 4,261,997	$ 3,999,965
Commitments and contingencies (Note 1)
Shareholders’ deficit:
Common stock and additional paid-in capital, 300,000 shares authorized, $0.01 par value, 119,378 and 124,129 shares issued and outstanding at December 31, 2015 and 2014, respectively	$ 8,784	$ 143,828
Accumulated deficit	(461,635)	(788,798)
Accumulated other comprehensive loss	(111,366)	(59,091)
Deficit attributable to Quintiles Transnational Holdings Inc.’s shareholders	(564,217)	(704,061)
Noncontrolling interests	228,536	49
Total shareholders’ deficit	(335,681)	(704,012)
Total liabilities and shareholders’ deficit	$ 3,926,316	$ 3,295,953

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]
Common stock, shares authorized	300,000,000	300,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares issued	119,378,000	124,129,000
Common stock, shares outstanding	119,377,731	124,129,340	129,651,907	115,763,510

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating activities:
Net income	$ 388,304	$ 356,501	$ 226,027
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization	127,742	121,013	107,504
Amortization of debt issuance costs and discount	9,170	6,688	21,825
Amortization of accumulated other comprehensive loss on terminated interest rate swaps	7,881
Share-based compensation	37,758	30,001	22,826
Gain on disposals of property and equipment, net	(710)	(975)	(1,153)
Impairment of long-lived assets	2,484
(Earnings) loss from unconsolidated affiliates	(8,265)	(4,346)	1,004
Loss (gain) on investments, net	1,012	(4,797)	(183)
Provision for (benefit from) deferred income taxes	18,351	(6,168)	(24,236)
Excess income tax benefits from share-based award activities	(39,071)	(20,303)	(16,204)
Changes in operating assets and liabilities:
Accounts receivable and unbilled services	(246,028)	(78,630)	(151,681)
Prepaid expenses and other assets	14,436	(40,832)	(18,576)
Accounts payable and accrued expenses	104,350	45,804	107,047
Unearned income	53,847	19,943	71,852
Income taxes payable and other liabilities	4,430	7,855	47,319
Net cash provided by operating activities	475,691	431,754	393,371
Investing activities:
Acquisition of property, equipment and software	(78,391)	(82,650)	(88,347)
Acquisition of businesses, net of cash acquired	31,725	(92,201)	(144,970)
Proceeds from disposition of property and equipment	2,491	1,611	2,021
Proceeds from sale of equity securities		5,861	60
Investments in and advances to unconsolidated affiliates, net of payments received	(12,350)	(4,472)	(7,353)
Termination of interest rate swaps	(10,981)
Other	551	(1,263)	2,413
Net cash used in investing activities	(66,955)	(173,114)	(236,176)
Financing activities:
Proceeds from issuance of debt	2,248,500	275,000	2,060,755
Payment of debt issuance costs	(22,028)	(1,455)	(2,607)
Repayment of debt	(2,056,780)	(30,157)	(2,444,600)
Proceeds from revolving credit facility		150,000
Repayment of revolving credit facility		(150,000)
Principal payments on capital lease obligations	(4,296)	(2,612)	(3,812)
Contingent consideration paid	(3,000)	(3,000)
Issuance of common stock			525,000
Payment of common stock issuance costs		(105)	(35,439)
Stock issued under employee stock purchase and option plans	64,297	35,228	12,539
Repurchase of common stock	(515,010)	(415,131)	(6,434)
Repurchase of stock options		(8,415)	(50,649)
Excess income tax benefits from share-based award activities	39,071	20,303	16,204
Net cash (used in) provided by financing activities	(249,246)	(130,344)	70,957
Effect of foreign currency exchange rate changes on cash	(49,697)	(39,081)	(17,737)
Increase (decrease) in cash and cash equivalents	109,793	89,215	210,415
Cash and cash equivalents at beginning of period	867,358	778,143	567,728
Cash and cash equivalents at end of period	$ 977,151	$ 867,358	$ 778,143

CONSOLIDATED STATEMENTS OF SHAR

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT - USD ($) $ in Thousands	Total	(Accumulated Deficit) [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Noncontrolling Interest [Member]
Beginning Balance, Value at Dec. 31, 2012	$ (1,359,044)	$ (1,371,772)	$ 7,695	$ 1,158	$ 3,396	$ 479
Issuance of common stock, Value	537,539			141	537,398
Stock issuance costs	(35,439)				(35,439)
Repurchase of common stock, Value	(6,434)			(2)	(6,432)
Repurchase of stock options	(59,064)				(59,064)
Share-based compensation	20,784				20,784
Income tax benefits from share-based award activities	16,204				16,204
Net income	226,027	226,591				(564)
Unrealized gain (loss) on marketable securities, net of tax	3,225		3,225
Unrealized gain (loss) on derivative instruments, net of tax	358		358
Defined benefit plan adjustments, net of tax	2,278		2,278
Foreign currency translation, net of tax	(22,663)		(22,676)			13
Reclassification adjustments, net of tax	8,744		8,744
Ending Balance, Value at Dec. 31, 2013	(667,485)	(1,145,181)	(376)	1,297	476,847	(72)
Issuance of common stock, Value	35,302			21	35,281
Stock issuance costs	(105)				(105)
Repurchase of common stock, Value	(415,131)			(76)	(415,055)
Share-based compensation	25,315				25,315
Income tax benefits from share-based award activities	20,303				20,303
Net income	356,501	356,383				118
Unrealized gain (loss) on marketable securities, net of tax	(600)		(600)
Unrealized gain (loss) on derivative instruments, net of tax	(5,067)		(5,067)
Defined benefit plan adjustments, net of tax	(7,237)		(7,237)
Foreign currency translation, net of tax	(47,807)		(47,810)			3
Reclassification adjustments, net of tax	1,999		1,999
Ending Balance, Value at Dec. 31, 2014	(704,012)	(788,798)	(59,091)	1,242	142,586	49
Issuance of common stock, Value	64,614			31	64,583
Repurchase of common stock, Value	(515,010)	(60,042)		(79)	(454,889)
Share-based compensation	31,582				31,582
Income tax benefits from share-based award activities	39,071				39,071
Q2 Solutions business combination	423,268				423,268
Noncontrolling interest related to Q2 Solutions transaction					(231,903)	231,903
Deferred tax impact of the Q2 Solutions transaction	(6,708)				(6,708)
Net income	388,304	387,205				1,099
Unrealized gain (loss) on marketable securities, net of tax	(268)		(268)
Unrealized gain (loss) on derivative instruments, net of tax	(9,523)		(9,523)
Defined benefit plan adjustments, net of tax	(36)		(36)
Foreign currency translation, net of tax	(60,024)		(55,509)			(4,515)
Reclassification adjustments, net of tax	13,061		13,061
Ending Balance, Value at Dec. 31, 2015	$ (335,681)	$ (461,635)	$ (111,366)	$ 1,194	$ 7,590	$ 228,536

CONSOLIDATED STATEMENTS OF SHA9

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT (Parenthetical) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement Of Stockholders Equity [Abstract]
Beginning Balance, Shares	124,129,340	129,651,907	115,763,510
Issuance of common stock, Shares	3,104,187	2,068,608	14,041,620
Repurchase of common stock, Shares	7,855,796	7,591,175	153,223
Ending Balance, Shares	119,377,731	124,129,340	129,651,907

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies The Company Conducting business in approximately 100 countries with approximately 36,100 employees, Quintiles Transnational Holdings Inc. (together with its subsidiaries, the “Company”) is a provider of pharmaceutical development services and commercial outsourcing services that helps its biopharmaceutical customers, as well as customers in the broader healthcare industry, to make decisions regarding drug development, commercialization and drug therapy choices. The Company also offers a number of services designed to address the outcomes and analytical needs of the broader healthcare industry. Reclassifications Certain immaterial prior period amounts have been reclassified to conform to the current presentation including the reclassification of debt issuance costs related to non-revolving debt from deposits and other assets to a direct reduction to the carrying amount of the long-term debt on the balance sheet. These changes had no effect on previously reported total revenues, net income, comprehensive income, shareholders’ deficit or cash flows. Principles of Consolidation The accompanying consolidated financial statements include the accounts and operations of the Company and its subsidiaries. Amounts pertaining to the noncontrolling ownership interests held in third parties in the operating results and financial position of the Company’s majority-owned subsidiaries are reported as noncontrolling interests. Intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. These estimates are based on historical experience and various other assumptions believed reasonable under the circumstances. The Company evaluates its estimates on an ongoing basis and makes changes to the estimates and related disclosures as experience develops or new information becomes known. Actual results may differ from those estimates. Foreign Currencies The Company’s financial statements are reported in United States dollars and, accordingly, the Company’s results of operations are impacted by fluctuations in exchange rates that affect the translation of its revenues and expenses denominated in foreign currencies into United States dollars for purposes of reporting its consolidated financial results. Assets and liabilities recorded in foreign currencies on the books of foreign subsidiaries are translated at the exchange rate on the balance sheet date. Revenues, costs and expenses are translated at average rates of exchange during the year. Translation adjustments resulting from this process are charged or credited to the accumulated other comprehensive income (loss) (“AOCI”) component of shareholders’ deficit. The Company is subject to foreign currency transaction risk for fluctuations in exchange rates during the period of time between the consummation and cash settlement of a transaction. The Company earns revenue from its service contracts over a period of several months and, in some cases, over a period of several years. Accordingly, exchange rate fluctuations during this period may affect the Company’s profitability with respect to such contracts. Other expense (income), net includes foreign currency net (gains) losses for 2015, 2014 and 2013 of approximately ($4.6) million, $4.9 million and $4.0 million, respectively. Cash Equivalents, Restricted Cash and Investments The Company considers all highly liquid investments with an initial maturity of three months or less when purchased to be cash equivalents. The Company’s restricted cash primarily consisted of amounts collateralizing standby letters of credit issued in favor of certain suppliers and health insurance funds. Investments in marketable equity securities are classified as available-for-sale and measured at fair market value with net unrealized gains and losses recorded in the AOCI component of shareholders’ deficit until realized. The fair market value is based on the closing price as quoted by the respective stock exchange. In addition, the Company has investments in equity securities of companies for which there are not readily available market values and for which the Company does not exercise significant influence or control; such investments are accounted for using the cost method. Any gains or losses from the sales of investments or other-than-temporary declines in fair value are computed by specific identification. Equity Method Investments The Company’s investments in and advances to unconsolidated affiliates are accounted for under the equity method if the Company exercises significant influence or has an investment in a limited partnership that is considered to be greater than minor. These investments and advances are classified as investments in and advances to unconsolidated affiliates on the accompanying consolidated balance sheets. The Company records its pro rata share of the earnings, adjusted for accretion of basis difference, of these investments in equity in earnings of unconsolidated affiliates on the accompanying consolidated statements of income. The Company reviews its investments in and advances to unconsolidated affiliates for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. Derivatives The Company uses derivative instruments to manage exposures to interest rates and foreign currencies. Derivatives are recorded on the balance sheet at fair value at each balance sheet date utilizing pricing models for non-exchange-traded contracts. At inception, the Company designates whether or not the derivative instrument is an effective hedge of an asset, liability or firm commitment which is then classified as either a cash flow hedge or a fair value hedge. If determined to be an effective cash flow hedge, changes in the fair value of the derivative instrument are recorded as a component of AOCI until realized. We include the impact from these hedges in the same line item as the hedged item on the consolidated statements of cash flows. Changes in fair value of effective fair value hedges are recorded in earnings as an offset to the changes in the fair value of the related hedged item. Hedge ineffectiveness, if any, is immediately recognized in earnings. Changes in the fair values of derivative instruments that are not an effective hedge are recognized in earnings. The Company has entered, and may in the future enter, into derivative contracts (swaps, forwards, calls or puts, warrants, for example) related to its debt, investments in marketable equity securities and forecasted foreign currency transactions. Billed and Unbilled Services and Unearned Income In general, prerequisites for billings and payments are established by contractual provisions including predetermined payment schedules, which may or may not correspond to the timing of the performance of services under the contract. Unbilled services arise when services have been rendered for which revenue has been recognized but the customers have not been billed. In some cases, payments received are in excess of revenue recognized. Payments received in advance of services being provided are deferred as unearned income on the consolidated balance sheet. As the contracted services are subsequently performed and the associated revenue is recognized, the unearned income balance is reduced by the amount of the revenue recognized during the period. Allowance for Doubtful Accounts The Company’s allowance for doubtful accounts is determined based on a variety of factors that affect the potential collectability of the related receivables, including length of time the receivables are past due, customer credit ratings, financial stability of the customer, specific one-time events and past customer history. In addition, in circumstances where the Company is made aware of a specific customer’s inability to meet its financial obligations, a specific allowance is established. The accounts are individually evaluated on a regular basis and appropriate reserves are established as deemed appropriate based on the above criteria. Receivables Financing Facility Advances received under the Company’s receivables financing facility are accounted for as borrowings secured by the receivables and included in net cash provided by financing activities. The Company services the collateralized accounts receivable and the cash flows for the underlying receivables are included in cash provided by operating activities. The collateralized accounts receivable are included in trade accounts receivable and unbilled services, net. Business Combinations Business combinations are accounted for using the acquisition method, and accordingly, the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree are recorded at their estimated fair values on the date of the acquisition. Goodwill represents the excess of the purchase price over the estimated fair value of the net assets acquired, including the amount assigned to identifiable intangible assets. When a business combination involves contingent consideration, the Company recognizes a liability equal to the estimated fair value of the contingent consideration obligation at the date of the acquisition. Subsequent changes in the estimated fair value of the contingent consideration are recognized in earnings in the period of the change. Long-Lived Assets Property and equipment are stated at cost and are depreciated using the straight-line method over the shorter of the asset’s estimated useful life or the lease term, if related to leased property, as follows: Buildings and leasehold improvements 3 - 40 years Equipment 3 - 10 years Furniture and fixtures 5 - 10 years Motor vehicles 3 - 5 years Definite-lived identifiable intangible assets are amortized primarily using an accelerated method that reflects the pattern in which the Company expects to benefit from the use of the asset over its estimated remaining useful life as follows: Trademarks and trade names 2 - 6 years Non-compete agreements 3 years Contract backlog and customer relationships 1 - 10 years Software and related assets 2 - 9 years Goodwill and indefinite-lived identifiable intangible assets, which consist of certain trade names, are not amortized but evaluated for impairment annually, or more frequently if events or changes in circumstances indicate an impairment. Included in software and related items is the capitalized cost of internal-use software used in supporting the Company’s business. Qualifying costs incurred during the application development stage are capitalized and amortized over their estimated useful lives. The Company recognized $37.7 million, $33.1 million and $32.2 million of amortization expense in 2015, 2014 and 2013, respectively, related to software and related assets. The carrying values of property, equipment and intangible and other long-lived assets are reviewed for recoverability if the facts and circumstances suggest that a potential impairment may have occurred. If this review indicates that carrying values will not be recoverable, as determined based on undiscounted cash flow projections, the Company will record an impairment charge to reduce carrying values to estimated fair value. During 2015, the Company recognized a $2.5 million impairment charge for long-lived assets related to a facility closure in Japan. There were no events, facts or circumstances in 2014 and 2013 that resulted in any impairment charges to the Company’s property, equipment, intangible or other long-lived assets. Revenue Recognition The Company recognizes revenue when all of the following conditions are satisfied: (1) there is persuasive evidence of an arrangement; (2) the service offering has been delivered to the customer; (3) the collection of the fees is probable; and (4) the arrangement consideration is fixed or determinable. The Company’s arrangements are primarily service contracts that range in duration from a few months to several years. Most contracts may be terminated upon 30 to 90 days notice by the customer, however, in the event of termination, contract provisions typically require payment for services rendered through the date of termination, as well as for subsequent services rendered to close out the contract. In some cases, contracts provide for consideration that is contingent upon the occurrence of uncertain future events. The Company recognizes contingent revenue when the contingency has been resolved and all other criteria for revenue recognition have been met. The Company treats cash payments to customers as incentives to induce the customers to enter into such a service agreement with the Company. The related asset is amortized as a reduction of revenue over the period the services are performed. The Company records revenues net of any tax assessments by governmental authorities, such as value added taxes, that are imposed on and concurrent with specific revenue generating transactions. The Company does not recognize revenue with respect to start-up activities including contract and scope negotiation, feasibility analysis and conflict of interest review associated with contracts. The costs for these activities are expensed as incurred. For the arrangements that include multiple elements, arrangement consideration is allocated to units of accounting based on the relative selling price. The best evidence of selling price of a unit of accounting is vendor-specific objective evidence (“VSOE”), which is the price the Company charges when the deliverable is sold separately. When VSOE is not available to determine selling price, management uses relevant third-party evidence (“TPE”) of selling price, if available. When neither VSOE nor TPE of selling price exists, management uses its best estimate of selling price considering all relevant information that is available without undue cost and effort. The majority of the Company’s contracts within the Product Development segment are service contracts for clinical research that represent a single unit of accounting. The Company recognizes revenue on its clinical research services contracts as services are performed primarily on a proportional performance basis, generally using output measures that are specific to the service provided. Examples of output measures include among others, number of investigators enrolled, number of site initiation visits and number of monitoring visits completed. Revenue is determined by dividing the actual units of work completed by the total units of work required under the contract and multiplying that ratio by the total contract value. The total contract value, or total contractual payments, represents the aggregate contracted price for each of the agreed upon services to be provided. Changes in the scope of work are common, especially under long-term contracts, and generally result in a change in contract value. Once the customer has agreed to the changes in scope and renegotiated pricing terms, the contract value is amended and revenue is recognized, as described above. To the extent that contracts involve multiple elements, the Company follows the allocation methodology described above and recognizes revenue for each unit of accounting on a proportional performance basis. The Company derives the majority of its revenues in its Integrated Healthcare Services segment from providing commercialization services on a fee-for-service basis to customers within the biopharmaceutical industry. Fees on these arrangements are billed based on a contractual per-diem or hourly rate basis. The Company recognizes revenue on commercialization services contracts primarily on a time and materials basis. Some of the Company’s commercialization contracts are multiple element arrangements, with elements including recruiting, training and deployment of sales representatives. The nature of the terms of these multiple element arrangements will vary based on the customized needs of the Company’s customers. For contracts that have multiple elements, the Company follows the allocation methodology described above and recognizes revenue for each unit of accounting on a time and materials basis. The Company’s commercialization contracts sometimes include variable fees that are based on a percentage of product sales (royalty payments). The Company recognizes revenue on royalty payments when the variable components become fixed or determinable and all other revenue recognition criteria have been met, which generally only occurs upon the sale of the underlying product(s) and upon the Company’s receipt of information necessary to make a reasonable estimate. Reimbursed Expenses The Company includes reimbursed expenses in total revenues and costs of revenue as the Company is deemed to be the primary obligor in the applicable arrangements. These costs include such items as payments to investigators and travel expenses for the Company’s clinical monitors and sales representatives. Expenses Costs of revenue include reimbursed expenses, compensation and benefits for billable employees, depreciation of assets used in generating revenue and other expenses directly related to service contracts such as courier fees and laboratory supplies for the Company’s laboratory services, professional services and travel expenses. Selling, general and administrative expenses primarily include costs related to administrative functions such as compensation and benefits, travel, professional services, training and expenses for advertising, information technology, facilities and depreciation and amortization. Concentration of Credit Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. Investment policies have been implemented that limit purchases of marketable securities to investment grade securities. Substantially all service revenues for Product Development and Integrated Healthcare Services are earned by performing services under contracts with various pharmaceutical, biotechnology, medical device and healthcare companies. The concentration of credit risk is equal to the outstanding accounts receivable and unbilled services balances, less the unearned income related thereto, and such risk is subject to the financial and industry conditions of the Company’s customers. The Company does not require collateral or other securities to support customer receivables. Credit losses have been immaterial and reasonably within management’s expectations. No customer accounted for 10.0% or more of consolidated service revenues in 2015, 2014 or 2013. Research and Development Costs Research and development costs consist primarily of employee compensation and related expenses and information technology contract services and are charged to expense as incurred. The following is a summary of the research and development expenses (in thousands): Year Ended December 31, 2015 2014 2013 Internally developed software applications and computer technology $ 3,198 $ 4,980 $ 3,955 Funding of customer's research and development activity 139 811 1,000 $ 3,337 $ 5,791 $ 4,955 Advertising Costs Advertising costs, which include the development and production of advertising materials and the communication of these materials, are charged to expense as incurred. The Company incurred approximately $12.8 million, $16.0 million and $14.8 million in advertising expense in 2015, 2014 and 2013, respectively. Restructuring Costs Restructuring costs, which primarily include termination benefits and facility closure costs, are recorded at estimated fair value. Key assumptions in determining the restructuring costs include the terms and payments that may be negotiated to terminate certain contractual obligations and the timing of employees leaving the Company. Contingencies The Company records accruals for claims, suits, investigations and proceedings when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company reviews claims, suits, investigations and proceedings at least quarterly and records or adjusts accruals related to such matters to reflect the impact and status of any settlements, rulings, advice of counsel or other information pertinent to a particular matter. Legal costs associated with contingencies are charged to expense as incurred. The Company is party to legal proceedings incidental to its business. While the outcome of these matters could differ from management’s expectations, the Company does not believe the resolution of these matters has a reasonable possibility of having a material adverse effect to the Company’s financial statements. Income Taxes Income tax expense includes United States federal, state and international income taxes. Certain items of income and expense are not reported in income tax returns and financial statements in the same year. The income tax effects of these differences are reported as deferred income taxes. Valuation allowances are provided to reduce the related deferred income tax assets to an amount which will, more likely than not, be realized. Beginning in 2013, the undistributed earnings of most of the Company’s foreign subsidiaries are considered to be indefinitely reinvested outside of the United States. Accordingly, a deferred income tax liability has not been provided related to those undistributed earnings. Interest and penalties related to unrecognized income tax benefits are recognized as a component of income tax expense as discussed further in Note 16. Employee Stock Compensation The Company accounts for share-based compensation for stock options and stock appreciation rights (“SARs”) under the fair value method and uses the Black-Scholes-Merton model to estimate the value of such share-based awards granted to its employees and non-executive directors. Expected volatility is based upon the historical volatility of a peer group for a period equal to the expected term, as the Company does not have adequate history to calculate its own volatility and believes the expected volatility will approximate the historical volatility of the peer group. Prior to the completion of the Company’s initial public offering (“IPO”) on May 14, 2013, the expected dividends were based on the historical dividends paid by the Company, excluding dividends that resulted from activities that the Company deemed to be one-time in nature. Following the IPO, the Company does not currently anticipate paying dividends. The expected term represents the period of time the grants are expected to be outstanding. The risk-free interest rate is based on the United States Treasury yield curve in effect at the time of the grant. The Company accounts for its share-based compensation for restricted stock units (“RSUs”) and performance awards based on the closing market price of the Company’s common stock on the date of grant. The Company recognized share-based compensation expense of $37.8 million, $30.0 million and $22.8 million in 2015, 2014 and 2013, respectively. Share-based compensation expense is included in selling, general and administrative expenses on the accompanying consolidated statements of income which is consistent with the classification of all other compensation costs incurred for the employees who were granted the share-based awards. The associated future income tax benefit recognized was $8.9 million, $7.6 million and $8.1 million in 2015, 2014 and 2013, respectively. As of December 31, 2015, there was approximately $38.8 million of total unrecognized share-based compensation expense related to outstanding non-vested share-based compensation arrangements, which the Company expects to recognize over a weighted average period of 1.3 years. Earnings Per Share The calculation of earnings per share is based on the weighted average number of common shares or common stock equivalents outstanding during the applicable period. The dilutive effect of common stock equivalents is excluded from basic earnings per share and is included in the calculation of diluted earnings per share. Potentially dilutive securities include outstanding stock options, shares to be purchased under the Company’s employee stock purchase plan (see Note 17) and unvested RSUs. Recently Issued Accounting Standards In November 2015, the FASB issued new accounting guidance which requires entities to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. The new standard will be effective for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The Company expects to early adopt this new accounting guidance on January 1, 2016. As of December 31, 2015, the Company had approximately $101.0 million and $148,000 of current deferred income tax assets and current deferred income tax liabilities, respectively. In September 2015, the FASB issued new guidance that will change the requirements for reporting measurement period adjustments to provisional amounts initially recognized in connection with a business combination. Currently, an acquiring entity is required to retrospectively adjust, in prior period financial statements, the provisional amounts to reflect new information obtained during the measurement period. Under the new guidance, adjustments to the provisional amounts will be reflected in the financial statements for the reporting period in which the adjustments are determined, including by recognizing in current period earnings the full effect of changes in depreciation, amortization or other income effects. The new guidance requires that the acquiring entity either present separately on the face of the current period income statement or disclose in the notes to the current period financial statements, by line item, the amount of the adjustments made during the current period. The Company will adopt the new guidance on January 1, 2016, as required. The adoption is not expected to have a material impact on the Company’s financial statements. In February 2015, the FASB issued new accounting guidance which changes the analysis in determining whether an entity is considered a variable interest entity (“VIE”) and the identification of the primary beneficiary of the VIE to determine whether the VIE should be included in an entity’s consolidated financial statements. The Company will adopt the new accounting guidance on January 1, 2016, as required. The adoption of the new accounting guidance is not expected to have a material effect on the Company’s financial statements. In May 2014, the FASB and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with customers. The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also will require expanded disclosures on revenue recognition including information about changes in assets and liabilities that result from contracts with customers. Companies have an option to use either a retrospective approach or a cumulative effect adjustment approach to implement the new guidance. The new standard will be effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted for annual reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact of this new standard on its consolidated financial statements, the date of adoption, and the transition approach to implement the new guidance.

Accounts Receivable and Unbille

Accounts Receivable and Unbilled Services	12 Months Ended
	Dec. 31, 2015
Receivables [Abstract]
Accounts Receivable and Unbilled Services	2. Accounts Receivable and Unbilled Services Accounts receivable and unbilled services consist of the following (in thousands): December 31, 2015 2014 Trade: Billed $ 553,652 $ 444,941 Unbilled services 614,381 532,312 1,168,033 977,253 Allowance for doubtful accounts (2,284 ) (1,998 ) $ 1,165,749 $ 975,255 Substantially all of the Company’s trade accounts receivable and unbilled services are due from companies in the pharmaceutical, biotechnology, medical device and healthcare industries and are a result of contract research, sales, marketing, healthcare consulting and health information management services provided by the Company on a global basis. The percentage of accounts receivable and unbilled services by region is as follows: December 31, 2015 2014 Americas: United States 58 % 55 % Other 1 2 Americas 59 57 Europe and Africa: United Kingdom 23 23 Other 10 11 Europe and Africa 33 34 Asia-Pacific: Japan 3 4 Other 5 5 Asia-Pacific 8 9 100 % 100 %

Investments-Debt, Equity and Ot

Investments-Debt, Equity and Other Securities	12 Months Ended
	Dec. 31, 2015
Investments Debt And Equity Securities [Abstract]
Investments-Debt, Equity and Other Securities	3. Investments – Debt, Equity and Other Securities The following is a summary of the Company’s debt, equity and other securities (in thousands): December 31, 2015 2014 Marketable securities $ 395 $ 831 Cost method 32,516 33,672 $ 32,911 $ 34,503 Investments in Marketable Securities: The following is a summary of available-for-sale securities (in thousands): December 31, 2015 December 31, 2014 Gross Gross Amortized Unrealized Market Amortized Unrealized Market Cost Loss Value Cost Loss Value Marketable equity $ 1,103 $ (708 ) $ 395 $ 1,103 $ (272 ) $ 831 The Company recognized a $5.0 million gain from the sale of marketable equity securities in 2014. The Company did not recognize any gains from the sale of marketable equity securities in 2015 and 2013. The Company did not recognize any losses from the sale of marketable equity securities in 2015, 2014 and 2013. The net after-tax adjustment to unrealized holding gains (losses) on available-for-sale securities included in the AOCI component of shareholders’ deficit was ($438,000), ($170,000) and $3.5 million in 2015, 2014 and 2013, respectively. The Company’s policy is to continually review declines in fair value of marketable equity securities for declines that may be other than temporary. As part of this review, the Company considers the financial statements of the investee, analysts’ reports, duration of the decline in fair value and general market factors. The Company did not recognize any such losses in 2015, 2014 and 2013. Investments – Cost Method The Company has investments in equity securities of companies for which there are not readily available market values and for which the Company does not exercise significant influence or control. These investments are accounted for using the cost method. Below is a summary of the Company’s portfolio of cost method investments (in thousands): December 31, 2015 2014 Equity investments $ 32,516 $ 32,516 Convertible notes — 1,156 $ 32,516 $ 33,672 On February 25, 2011, the Company and the Samsung Group entered into an agreement to form a joint venture intended to provide biopharmaceutical contract manufacturing services in South Korea. The Company committed to invest up to $30.0 million for a noncontrolling interest and has funded all of this commitment. As of December 31, 2015 and 2014, the Company has an approximately 2.2% and 3.0%, respectively, ownership interest in the joint venture. In December 2011, the Company and Intarcia Therapeutics (“Intarcia”) entered into an alliance to develop a new therapy for type 2 diabetes whereby Intarcia will use the Company to conduct Phase III pivotal clinical trials and a cardiovascular outcomes clinical trial. Under the alliance, the Company provided Intarcia a customer incentive of $12.5 million and acquired $5.0 million of preferred stock of Intarcia. The customer incentive is being amortized in proportion to the revenues earned as a reduction of revenue recorded under the service arrangements. As of December 31, 2015 and 2014, the customer incentive of $2.5 million and $7.1 million, respectively, was recorded in deposits and other assets on the accompanying consolidated balance sheets. The $5.0 million investment in preferred stock of Intarcia is recorded in “investments — debt, equity and other securities” on the accompanying consolidated balance sheets. The Company reviews the carrying value of each individual investment at each balance sheet date to determine whether or not an other-than-temporary decline in fair value has occurred. The Company employs alternative valuation techniques including the following: (i) the review of financial statements including assessments of liquidity, (ii) the review of valuations available to the Company prepared by independent third parties used in raising capital, (iii) the review of publicly available information including press releases and (iv) direct communications with the investee’s management, as appropriate. If the review indicates that such a decline in fair value has occurred, the Company adjusts the carrying value to the estimated fair value of the investment and recognizes a loss for the amount of the adjustment.

Investments in and Advances to

Investments in and Advances to Unconsolidated Affiliates	12 Months Ended
	Dec. 31, 2015
Investments In And Advances To Affiliates Schedule Of Investments [Abstract]
Investments in and Advances to Unconsolidated Affiliates	4. Investments in and Advances to Unconsolidated Affiliates The Company accounts for its investments in and advances to unconsolidated affiliates under the equity method of accounting and records its pro rata share of its losses or earnings from these investments in equity in earnings (losses) of unconsolidated affiliates. The following is a summary of the Company’s investments in and advances to unconsolidated affiliates (in thousands): December 31, 2015 2014 NovaQuest Pharma Opportunities Fund III, L.P. $ 39,785 $ 22,633 NovaQuest Pharma Opportunities Fund IV, L.P. 2,524 — Cenduit TM 9,478 8,271 Other 595 604 $ 52,382 $ 31,508 NovaQuest Pharma Opportunities Funds The Company has committed to invest up to $50 million as a limited partner in NovaQuest Pharma Opportunities Fund III, L.P. (“Fund III”). As of December 31, 2015, the Company has funded approximately $34.7 million and has approximately $15.3 million of remaining funding commitments. As of December 31, 2015 and 2014, the Company had a 10.9% ownership interest in Fund III. In February 2015, the Company committed to invest up to $20 million as a limited partner in a new private equity fund, NovaQuest Pharma Opportunities Fund IV, L.P. (“Fund IV”). As of December 31, 2015, the Company has funded approximately $2.7 million and has approximately $17.3 million of remaining funding commitments. As of December 31, 2015, the Company had a 2.3% ownership interest in Fund IV. Cenduit™ In May 2007, the Company and Thermo Fisher Scientific Inc. (“Thermo Fisher”) completed the formation of a joint venture, Cenduit™. The Company contributed its Interactive Response Technology operations in India and the United States. Thermo Fisher contributed its Fisher Clinical Services Interactive Response Technology operations in three locations — the United Kingdom, the United States and Switzerland. Additionally, each company contributed $3.5 million in initial capital. The Company and Thermo Fisher each own 50% of Cenduit™.

Derivatives

Derivatives	12 Months Ended
	Dec. 31, 2015
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivatives	5. Derivatives As of December 31, 2015, the Company held the following derivative positions: (i) forward exchange contracts to protect against foreign exchange movements for certain forecasted foreign currency cash flows related to service contracts and (ii) interest rate swaps to hedge the exposure to variability in interest payments on variable interest rate debt. The Company does not use derivative financial instruments for speculative or trading purposes. As of December 31, 2015, the Company had 15 open foreign exchange forward contracts to hedge certain forecasted foreign currency cash flow transactions occurring in 2016 with notional amounts totaling $117.5 million. As of December 31, 2014, the Company had 13 open foreign exchange forward contracts to hedge certain forecasted foreign currency cash flow transactions occurring in 2015 with notional amounts totaling $76.0 million. These contracts were executed to hedge the risk of the potential volatility in the cash flows resulting from fluctuations in currency exchange rates during the first nine months of 2016. These transactions are accounted for as cash flow hedges, as such, the effective portion of the gain or loss on the contracts is recorded as unrealized gains (losses) on derivatives included in the AOCI component of shareholders’ deficit. These hedges are highly effective. As of December 31, 2015 and 2014, the Company had recorded gross unrealized losses of $5.2 million and $4.6 million, respectively, related to foreign exchange forward contracts. Upon expiration of the hedge instruments in 2016, the Company will reclassify the unrealized holding gains and losses on the derivative instruments included in AOCI into earnings. The unrealized losses are included in other current liabilities on the accompanying consolidated balance sheets as of December 31, 2015 and 2014, respectively. On June 9, 2011, the Company entered into six interest rate swaps which expired between September 30, 2013 and March 31, 2016 in an effort to limit its exposure to changes in the variable interest rate on its senior secured credit facilities. During May 2015, in conjunction with the debt refinancing described in Note 10, the Company terminated the remaining open interest rate swaps for a cash payment to the counterparty of $12.4 million, which included $1.4 million of accrued interest. Since the hedged forecasted cash transactions continue to be probable of occurring, the accumulated loss ($3.1 million at December 31, 2015) related to the terminated interest rate swaps in AOCI will be reclassified to earnings as a component of interest expense in the same periods as the hedged forecasted transactions occur over the next three months. On June 3, 2015, the Company entered into seven forward starting interest rate swaps with a notional value of $440.0 million in an effort to limit its exposure to changes in the variable interest rate on its senior secured credit facilities. Interest on the swaps begins to accrue on June 30, 2016 and the interest rate swaps expire between March 31, 2017 and March 31, 2020. The critical terms of the interest rate swaps are substantially the same as those of the Company’s senior secured credit facilities, including quarterly interest settlements. These interest rate swaps are being accounted for as cash flow hedges as these transactions were executed to hedge the Company’s interest payments, and these hedges are deemed to be highly effective. As such, changes in the fair value of these derivative instruments are recorded as unrealized gains (losses) on derivatives included in AOCI. The fair value of these interest rate swaps represents the present value of the anticipated net payments the Company will make to the counterparty, which, when they occur, are reflected as interest expense on the consolidated statements of income. These payments, together with the variable rate of interest incurred on the underlying debt, result in a fixed rate of interest of 2.1% plus the applicable margin on the affected borrowings. These interest rate swaps will result in a total debt mix of approximately 50% fixed rate debt and 50% variable rate debt. The Company expects that $3.2 million of unrealized losses will be reclassified out of AOCI and will form the interest rate swap component of the 2.1% fixed rate of interest incurred over the next 12 months as the underlying net payments are settled. The fair values of the Company’s derivative instruments designated as hedging instruments and the line items on the accompanying consolidated balance sheets to which they were recorded are summarized in the following table (in thousands): December 31, Balance Sheet Classification 2015 2014 Foreign exchange forward contracts Other current liabilities $ 5,194 $ 4,635 Interest rate swaps Other current liabilities $ 5,698 $ 14,424 The effect of the Company’s cash flow hedging instruments on other comprehensive income (loss) is summarized in the following table (in thousands): Year Ended December 31, 2015 2014 2013 Foreign exchange forward contracts $ (559 ) $ (8,585 ) $ 3,485 Interest rate swaps 5,626 10,381 9,202 Total $ 5,067 $ 1,796 $ 12,687

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	6. Fair Value Measurements The Company records certain assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: · Level 1 — Quoted prices in active markets for identical assets or liabilities. · Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. · Level 3 — Unobservable inputs that are supported by little or no market activity. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. Recurring Fair Value Measurements The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of December 31, 2015 (in thousands): Level 1 Level 2 Level 3 Total Assets: Marketable equity securities $ 395 $ — $ — $ 395 Total $ 395 $ — $ — $ 395 Liabilities: Foreign exchange forward contracts $ — $ 5,194 $ — $ 5,194 Interest rate swaps — 5,698 — 5,698 Contingent consideration — — 4,374 4,374 Total $ — $ 10,892 $ 4,374 $ 15,266 The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of December 31, 2014 (in thousands): Level 1 Level 2 Level 3 Total Assets: Marketable equity securities $ 831 $ — $ — $ 831 Total $ 831 $ — $ — $ 831 Liabilities: Foreign exchange forward contracts $ — $ 4,635 $ — $ 4,635 Interest rate swaps — 14,424 — 14,424 Contingent consideration — — 1,452 1,452 Total $ — $ 19,059 $ 1,452 $ 20,511 Below is a summary of the valuation techniques used in determining fair value: Marketable equity securities — The Company values marketable equity securities utilizing quoted market prices. Foreign exchange forward contracts — The Company values foreign exchange forward contracts using quoted market prices for identical instruments in less active markets or using other observable inputs. Interest rate swaps — The Company values interest rate swaps using market inputs with mid-market pricing as a practical expedient for bid-ask spread. Contingent consideration — The Company values contingent consideration related to business combinations using a weighted probability calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include revenue, net new business and operating forecasts and the probability of achieving the specific targets. The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the year ended December 31 (in thousands): Contingent Consideration – Accrued Expenses and Other Liabilities 2015 2014 2013 Balance as of January 1 $ 1,452 $ 13,014 $ 3,521 Initial estimate of contingent consideration — — 14,300 Contingent consideration paid (3,000 ) (3,000 ) — Revaluations included in earnings 5,922 (8,562 ) (4,807 ) Balance as of December 31 $ 4,374 $ 1,452 $ 13,014 The revaluation for the contingent consideration is recognized in other expense (income), net on the accompanying consolidated statements of income. Non-recurring Fair Value Measurements Certain assets are carried on the accompanying consolidated balance sheets at cost and are not remeasured to fair value on a recurring basis. These assets include cost and equity method investments and loans that are written down to fair value for declines which are deemed to be other-than-temporary, and goodwill and identifiable intangible assets which are tested for impairment annually and when a triggering event occurs. As of December 31, 2015, assets carried on the balance sheet and not remeasured to fair value on a recurring basis totaling approximately $1,172.7 million and were identified as Level 3. These assets are comprised of cost and equity method investments of $84.9 million, goodwill of $719.7 million and other identifiable intangibles, net of $368.1 million. Cost and Equity Method Investments — The inputs available for valuing investments in non-public portfolio companies are generally not easily observable. The valuation of non-public investments requires significant judgment by the Company due to the absence of quoted market values, inherent lack of liquidity and the long-term nature of such assets. When a triggering event occurs, the Company considers a wide range of available market data when assessing the estimated fair value. Such market data includes observations of the trading multiples of public companies considered comparable to the private companies being valued as well as publicly disclosed merger transactions involving comparable private companies. In addition, valuations are adjusted to account for company-specific issues, the lack of liquidity inherent in a non-public investment and the fact that comparable public companies are not identical to the companies being valued. Such valuation adjustments are necessary because in the absence of a committed buyer and completion of due diligence similar to that performed in an actual negotiated sale process, there may be company-specific issues that are not fully known that may affect value. Further, a variety of additional factors are reviewed by the Company, including, but not limited to, financing and sales transactions with third parties, current operating performance and future expectations of the particular investment, changes in market outlook and the third party financing environment. Because of the inherent uncertainty of valuations, estimated valuations may differ significantly from the values that would have been used had a ready market for the securities existed, and the differences could be material. Goodwill — Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets resulting from business combinations. The Company performs a qualitative analysis to determine whether it is more likely than not that the estimated fair value of a reporting unit is less than its book value. This includes a qualitative analysis of macroeconomic conditions, industry and market considerations, internal cost factors, financial performance, fair value history and other company specific events. If this qualitative analysis indicates that it is more likely than not that the estimated fair value is less than the book value for the respective reporting unit, the Company applies a two-step impairment test in which the Company determines whether the estimated fair value of the reporting unit is in excess of its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the estimated fair value of the reporting unit, the Company performs the second step of the impairment test to determine the implied estimated fair value of the reporting unit’s goodwill. The Company determines the implied estimated fair value of goodwill by determining the present value of the estimated future cash flows for each reporting unit and comparing the reporting unit’s risk profile and growth prospects to selected, reasonably similar publicly traded companies. No indication of impairment was identified during the Company’s annual review. Definite-lived Intangible Assets — If a triggering event occurs, the Company determines the estimated fair value of definite-lived intangible assets by determining the present value of the expected cash flows. Indefinite-lived Intangible Asset — The Company performs a qualitative analysis to determine whether it is more likely than not that the estimated fair value of the indefinite-lived intangible asset is less than its carrying value. If this qualitative analysis indicates that it is more likely than not that the estimated fair value is less than the carrying value of the indefinite-lived intangible asset, the Company determines the estimated fair value of the indefinite-lived intangible asset (trade name) by determining the present value of the estimated royalty payments on an after-tax basis that it would be required to pay the owner for the right to use such trade name. If the carrying amount exceeds the estimated fair value, an impairment loss is recognized in an amount equal to the excess. No indication of impairment was identified during the Company’s annual review.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Property and Equipment	7. Property and Equipment The major classes of property and equipment were as follows (in thousands): December 31, 2015 2014 Land, buildings and leasehold improvements $ 187,405 $ 185,940 Equipment 257,119 240,227 Furniture and fixtures 52,840 54,615 Motor vehicles 13,348 15,443 510,712 496,225 Less accumulated depreciation (322,319 ) (305,928 ) $ 188,393 $ 190,297

Goodwill and Identifiable Intan

Goodwill and Identifiable Intangible Assets	12 Months Ended
	Dec. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Identifiable Intangible Assets	8. Goodwill and Identifiable Intangible Assets As of December 31, 2015, the Company has approximately $368.1 million of identifiable intangible assets, of which approximately $128.2 million, relating to trade names, is deemed to be indefinite-lived and, accordingly, is not being amortized. Amortization expense associated with identifiable definite-lived intangible assets was as follows (in thousands): Year Ended December 31, 2015 2014 2013 Amortization expense $ 66,545 $ 58,457 $ 51,450 Estimated amortization expense for existing identifiable intangible assets is expected to be approximately $61.7 million, $50.2 million, $39.2 million, $32.5 million and $20.8 million for the years ending December 31, 2016, 2017, 2018, 2019 and 2020, respectively. Estimated amortization expense can be affected by various factors, including future acquisitions or divestitures of product and/or licensing and distribution rights or impairments. The following is a summary of identifiable intangible assets (in thousands): As of December 31, 2015 As of December 31, 2014 Gross Accumulated Net Gross Accumulated Net Amount Amortization Amount Amount Amortization Amount Definite-lived identifiable intangible assets: Product licensing and distribution rights and customer relationships $ 224,149 $ (75,606 ) $ 148,543 $ 123,227 $ (54,413 ) $ 68,814 Trademarks, trade names and other 14,620 (6,081 ) 8,539 18,571 (6,399 ) 12,172 Software and related assets 279,266 (196,489 ) 82,777 260,052 (170,471 ) 89,581 $ 518,035 $ (278,176 ) $ 239,859 $ 401,850 $ (231,283 ) $ 170,567 Indefinite-lived identifiable intangible assets: Trade names $ 128,247 $ — $ 128,247 $ 109,676 $ — $ 109,676 Accumulated amortization of identifiable intangible assets includes the impact of amortization expense, foreign exchange fluctuations and disposals of software and related assets. The following is a summary of goodwill by segment for the years ended December 31, 2015 and 2014 (in thousands): Integrated Product Healthcare Development Services Consolidated Balance as of December 31, 2013 $ 351,144 $ 58,482 $ 409,626 Business combinations — 62,778 62,778 Impact of foreign currency fluctuations and other (4,536 ) (3,434 ) (7,970 ) Balance as of December 31, 2014 346,608 117,826 464,434 Business combinations 262,377 — 262,377 Impact of foreign currency fluctuations and other (6,879 ) (192 ) (7,071 ) Balance as of December 31, 2015 $ 602,106 $ 117,634 $ 719,740

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2015
Payables And Accruals [Abstract]
Accrued Expenses	9. Accrued Expenses Accrued expenses consist of the following (in thousands): December 31, 2015 2014 Compensation, including bonuses, fringe benefits and payroll taxes $ 400,748 $ 403,250 Restructuring 13,564 6,083 Interest 5,115 274 Contract related 271,076 255,530 Other 70,254 68,507 $ 760,757 $ 733,644

Credit Arrangements

Credit Arrangements	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Credit Arrangements	10. Credit Arrangements The following is a summary of the Company’s revolving credit facilities at December 31, 2015: Facility Interest Rates $500.0 million (revolving credit facility) London Interbank Offer Rate (“LIBOR”) (0.61% at December 31, 2015) plus 1.75% $25.0 million (receivables financing facility) LIBOR Market Index Rate (0.43% at December 31, 2015) plus 0.85% to 1.35% depending upon the Company’s debt rating £10.0 million (approximately $14.8 million) general banking facility with a European headquartered bank Bank’s base rate (0.5% at December 31, 2015) plus 1% During 2014, the Company borrowed and repaid $150.0 million from its then outstanding revolving credit facility. The Company did not have any outstanding borrowings under any of the revolving credit facilities at December 31, 2015 or 2014. At December 31, 2015, there were bank guarantees totaling approximately £3.9 million (approximately $5.8 million) issued against the availability of the general banking facility with a European headquartered bank through their operations in the United Kingdom. Long-term debt consists of the following (in thousands): December 31, 2015 2014 4.875% Senior Notes due 2023 $ 800,000 $ — Term Loan A due 2020 (LIBOR plus 1.75%, or 2.36% at December 31, 2015) 828,750 — Term Loan B due 2022 (the greater of LIBOR or 0.75% plus 2.50%, or 3.25% at December 31, 2015) 597,000 — Term Loan B-3 due 2018 (the greater of three month LIBOR or 1.25% plus 2.50%, or 3.75% at December 31, 2014) — 2,030,606 Receivables financing facility due 2018 (LIBOR plus 1.05%, or 1.48% at December 31, 2015) 275,000 275,000 2,500,750 2,305,606 Less: unamortized discount (24,020 ) (12,379 ) Less: unamortized debt issuance costs (8,955 ) (9,879 ) Less: current portion (48,500 ) (750 ) $ 2,419,275 $ 2,282,598 Contractual maturities of long-term debt at December 31, 2015 are as follows (in thousands): 2016 $ 48,500 2017 48,500 2018 323,500 2019 48,500 2020 664,750 Thereafter 1,367,000 $ 2,500,750 The estimated fair value of the Company’s long-term debt approximates its carrying value as of December 31, 2015 and 2014. The estimated fair value of the long-term debt is primarily based on rates in which the debt is traded among banks. Senior Secured Credit Agreement 2015 Senior Secured Credit Agreement On May 12, 2015, the Company through its wholly-owned subsidiary, Quintiles Transnational, entered into new senior secured credit facilities (the “New Facilities”) totaling $1.95 billion. The New Facilities consist of a five-year $500.0 million revolving credit facility (the “New Revolver”) and $1.45 billion of term loans ($850 million in New Term Loan A due 2020 (the “New Term Loan A”) and $600 million in New Term Loan B due in 2022 (the “New Term Loan B”)). In addition, Quintiles Transnational issued $800 million of 4.875% senior unsecured notes due 2023 (the “Senior Notes”) in a private placement. The New Facilities and the Senior Notes are referred to collectively as the “New Debt.” Annual maturities on the New Term Loan A and the New Term Loan B are 5% and 1%, respectively, of the respective original principal amount with the remaining balance to be repaid on their respective maturity dates. Beginning with the fiscal year ending December 31, 2016, the Company will be required to make mandatory repayments on New Term Loan A and New Term Loan B of 50% of excess cash flow (as defined in the credit agreement covering the New Facilities, subject to a reduction to 25% or 0% depending upon the Company’s leverage ratio). Mandatory repayments will be allocated pro rata between New Term Loan A and New Term Loan B (subject to increases in the amount of New Term Loan A repayments with amounts declined by New Term Loan B lenders), and applied, first, to reduce the next eight quarterly amortization installments in direct order of maturity, and, second, to reduce all remaining amortization installments pro rata. The Company will also be required to make mandatory repayments with 100% of the net cash proceeds of certain asset dispositions, subject to thresholds and reinvestment rights. Any amounts outstanding under the New Facilities may be voluntarily repaid at any time without penalty. The new senior secured credit facilities arrangements are collateralized by substantially all of the assets of Quintiles Transnational and the assets of Quintiles Transnational’s domestic subsidiaries including 100% of the equity interests of substantially all of Quintiles Transnational’s domestic subsidiaries and 65% of the equity interests of substantially all of the first-tier foreign subsidiaries of Quintiles Transnational and its domestic subsidiaries. Interest on the Senior Notes is paid semiannually on May 15 and November 15 of each year until maturity. The Senior Notes are unsecured senior obligations of Quintiles Transnational and are effectively subordinated in right of payment to all secured obligations of Quintiles Transnational, to the extent of the value of any collateral. The Company used the proceeds from the New Debt (i) to repay the then outstanding Term Loan B-3 (defined below) which was due in 2018, (ii) to pay related fees and expenses including $11.0 million of breakage fees associated with the terminated interest rate swaps discussed further in Note 5, and (iii) for general corporate purposes including the share repurchase discussed further in Note 12. 2014 Revolving Credit Facility Amendment On November 7, 2014, the Company entered into an amendment to its then outstanding senior secured credit agreement that increased its revolving credit facility from $300.0 million to $400.0 million and extended the maturity date for most of the then outstanding revolving credit facility by six months. The other terms of the then outstanding senior secured credit agreement were not altered by the amendment. On May 12, 2015, the Company’s then outstanding revolving credit facility was replaced with the New Revolver (defined and discussed above). 2013 Senior Secured Credit Agreement On December 20, 2013, the Company entered into an amendment to its then outstanding senior secured credit agreement to provide a Term Loan B-3 (the “Term Loan B-3”) with a syndicate of banks for an aggregate principal amount of $2.061 billion due in 2018. The proceeds from the Term Loan B-3 were used to repay the then outstanding balances of the Company’s term loan B-1 and term loan B-2 and related fees and expenses. On May 12, 2015, the Term Loan B-3 was repaid with the proceeds of the New Debt (defined and discussed above). Receivables Financing Facility On December 5, 2014, the Company entered into a four-year arrangement to securitize certain of its accounts receivable. Under the receivables financing facility, certain of the Company’s accounts receivable are sold on a non-recourse basis by certain of its consolidated subsidiaries to another of its consolidated subsidiaries, a bankruptcy-remote special purpose entity (“SPE”). The SPE obtained a term loan and revolving loan commitment from a third party lender, secured by liens on the assets of the SPE, to finance the purchase of the accounts receivable, which included a $275.0 million term loan and a $25.0 million revolving loan commitment. The revolving loan commitment may be increased by an additional $35.0 million as amounts are repaid under the term loan. Quintiles Transnational has guaranteed the performance of the obligations of existing and future subsidiaries that sell and service the accounts receivable under the receivables financing facility. The assets of the SPE are not available to satisfy any of the Company’s obligations or any obligations of its subsidiaries. As of December 31, 2015, $25.0 million of revolving loans were available under the receivables financing facility. The Company used the proceeds from the term loan under the receivables financing facility to repay in full the amount outstanding on the then outstanding revolving credit facility under its then outstanding senior secured credit agreement ($150.0 million), to repay $25.0 million of the then outstanding Term Loan B-3, to pay related fees and expenses and the remainder was used for general working capital purposes. Loss on Extinguishment of Debt On May 12, 2015, the then outstanding Term Loan B-3 was repaid with the proceeds of the New Debt (defined and discussed above). In connection with this refinancing transaction, in 2015 the Company recognized a $7.8 million loss on extinguishment of debt which included $1.1 million of unamortized debt issuance costs, $1.3 million of unamortized discount and $5.4 million of related fees and expenses. On December 20, 2013, the balance of a then outstanding term loan was repaid with the proceeds from Term Loan B-3 (defined and discussed above). In 2013, in connection with the repayment of debt, the Company recognized a $3.3 million loss on extinguishment of debt which included approximately $1.6 million of unamortized debt issuance costs, approximately $1.6 million of unamortized discount and approximately $25,000 of related fees and expenses. In May 2013, the Company used $50.0 million of cash to pay down indebtedness under its then outstanding term loan B-1. In connection with this pay down of indebtedness, the Company recognized a $1.0 million loss on extinguishment of debt which included approximately $930,000 of unamortized debt issuance costs and $112,000 of unamortized discount. Also in May 2013, the Company used $308.9 million of cash to pay all amounts then outstanding under a term loan (including accrued interest and related fees and expenses). In connection with the repayment of debt, the Company recognized a $15.5 million loss on extinguishment of debt which included approximately $4.7 million of unamortized debt issuance costs, $4.7 million of unamortized discount and $6.1 million of related fees and expenses. Restrictive Covenants The credit agreement governing the Quintiles Transnational senior secured credit facilities contains usual and customary restrictive covenants (subject to significant exceptions) that place limitations on Quintiles Transnational’s ability, and the ability of Quintiles Transnational’s restricted subsidiaries, to incur liens; engage in acquisitions, loans and other investments; incur additional indebtedness; merge, dissolve, liquidate or consolidate with or into other persons; sell or otherwise dispose of assets; declare dividends, including to Quintiles Transnational Holdings Inc., and make other restricted payments; engage in businesses that are not related to Quintiles Transnational’s and its restricted subsidiaries’ existing business; transact with affiliates; enter into agreements that restrict subsidiaries from paying intercompany dividends or completing intercompany property transfers or that restrict the ability to create liens in favor of Quintiles Transnational’s lenders; amend or otherwise modify organizational documents or terms and conditions of junior financing documents, if any; change the fiscal year of Quintiles Transnational; prepay, redeem or purchase junior financing, if any; designate any other indebtedness as “designated senior indebtedness” or “senior secured financing”; and engage in sale and leaseback transactions. The credit agreement also contains one financial covenant, which is a total leverage ratio that provides for a maximum ratio of consolidated total debt to consolidated EBITDA, as defined in the credit agreement, for any period of four consecutive fiscal quarters, measured as of the end of such period, of 5.75 to 1.00, and applies at any time that the Term Loan A or New Revolver commitments remain outstanding. Violations of the financial covenant will not entitle the Term Loan B lenders to take any enforcement action prior to an acceleration of the New Revolver and the Term Loan A and, subject to customary limitations, may be cured with an equity contribution. The agreement governing the Senior Notes limits Quintiles Transnational’s and its restricted subsidiaries’ (as defined in the agreement) ability to create liens and enter into sale and lease-back transactions. The agreement governing the receivables financing facility contains certain usual and customary covenants and termination events for a securitization transaction, including certain financial reporting covenants and requirements to maintain the existence of the SPE separate from Quintiles Transnational and its other affiliates. An occurrence of an event of default or a termination event under this facility may give rise to the right of the third party lender to terminate this facility. In 2015, 2014 and 2013, the Company was in compliance with its restrictive covenants.

Leases

Leases	12 Months Ended
	Dec. 31, 2015
Leases [Abstract]
Leases	11. Leases The Company leases facilities under operating leases, many of which contain renewal and escalation clauses. The Company also leases certain equipment under operating leases. The leases expire at various dates through 2029 with options to cancel certain leases at various intervals. Rental expenses under these agreements were $109.4 million, $114.6 million and $125.6 million in 2015, 2014 and 2013, respectively. The Company leases certain assets, primarily vehicles, under capital leases. Capital lease amortization is included with costs of revenue and accumulated depreciation on the accompanying financial statements. The following is a summary of future minimum payments under capital and operating leases that have initial or remaining non-cancelable lease terms in excess of one year at December 31, 2015 (in thousands): Capital Operating Leases Leases 2016 $ 15 $ 84,747 2017 18 62,485 2018 — 41,907 2019 — 29,201 2020 — 25,713 Thereafter — 111,267 Total minimum lease payments 33 $ 355,320 Amounts representing interest (2 ) Present value of net minimum payments 31 Current portion (13 ) Long-term capital lease obligations $ 18

Shareholders' Deficit

Shareholders' Deficit	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Shareholders' Deficit	12. Shareholders’ Deficit Initial Public Offering On May 9, 2013, the Company’s common stock began trading on the New York Stock Exchange (“NYSE”) under the symbol “Q.” On May 14, 2013, the Company completed its IPO of its common stock at a price to the public of $40.00 per share. The Company issued and sold 13,125,000 shares of common stock in the IPO. The selling shareholders offered and sold 14,111,841 shares of common stock in the IPO, including 3,552,631 shares that were offered and sold by the selling shareholders pursuant to the full exercise of the underwriters’ option to purchase additional shares. The IPO raised proceeds to the Company of approximately $489.5 million, after deducting underwriting discounts, commissions and related expenses. The Company did not receive any of the proceeds from the sale of the shares sold by the selling shareholders. Preferred Stock The Company is authorized to issue 1.0 million shares of preferred stock, $0.01 per share par value. No shares of preferred stock were issued and outstanding as of December 31, 2015 or 2014. Equity Repurchases Since 2013, the Company has repurchased approximately $995.6 million of its equity securities as discussed further below. Equity Repurchase Program On October 30, 2013, the Company’s Board of Directors (the “Board”) approved an equity repurchase program (the “Repurchase Program”) authorizing the repurchase of up to $125.0 million of either the Company’s common stock or vested in-the-money employee stock options, or a combination thereof. During 2015, the Board increased the share repurchase authorization under the Repurchase Program by $600.0 million which increased the total amount that has been authorized under the Repurchase Program to $725.0 million. The Repurchase Program does not obligate the Company to repurchase any particular amount of common stock or vested in-the-money employee stock options, and it could be modified, suspended or discontinued at any time. The timing and amount of repurchases are determined by the Company’s management based on a variety of factors such as the market price of the Company’s common stock, the Company’s corporate requirements, and overall market conditions. Purchases of the Company’s common stock may be made in open market transactions effected through a broker-dealer at prevailing market prices, in block trades, or in privately negotiated transactions. The Company may also repurchase shares of its common stock pursuant to a trading plan meeting the requirements of Rule 10b5-1 under the Exchange Act, which would permit shares of the Company’s common stock to be repurchased when the Company might otherwise be precluded from doing so by law. Repurchases of vested in-the-money employee stock options were made through transactions between the Company and its employees (other than its executive officers, who were not eligible to participate in the program), and this aspect of the Repurchase Program expired in November 2013. The Repurchase Program for common stock does not have an end date. Below is a summary of the share repurchases made under the Repurchase Program (in thousands except share data): Year Ended December 31, 2015 2014 2013 Number of shares repurchased 7,855,796 300 153,223 Aggregate purchase price $ 515,010 $ 14 $ 6,434 Average price per share $ 65.56 $ 47.51 $ 42.01 In addition, in 2013, the Company repurchased 2.0 million of vested in-the-money employee stock options at fair value for an aggregate purchase price of $59.1 million (representing an average market price per share of $43.42 and an average exercise price per option of $13.74). As of December 31, 2015, the Company has remaining authorization under the Repurchase Program to repurchase up to $144.5 million of its common stock. Other Equity Repurchases On May 28, 2014, the Company completed the repurchase of 3,287,209 shares of its common stock for $50.23 per share from TPG Quintiles Holdco, L.P., one of its existing shareholders, in a private transaction for an aggregate purchase price of approximately $165.1 million. The repurchase price per share of common stock was equal to 98% of the closing market price of the Company’s common stock on the NYSE on May 27, 2014 (which was $51.26). The repurchase of shares from its existing shareholder was authorized in compliance with the Company’s related party transactions approval policy. The Company funded this private repurchase transaction with cash on hand. This private repurchase transaction was separate from and in addition to the Repurchase Program. On November 10, 2014, the Company completed the repurchase of 4,303,666 shares of its common stock for $58.09 per share, which was the price per share the underwriter paid to selling shareholders, for an aggregate purchase price of approximately $250.0 million. The Company funded this repurchase transaction with a combination of cash on hand and a $150.0 million draw on its revolving credit facility. This repurchase transaction was separate from and in addition to the Repurchase Program. Noncontrolling Interests As discussed further in Note 14, the Company’s contribution of its businesses to the joint venture was recorded at book value (carryover basis) because the Company maintains control of these businesses. As a result, Quest Diagnostics Incorporated (“Quest”) noncontrolling interest in Q 2

Management Fees

Management Fees	12 Months Ended
	Dec. 31, 2015
Management Fees Disclosure [Abstract]
Management Fees	13. Management Fees In January 2008, pursuant to a management agreement with affiliates of certain of the Company’s shareholders, the Company agreed to pay an annual management service fee of $5.0 million in the aggregate to (i) GF Management Company, LLC (“GFM”); (ii) Bain Capital Partners, LLC; (iii) TPG Capital, LP; (iv) 3i Corporation; (v) Cassia Fund Management Pte Ltd; and (vi) Aisling Capital, LLC (“Aisling Capital”). In 2013, the management agreement was terminated, and the Company paid a $25.0 million fee in connection with the termination. In 2013, the Company expensed $27.7 million in management fees under this agreement.

Business Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Business Combinations	14. Business Combinations Quest Diagnostics Incorporated On July 1, 2015, the Company and Quest closed on a joint venture transaction that resulted in the combination of their respective global clinical trials laboratory operations. The joint venture transaction was effected through the creation of two primary new legal entities that the Company controls. Both the Company’s and Quest’s clinical trials laboratory operations were contributed to these new legal entities. The Company accounted for the contribution of the Quest businesses as a business combination. Quest was issued a 40% equity interest in the legal entities, the fair value of which was $423.3 million (40% of the fair value of all operations contributed by both parties) and represents the purchase price paid by the Company for the clinical trials laboratory operations that Quest contributed to the joint venture transaction. The resulting combined capabilities are designed to provide its customers with globally scaled end-to-end clinical trials laboratory services and the combined business is referred to and marketed as Q 2 2 2 Encore Health Resources On July 1, 2014, the Company completed the acquisition of Encore Health Resources, LLC (“Encore”) effected through a merger for approximately $91.5 million in cash (net of approximately $2.2 million of acquired cash). Encore has operations in the United States, and its business is primarily focused on providing electronic health records (“EHR”) implementation and advisory services to healthcare providers. As part of its Integrated Healthcare Services segment, the Company acquired Encore to enhance its EHR expertise. Novella Clinical Inc. On September 16, 2013, the Company completed the acquisition of Novella Clinical Inc. (“Novella”) through the purchase of 100% of Novella’s outstanding stock for approximately $146.6 million in cash (net of approximately $26.2 million of acquired cash) plus potential annual earn-out payments totaling up to $21.0 million contingent upon the achievement of certain revenue and net new business targets for approximately three years following closing. The Company initially recognized a liability of approximately $14.3 million as the estimated acquisition date fair value of the earn-out. Changes in the fair value of the earn-out subsequent to the acquisition date are recognized in earnings in the period of the change. Novella has operations primarily in the United States and Europe and is a clinical research organization focused primarily on emerging oncology customers as well as those in the medical device and diagnostics sectors. As part of its Product Development segment, the Company acquired Novella to complement its clinical service offerings through its focus on emerging companies and by adding expertise in oncology and medical devices. Accounting for Acquisitions Acquisitions are accounted for as business combinations and, accordingly, the assets acquired and the liabilities assumed have been recorded at their respective estimated fair values as of the acquisition date. The Company accounted for the contribution of the Quest businesses as a business combination and consolidated the related new legal entities in its financial statements with a noncontrolling interest for the portion owned by Quest. The Company recorded goodwill, primarily attributable to assembled workforce and expected synergies. This business combination is part of the Product Development segment and the resulting goodwill is not deductible for income tax purposes. The Company is continuing to evaluate the initial fair value measurement of the assets acquired and liabilities assumed in the Q 2 The following table summarizes the estimated fair value of the net assets acquired at the date of the acquisitions (in thousands): Quest Encore Novella Assets acquired: Cash and cash equivalents $ 31,783 $ 2,223 $ 26,190 Accounts receivable and unbilled services 6,186 17,714 28,644 Prepaid expenses 1,185 — — Other current assets 4,426 443 1,441 Property and equipment 16,422 289 9,616 Goodwill 261,710 62,778 116,542 Other identifiable intangibles 125,900 14,150 42,740 Deferred income tax asset – long-term — 396 — Other long-term assets 266 — 2,203 Liabilities assumed: Accounts payable and accrued expenses (12,790 ) (4,206 ) (12,716 ) Unearned income — (31 ) (7,782 ) Other current liabilities — — (132 ) Deferred income tax liability – long-term (10,412 ) — (18,364 ) Other long-term liabilities (1,408 ) — (1,334 ) Net assets acquired $ 423,268 $ 93,756 $ 187,048 The other identifiable intangible assets consisted of the following (in thousands): Quest Encore Novella Customer relationships $ 74,000 $ 8,800 $ 20,800 Backlog 32,900 800 14,000 Trade names 19,000 1,100 7,500 Non-compete agreements — 450 440 Software — 3,000 — Total other identifiable intangibles $ 125,900 $ 14,150 $ 42,740 Amortized over a weighted average useful life (in years) 9 8 7 The acquired Quest trade name is an indefinite-lived intangible asset that is not amortized.

Restructuring

Restructuring	12 Months Ended
	Dec. 31, 2015
Restructuring And Related Activities [Abstract]
Restructuring	15. Restructuring 2015 Plans In February 2015 , the Board In 2015, the Company has recognized approximately $11.8 million, $8.9 million and $749,000 of restructuring costs related to this plan for activities in the Product Development segment, Integrated Healthcare Services segment and corporate activities, respectively. Also, in connection with consummating the joint venture transaction with Quest, during the third quarter of 2015, a restructuring plan was approved to reduce facility overcapacity and eliminate redundant roles. These actions are expected to continue throughout 2016 and 2017, and are expected to consist of severance, facility closure and other exit-related costs of approximately $14.0 million. During 2015, the Company has recognized approximately $8.7 million of restructuring costs related to this plan for activities in the Product Development segment. 2014 Plans In 2014, the Board approved restructuring plans of approximately $13 million to better align resources with the Company’s strategic direction, which resulted in a reduction of approximately 250 positions. Since the start of these plans in 2014, the Company recognized approximately $11.0 million of restructuring costs related to these plans including reversals. All of the restructuring costs are related to severance and lease costs. Of the $11.0 million in total restructuring costs recognized for these plans, approximately $8.0 million and $3.0 million were related to activities in the Product Development and Integrated Healthcare Services segments, respectively. 2013 Plan In February 2013, the Board approved a restructuring plan of up to $15.0 million to migrate the delivery of services, primarily in the Product Development segment, and to reduce anticipated overcapacity in selected areas, primarily in the Integrated Healthcare Services segment, which resulted in a reduction of approximately 400 positions. Since February 2013, the Company has recognized approximately $13.6 million of restructuring costs related to this plan including reversals. All of the restructuring costs are related to severance costs. Of the $13.6 million in total restructuring costs recognized for this plan, approximately $8.4 million, $4.7 million and $500,000 were related to activities in the Product Development segment, Integrated Healthcare Services segment and corporate activities, respectively. The following amounts were recorded for the restructuring plans (in thousands): Severance and Related Costs Exit Costs Total Balance at December 31, 2013 $ 5,276 $ 198 $ 5,474 Expense, net of reversals 8,421 567 8,988 Payments (7,998 ) (160 ) (8,158 ) Foreign currency translation (221 ) — (221 ) Balance at December 31, 2014 5,478 605 6,083 Expense, net of reversals 29,843 909 30,752 Payments (22,943 ) (723 ) (23,666 ) Foreign currency translation and other (199 ) 594 395 Balance at December 31, 2015 $ 12,179 $ 1,385 $ 13,564 The reversals were due to changes in estimates primarily resulting from the redeployment of staff and higher than expected voluntary terminations. Restructuring costs are not allocated to the Company’s reportable segments as they are not part of the segment performance measures regularly reviewed by management. The Company expects the majority of the restructuring accruals at December 31, 2015 will be paid in 2016 and 2017.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	16. Income Taxes The components of income before income taxes and equity in earnings of unconsolidated affiliates are as follows (in thousands): Year Ended December 31, 2015 2014 2013 Domestic $ 68,455 $ 96,917 $ 68,425 Foreign 470,540 405,272 254,691 $ 538,995 $ 502,189 $ 323,116 The components of income tax expense attributable to continuing operations are as follows (in thousands): Year Ended December 31, 2015 2014 2013 Current expense (benefit): Federal $ 47,311 $ 58,403 $ 38,573 State 3,559 4,618 (4,309 ) Foreign 109,273 95,010 83,744 160,143 158,031 118,008 Deferred (benefit) expense: Federal and state 4,613 (4,549 ) (15,807 ) Foreign (5,767 ) (3,426 ) (6,236 ) (1,154 ) (7,975 ) (22,043 ) $ 158,989 $ 150,056 $ 95,965 The differences between the Company’s consolidated income tax expense attributable to continuing operations and the expense computed at the 35% United States statutory income tax rate were as follows (in thousands): Year Ended December 31, 2015 2014 2013 Federal income tax expense at statutory rate $ 188,648 $ 175,766 $ 113,091 State and local income taxes, net of federal benefit 1,682 2,312 (1,088 ) Research and development (12,634 ) (16,765 ) (12,788 ) Foreign nontaxable interest income (9,351 ) (10,217 ) (9,751 ) Gain on note settlement — — 10,794 United States taxes recorded on foreign earnings 38,246 18,631 (1,616 ) Foreign rate differential (49,288 ) (30,734 ) (10,753 ) Tax contingencies (8,304 ) 4,043 (1,012 ) Other 9,990 7,020 9,088 $ 158,989 $ 150,056 $ 95,965 Prior to June 2013, the Company had not considered the majority of the undistributed earnings of its foreign subsidiaries to be indefinitely reinvested. Management reevaluated this assertion following the IPO, as a portion of the IPO proceeds were used to pay down debt held in the United States as well as the fact the Company does not anticipate paying dividends to shareholders in the foreseeable future, which had been significant in the past. Given the Company’s current debt balance, and related interest expense and the change in approach related to payment of dividends, the Company expects to be able to support the cash needs of the domestic subsidiaries without repatriating cash from the affected foreign subsidiaries. The Company expects to utilize the cash generated outside of the United States to fund growth outside of the United States. As a result of the assertion change, the Company recorded an $8.1 million income tax benefit in the second quarter of 2013 to reverse the deferred income tax liability previously recorded on undistributed foreign earnings prior to 2013 that are now considered indefinitely reinvested outside of the United States. Undistributed earnings of the Company’s foreign subsidiaries amounted to approximately $862.3 million at December 31, 2015. Approximately $283.9 million of this total is not considered to be indefinitely reinvested and would be taxable upon repatriation. The Company has recorded a deferred income tax liability, net of foreign income tax credits that would be generated upon repatriation, of $34.9 million as of December 31, 2015 associated with those earnings based upon the United States federal income tax rate. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to both United States income taxes (subject to an adjustment for foreign tax credits, if available) and withholding taxes payable to the various countries in which the Company’s foreign subsidiaries are located. If the approximately $578.4 million of indefinitely reinvested earnings were repatriated to the United States, it would generate an estimated $94.6 million of additional tax liability for the Company. The income tax effects of temporary differences from continuing operations that give rise to significant portions of deferred income tax (liabilities) assets are presented below (in thousands): December 31, 2015 2014 Deferred income tax liabilities: Undistributed foreign earnings $ (36,624 ) $ (27,717 ) Depreciation and amortization (53,171 ) (65,614 ) Other (11,830 ) (15,346 ) Total deferred income tax liabilities (101,625 ) (108,677 ) Deferred income tax assets: Net operating loss, capital loss and tax credit carryforwards 41,707 43,535 Accrued expenses and unearned income 23,315 34,048 Employee benefits 123,775 130,217 Other 12,801 17,784 201,598 225,584 Valuation allowance for deferred income tax assets (22,162 ) (24,695 ) Total deferred income tax assets 179,436 200,889 Net deferred income tax assets $ 77,811 $ 92,212 The Company has net operating loss and capital loss carryforwards of approximately $44.9 million in various entities within the United Kingdom which have no expiration date and has $40.7 million of net operating loss and capital loss carryforwards from various foreign jurisdictions which have different expiration periods. The Company has United States net operating loss carryforwards of $16.6 million, which were obtained through the acquisitions of Novella, Expression Analysis, Inc., and Advion BioSciences, Inc. in 2013, 2012, and 2011, respectively, and expire through 2023. These losses are subject to IRC Section 382 limitations; however, management expects all losses to be utilized during the carryforward periods. In addition, the Company has approximately $44.0 million of United States state operating loss carryforwards which expire through 2035. In 2015, the Company decreased its valuation allowance $2.5 million to $22.2 million at December 31, 2015 from $24.7 million at December 31, 2014. The valuation allowance is primarily related to loss carryforwards in various foreign and state jurisdictions. A reconciliation of the beginning and ending amount of gross unrecognized income tax benefits is presented below (in thousands): Year Ended December 31, 2015 2014 2013 Balance at January 1 $ 40,821 $ 54,936 $ 43,393 Additions based on tax positions related to the current year 2,068 2,807 4,493 Additions for income tax positions of prior years 8,838 1,588 12,854 Impact of changes in exchange rates (608 ) (376 ) (71 ) Settlements with tax authorities (121 ) (135 ) (1,052 ) Reductions for income tax positions of prior years (1,945 ) (6,023 ) (3,520 ) Reductions due to the lapse of the applicable statute of limitations (19,387 ) (11,976 ) (1,161 ) Balance at December 31 $ 29,666 $ 40,821 $ 54,936 As of December 31, 2015, the Company had total gross unrecognized income tax benefits of $29.7 million associated with over 50 jurisdictions in which the Company conducts business. This amount includes $29.3 million of unrecognized benefits that, if recognized, would reduce the Company’s effective income tax rate. This amount excludes $2.9 million of accrued interest and penalties. The Company’s policy for recording interest and penalties relating to uncertain income tax positions is to record them as a component of income tax expense in the accompanying consolidated statements of income. In 2015, 2014 and 2013, the amount of interest and penalties recorded as a (reduction)/addition to income tax expense in the accompanying consolidated statements of income was ($2.0) million, $1.3 million and $843,000, respectively. As of December 31, 2015 and 2014, the Company accrued approximately $2.9 million and $4.8 million, respectively, of interest and penalties. The Company believes that it is reasonably possible that a decrease of up to $8.1 million in gross unrecognized income tax benefits for federal, state and foreign exposure items may be necessary within the next 12 months due to lapse of statutes of limitations or uncertain tax positions being effectively settled. The Company believes that it is reasonably possible that a decrease of up to $160,000 in gross unrecognized benefits for foreign items may be necessary within the next 12 months due to payments. For the remaining uncertain income tax positions, it is difficult at this time to estimate the timing of the resolution. The Company conducts business globally and, as a result, files income tax returns in the United States federal jurisdiction and various state and foreign jurisdictions. In the normal course of business, the Company is subject to examination by taxing authorities throughout the world. The following table summarizes the tax years that remain open for examination by tax authorities in the most significant jurisdictions in which the Company operates: United States 2012-2014 India 2006-2015 Japan 2010-2014 United Kingdom 2014 In certain of the jurisdictions noted above, the Company operates through more than one legal entity, each of which has different open years subject to examination. The table above presents the open years subject to examination for the most material of the legal entities in each jurisdiction. Additionally, it is important to note that tax years are technically not closed until the statute of limitations in each jurisdiction expires. In the jurisdictions noted above, the statute of limitations can extend beyond the open years subject to examination. Due to the geographic breadth of the Company’s operations, numerous tax audits may be ongoing throughout the world at any point in time. Income tax liabilities are recorded based on estimates of additional income taxes which will be due upon the conclusion of these audits. Estimates of these income tax liabilities are made based upon prior experience and are updated in light of changes in facts and circumstances. However, due to the uncertain and complex application of income tax regulations, it is possible that the ultimate resolution of audits may result in liabilities which could be materially different from these estimates. In such an event, the Company will record additional income tax expense or income tax benefit in the period in which such resolution occurs. The Company had a tax holiday for Quintiles East Asia Pte. Ltd. in Singapore through June 2015, provided the Company maintains specific levels of spending and employment. The income tax benefit of this holiday was approximately $2.0 million, $2.4 million and $798,000 in 2015, 2014 and 2013, respectively. The Company also had a tax holiday for Outcome Europe Sarl in Switzerland for 2013. The income tax benefit of this holiday was approximately $64,000 in 2013. The tax holiday in 2015 and 2014 increased earnings per share by approximately $0.02. The tax holidays in 2013 did not have a notable impact on earnings per share.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2015
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plans	17. Employee Benefit Plans The Company has numerous employee retirement benefit plans, which cover substantially all eligible employees in the countries where the plans are offered either voluntarily or statutorily. Contributions are primarily discretionary, except in some countries where contributions are contractually required. Defined Contribution Plans Defined contribution or profit sharing style plans are offered in Austria, Belgium, Bulgaria, Canada, the Czech Republic, Denmark, Finland, France, Germany, Hungary, India, Ireland, Israel, Malaysia, the Netherlands, Poland, Slovakia, South Africa, Sweden, Switzerland, Thailand, the United States and the United Kingdom. In some cases these plans are required by local laws or regulations. In the United States, the Company has a 401(k) Plan under which the Company matches employee deferrals at varying percentages, set at the discretion of the Board. In 2015, 2014 and 2013, the Company expensed $36.3 million, $31.2 million and $26.1 million, respectively, related to matching contributions. Defined Benefit Plans Defined benefit plans are offered in Austria, France, Germany, Greece, India, Indonesia, Israel, Japan, Mexico, Philippines, Poland, Turkey and the United Kingdom. The following table summarizes the components of pension expense related to these defined benefit plans (in thousands): Year Ended December 31, 2015 2014 2013 Service cost $ 15,486 $ 12,944 $ 13,227 Interest cost 3,453 3,821 3,684 Expected return on plan assets (3,555 ) (4,277 ) (3,442 ) Amortization of prior service costs — 107 336 Amortization of actuarial losses 973 636 708 $ 16,357 $ 13,231 $ 14,513 The Company expects to recognize approximately $870,000 in its pension expense in 2016 related to the amortization of net actuarial losses. The weighted average assumptions used in determining pension expense were as follows: Year Ended December 31, 2015 2014 2013 Discount rate 2.46 % 3.01 % 3.06 % Rate of compensation increases 4.32 % 4.36 % 4.74 % Expected return on plan assets 4.05 % 5.21 % 5.33 % The following table summarizes financial information about the Company’s defined benefit plans (in thousands): December 31, 2015 2014 Projected benefit obligation January 1 $ 147,127 $ 135,110 Service costs 15,486 12,944 Interest cost 3,453 3,821 Expected return on plan assets (3,555 ) (4,277 ) Actuarial (gains) losses (2,306 ) 16,396 Business combination 1,746 — Benefits paid (6,325 ) (7,409 ) Foreign currency fluctuations and other (1,732 ) (9,458 ) Projected benefit obligation December 31 $ 153,894 $ 147,127 Plan assets at fair value, January 1 $ 88,420 $ 82,787 Actual return on plan assets 1,312 10,004 Contributions 5,982 8,594 Business combination 1,966 — Benefits paid (6,325 ) (7,409 ) Foreign currency fluctuations and other (4,212 ) (5,556 ) Plan assets at fair value, December 31 $ 87,143 $ 88,420 Unfunded balance $ 66,751 $ 58,707 The accumulated benefit obligation for all defined benefit plans was approximately $139.1 million and $127.9 million as of December 31, 2015 and 2014, respectively. As of December 31, 2015, the projected benefit obligation and accumulated benefit obligation for the defined benefit plans with accumulated benefit obligations in excess of plan assets were $94.6 million and $82.9 million, respectively, and were primarily related to unfunded plans. As of December 31, 2014, the projected benefit obligation and accumulated benefit obligation for the defined benefit plans with accumulated benefit obligations in excess of plan assets were $83.4 million and $66.4 million, respectively, and were primarily related to unfunded plans. As of December 31, 2015 and 2014, the projected benefit obligation exceeded the fair value of the plan assets for each defined benefit plan except for the defined benefit plans in the United Kingdom. The following table summarizes the amounts recognized in the consolidated balance sheets related to the defined benefit plans (in thousands): December 31, 2015 2014 Deposits and other assets $ 19,185 $ 18,690 Accrued expenses 4,520 6,075 Other long-term liabilities 81,410 71,322 AOCI $ (13,264 ) $ (14,519 ) The following table summarizes the amounts recognized in AOCI related to the defined benefit plans (in thousands): Prior Actuarial Deferred Service Net Income Costs (Gain) Loss Taxes Total Balance as of December 31, 2013 $ (107 ) $ (4,937 ) $ 2,956 $ (2,088 ) Reclassification adjustments included in pension expense: Amortization 107 636 (275 ) 468 Amounts arising during the period: Actuarial changes in benefit obligation — (10,218 ) 2,981 (7,237 ) Balance as of December 31, 2014 — (14,519 ) 5,662 (8,857 ) Reclassification adjustments included in pension expense: Amortization — 973 (355 ) 618 Amounts arising during the period: Actuarial changes in benefit obligation — 282 (318 ) (36 ) Balance as of December 31, 2015 $ — $ (13,264 ) $ 4,989 $ (8,275 ) The following table summarizes the weighted average assumptions used in determining the pension obligations: December 31, 2015 2014 Discount rate 2.50 % 2.46 % Rate of compensation increases 4.37 % 4.32 % The discount rate represents the interest rate used to determine the present value of the future cash flows currently expected to be required to settle the Company’s defined benefit plan obligations. The discount rates are derived using weighted average yield curves on AA-rated corporate bonds. The cash flows from the Company’s expected benefit obligation payments are then matched to the yield curve to derive the discount rates. The Company’s assumption for the expected return on plan assets was determined by the weighted average of the long-term expected rate of return on each of the asset classes invested as of the balance sheet date. For plan assets invested in government bonds, the expected return was based on the yields on the relevant indices as of the balance sheet date. There is considerable uncertainty for the expected return on plan assets invested in equity and diversified growth funds. The expected return on these plan assets was based on the expected return on long-term fixed interest rate government bonds as of the balance sheet date with a premium of 3% to 5% added to reflect the expected long-term returns expected from these types of investments. The investment objective for defined benefit plan assets is to meet the plan’s benefit obligations and maintaining adequate funding, while minimizing the potential for future required Company contributions. The defined benefit plans in the United Kingdom, India and Israel are funded. The plan assets of the defined benefit plans in India and Israel are held in a fund which holds debt investments, primarily government bonds in accordance with local laws and regulations. The plan assets of the defined benefit plan in the United Kingdom, which are held in a trust, are primarily held in funds which hold investments in government bonds, equity investments and diversified growth funds. The equity investments are diversified to include domestic (United Kingdom) and global equity investments. A “horizon based” approach is used to determine the asset allocation. Funds intended to meet the plan’s benefit obligation payments in a horizon period are invested in low risk assets such as bond investments. Funds intended to meet the plan’s benefit obligation payments outside of the horizon period are invested in more volatile assets which are expected to provide a higher return such as equity investments and diversified growth funds. The target allocation percentage for 2016 is approximately 45-55% in bond investments, 25-35% in equity investments and 15-25% in diversified growth funds. However, the trustees may reallocate the plan assets between equity investments and bond investments depending upon the actual investment performances. The Company’s plan assets have been identified within the fair value hierarchy as Level 2. Funds are valued using the net asset value reported by the managers of the funds. The following table summarizes the fair value of the Company’s defined benefit plans assets (in thousands): December 31, 2015 2014 Funds that hold debt investments primarily government bonds $ 49,355 $ 47,473 Funds that hold United Kingdom equity investments 15,700 19,547 Funds that hold global equity investments 6,277 8,255 Diversified growth fund 15,248 12,569 Other 563 576 Total $ 87,143 $ 88,420 The Company estimates that it will make contributions totaling approximately $5.5 million to the defined benefit plans in 2016. The following table summarizes the Company’s expected benefit payments under the defined benefit plans for each of the next five years and the aggregate of the five years thereafter (in thousands): 2016 $ 6,684 2017 6,615 2018 7,096 2019 7,802 2020 9,092 Years 2021 through 2025 66,117 $ 103,406 Stock Incentive Plans The stock incentive plans provide incentives to eligible employees, officers and directors in the form of non-qualified stock options, incentive stock options, SARs, restricted stock, RSUs, performance shares, performance units, covered annual incentive awards, cash-based awards and other share-based awards, in each case subject to the terms of the stock incentive plans. As of December 31, 2015, there were 7,372,127 shares available for future grants under the stock incentive plans. The following assumptions were used to estimate the fair value of stock options and SARs: Year Ended December 31, 2015 2014 2013 Expected volatility 26 – 41% 26 – 43% 18 – 47% Weighted average expected volatility 34% 36% 40% Expected dividends 0.0% 0.0% 0.0 - 5.45% Expected term (in years) 3.7 – 6.7 1.5 – 6.7 0.25 – 6.4 Risk-free interest rate 1.06 – 2.04% 0.28 – 2.21% 0.04 – 2.24% Stock Options The option price is determined by the Board at the date of grant and the options expire 10 years from the date of grant. The vesting schedule for options granted to employees is either (i) 20% per year beginning on the first anniversary of the date of grant; (ii) 25% per year beginning on the first anniversary of the date of grant; or (iii) 33% on the third anniversary of the date of grant and 67% on the fourth anniversary of the date of grant. Options granted to our non-employee directors vest either (i) 100% on the first anniversary of the date of grant; or (ii) 34% on the first anniversary of the date of grant and 33% on the second and third anniversaries of the date of grant. The Company’s stock option activity in 2015 is as follows: Weighted Number Average Aggregate of Exercise Intrinsic Options Price Value (in thousands) Outstanding at December 31, 2014 9,124,954 $ 29.15 $ 271,216 Granted 993,600 $ 65.05 Exercised (3,013,190 ) $ 19.41 Canceled (457,365 ) $ 42.08 Outstanding at December 31, 2015 6,647,999 $ 38.04 $ 203,679 The weighted average fair value per share of the options granted in 2015, 2014 and 2013 was $21.96, $18.72 and $14.39, respectively. The total intrinsic value of options exercised was approximately $143.7 million, $77.3 million and $27.1 million in 2015, 2014 and 2013, respectively. The Company received cash of approximately $58.5 million, $33.1 million and $12.5 million in 2015, 2014 and 2013, respectively, from options exercised. Selected information regarding the Company’s stock options as of December 31, 2015 is as follows: Options Outstanding Options Exercisable Weighted Weighted Average Weighted Number Exercise Average Remaining Number Average of Price Exercise Life of Exercise Options Range Price (in Years) Options Price 1,063,999 $ 5.76 - $ 21.69 $ 17.58 4.19 947,799 $ 17.14 1,069,630 $ 22.01 - $ 23.83 $ 23.79 6.32 661,630 $ 23.79 867,197 $ 24.59 - $ 30.07 $ 25.07 6.30 545,947 $ 24.97 1,241,087 $ 40.00 - $ 40.00 $ 40.00 7.10 421,837 $ 40.00 1,208,586 $ 42.74 - $ 53.26 $ 50.76 8.00 261,334 $ 50.30 1,197,500 $ 57.00 - $ 77.11 $ 63.44 8.87 58,375 $ 57.43 The weighted average remaining contractual life of the options outstanding and exercisable as of December 31, 2015 is 6.89 years and 5.90 years, respectively. The total aggregate intrinsic value of the exercisable stock options and the stock options expected to vest as of December 31, 2015 was approximately $201.0 million. Stock Appreciation Rights The Company’s SARs require the Company to settle in cash an amount equal to the difference between the fair value of the Company’s common stock on the date of exercise and the grant price, multiplied by the number of SARs being exercised. These awards either (i) vest 25% per year or (ii) vest 33% on the third anniversary of the date of grant and 67% on the fourth anniversary of the date of grant. The Company’s SAR activity in 2015 is as follows: Weighted Number Average Aggregate of Grant Intrinsic SARs Price Value (in thousands) Outstanding at December 31, 2014 418,801 $ 43.55 $ 6,417 Granted 176,200 $ 64.93 Exercised (33,262 ) $ 39.61 Canceled (31,038 ) $ 51.00 Outstanding at December 31, 2015 530,701 $ 50.46 $ 9,659 As of December 31, 2015, 2014 and 2013, the weighted average fair value per share of the SARs granted was $29.79, $27.17 and $19.07, respectively. The Company paid approximately $967,000, $408,000 and $83,000 to settle exercised SARs in 2015, 2014 and 2013, respectively. The weighted average remaining contractual life of the SARs outstanding and exercisable as of December 31, 2015 is 8.1 years and 7.4 years, respectively. The total aggregate intrinsic value of the exercisable SARs and the SARs expected to vest as of December 31, 2015 was approximately $9.5 million. Restricted Stock Units The Company’s RSUs will settle in shares of the Company’s common stock within 45 days of the applicable vesting date. RSUs granted to employees vest either (i) 25% per year beginning on the first anniversary of the date of grant; or (ii) 33% on the third anniversary of the date of grant and 67% on the fourth anniversary of the date of grant. RSUs granted to our non-employee directors vest either (i) 100% on the first anniversary of the date of grant; or (ii) 34% on the first anniversary of the date of grant and 33% on the second and third anniversaries of the date of grant. The Company’s RSU activity in 2015 is as follows: Weighted Average Number Grant-Date of Fair RSUs Value Non-vested at December 31, 2014 93,667 $ 45.89 Granted 276,922 $ 65.61 Vested (918 ) $ 47.87 Canceled (10,118 ) $ 62.77 Non-vested at December 31, 2015 359,553 $ 60.60 As of December 31, 2015, there are 359,553 RSUs outstanding with an intrinsic value of approximately $24.7 million. Performance Units In March 2015, the Company awarded performance units that contain both service and performance based vesting criteria. Vesting occurs if the recipient remains employed and depends on the degree to which the Company achieves certain cumulative adjusted diluted earnings per share goals during a three-year performance period (as defined in the award agreements). The fair value of these awards is equal to the closing price of the Company’s common stock on the grant date. The Company’s performance units activity in 2015 is as follows: Weighted Number Average of Grant-Date Performance Fair Units Value Non-vested at December 31, 2014 — $ — Granted 51,977 $ 64.93 Canceled (2,310 ) $ 64.93 Non-vested at December 31, 2015 49,667 $ 64.93 As of December 31, 2015, there are 49,667 performance units outstanding with an intrinsic value of approximately $3.4 million. Employee Stock Purchase Plan The Company sponsors an Employee Stock Purchase Plan (“ESPP”) which allows eligible employees to authorize payroll deductions of up to 10% of their base salary to be applied toward the purchase of full shares of the Company’s common stock on the last day of the offering period. Offering periods under the ESPP are six months in duration. The first two offering periods for the ESPP began March 1, 2014 and September 1, 2014, respectively. In November 2014, the ESPP was amended to change the start of the offering periods to begin on April 1 and October 1 of each year, beginning April 1, 2015. Participating employees purchase shares on the last day of each offering period at a discount of 15% of the closing price of the common stock on such date as reported on the NYSE. The aggregate number of shares of the Company’s common stock that may be issued under the ESPP may not exceed 2,500,000 shares and no one employee may purchase any shares under the ESPP having a collective fair market value greater than $25,000 in any one calendar year. The shares available for purchase under the ESPP will be drawn from authorized but unissued shares of common stock. During 2015 and 2014, the Company issued 90,079 shares and 46,032 shares, respectively, of common stock for purchases under the ESPP. Other The Company sponsors a supplemental non-qualified deferred compensation plan, covering certain management employees, and maintains other statutory indemnity plans as required by local laws or regulations. As of December 31, 2015 and 2014, the Company had a severance accrual included in accrued expenses on the accompanying consolidated balance sheets of $3.3 million and $6.3 million, respectively. The Company recognizes obligations associated with severance related to contractual termination benefits at fair value on the date that it is probable that the affected employees will be entitled to the benefit and the amount can reasonably be estimated. The severance accrual is related to cost reduction programs that will result in severance for approximately 270 positions, which are expected to lower operating costs and improve profitability. In 2015, the Company recognized approximately $1.0 million of net reversals related to these cost reduction programs, primarily as a result of affected individuals transferring into other positions within the Company. Of the $1.0 million decrease from net reversals recognized for these cost reduction programs, approximately $837,000 and $205,000 were related to activities in the Product Development segment and Integrated Healthcare Services segment, respectively. The Company expects the majority of the severance accrual at December 31, 2015 will be paid in 2016. The following amounts were recorded for the severance associated with cost reduction programs (in thousands): Balance at December 31, 2014 $ 6,274 Expense, net of reversals (1,042 ) Payments (1,873 ) Foreign currency translation (22 ) Balance at December 31, 2015 $ 3,337

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	18. Related Party Transactions As the Company has done in prior years, the Company reimbursed its former Executive Chairman, who retired effective December 31, 2015 but remains a director of the Company, for business-related travel services he provided for himself and other Company employees with the use of his own airplane. In 2015, 2014 and 2013, the Company expensed approximately $1.3 million, $1.8 million and $2.7 million, respectively, for such business-related travel expenses. In the second quarter of 2013, the Company paid a $1.5 million fee in connection with the modification of the agreement for the business usage of the airplane that limited reimbursements to $2.5 million per year. The Company’s reimbursement obligations terminated effective December 31, 2015 in connection with its former Executive Chairman’s retirement. In January 2010, the Company entered into a collaboration agreement with a related party, HUYA Bioscience International, LLC (“HUYA”), to fund up to $2.3 million of its research and development activity for a specific compound. Under the agreement, the Company had the potential to receive additional consideration which contractually would not exceed $16.5 million excluding interest if certain events had occurred. In February 2015, the Company and HUYA agreed to terminate the collaboration agreement. In connection with the termination, HUYA paid the Company $5.0 million to satisfy all of HUYA’s various payment obligations under the collaboration agreement. During 2015, 2014 and 2013, the Company entered into a number of contracts with HUYA, primarily in Asia, in which the Company will provide up to approximately $31.7 million, $416,000 and $19.2 million, respectively, of services on a fee for services basis at arm’s length and at market rates. In 2015, 2014 and 2013, the Company provided approximately $6.9 million, $2.3 million and $772,000, respectively, of services under these agreements. During 2014, HUYA subleased office space in Japan from the Company. The nine month sublease ended in September 2014 and the Company recognized $76,000 in sublease income during 2014. The Company has entered into other transactions with related parties including investments in and advances to unconsolidated affiliates which are discussed in Note 4 and management fees which are discussed in Note 13.

Operations by Geographic Locati

Operations by Geographic Location	12 Months Ended
	Dec. 31, 2015
Operations By Geographic Location [Abstract]
Operations by Geographic Location	19. Operations by Geographic Location The table below presents the Company’s operations by geographical location. The Company attributes revenues to geographical locations based upon where the services are performed. The Company’s operations within each geographical region are further broken down to show each country which accounts for 10% or more of the totals (in thousands): Year Ended December 31, 2015 2014 2013 Service revenues: Americas: United States $ 1,787,918 $ 1,589,402 $ 1,351,160 Other 185,583 194,597 181,814 Americas 1,973,501 1,783,999 1,532,974 Europe and Africa: United Kingdom 409,920 402,184 362,242 Other 1,050,070 1,121,354 1,139,262 Europe and Africa 1,459,990 1,523,538 1,501,504 Asia-Pacific: Japan 442,957 471,831 438,882 Other 449,971 386,454 334,980 Asia-Pacific 892,928 858,285 773,862 Total service revenues 4,326,419 4,165,822 3,808,340 Reimbursed expenses 1,411,200 1,294,176 1,291,205 Total revenues $ 5,737,619 $ 5,459,998 $ 5,099,545 As of December 31, 2015 2014 Property, equipment and software, net: Americas: United States $ 169,674 $ 167,890 Other 1,204 1,774 Americas 170,878 169,664 Europe and Africa: United Kingdom 46,042 48,409 Other 16,615 15,782 Europe and Africa 62,657 64,191 Asia-Pacific: Japan 12,660 20,752 Other 24,975 25,271 Asia-Pacific 37,635 46,023 Total property, equipment and software, net $ 271,170 $ 279,878

Segments

Segments	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Segments	20. Segments The following table presents the Company’s operations by reportable segment. The Company is managed through two reportable segments, Product Development and Integrated Healthcare Services. Product Development, which primarily serves biopharmaceutical customers engaged in research and development, provides clinical research and clinical trial services. Integrated Healthcare Services provides commercialization services to biopharmaceutical customers and research, analytics, real-world and late phase research, and other services to both biopharmaceutical customers and the broader healthcare market. Certain costs are not allocated to the Company’s segments and are reported as general corporate and unallocated expenses. These costs primarily consist of share-based compensation and expenses for corporate overhead functions such as finance, human resources, information technology, facilities and legal, as well as certain expenses incurred during 2013, including the $25.0 million fee incurred in connection with the termination of the management agreement with affiliates of certain shareholders and the $1.5 million fee paid in connection with the modification of an agreement for the business usage of an airplane owned by GFM, a company owned by the Company’s former Executive Chairman who retired effective December 31, 2015 but remains a director of the Company. The Company does not allocate restructuring or impairment charges to its segments. Information presented below is in thousands: Year Ended December 31, 2015 2014 2013 Service revenues Product Development $ 3,191,630 $ 3,097,831 $ 2,919,730 Integrated Healthcare Services 1,134,789 1,067,991 888,610 Total service revenues 4,326,419 4,165,822 3,808,340 Costs of revenue, service costs Product Development 1,828,734 1,820,937 1,752,800 Integrated Healthcare Services 896,852 863,169 718,626 Total costs of revenue, service costs 2,725,586 2,684,106 2,471,426 Selling, general and administrative Product Development 648,297 631,678 604,663 Integrated Healthcare Services 153,896 140,019 127,860 General corporate and unallocated 118,792 110,641 127,987 Total selling, general and administrative 920,985 882,338 860,510 Income from operations Product Development 714,599 645,216 562,267 Integrated Healthcare Services 84,041 64,803 42,124 General corporate and unallocated (118,792 ) (110,641 ) (127,987 ) Restructuring costs (30,752 ) (8,988 ) (14,071 ) Impairment charges (2,484 ) — — Total income from operations $ 646,612 $ 590,390 $ 462,333 As of December 31, 2015 2014 2013 Assets Product Development $ 3,343,502 $ 2,786,692 $ 2,571,502 Integrated Healthcare Services 405,411 330,689 299,284 General corporate and unallocated 177,403 178,572 183,437 Total assets $ 3,926,316 $ 3,295,953 $ 3,054,223 Year Ended December 31, 2015 2014 2013 Expenditures to acquire long-lived assets Product Development $ 67,660 $ 68,187 $ 69,375 Integrated Healthcare Services 8,667 8,279 17,398 General corporate and unallocated 2,064 6,184 1,574 Total expenditures to acquire long-lived assets $ 78,391 $ 82,650 $ 88,347 Year Ended December 31, 2015 2014 2013 Depreciation and amortization expense Product Development $ 100,913 $ 95,168 $ 82,047 Integrated Healthcare Services 21,961 20,821 20,475 General corporate and unallocated 4,868 5,024 4,982 Total depreciation and amortization expense $ 127,742 $ 121,013 $ 107,504

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share	21. Earnings Per Share The following table reconciles the basic to diluted weighted average shares outstanding (in thousands): Year Ended December 31, 2015 2014 2013 Basic weighted average common shares outstanding 123,038 127,994 124,147 Effect of dilutive stock options and share awards 2,592 3,089 3,715 Diluted weighted average common shares outstanding 125,630 131,083 127,862 The following table shows the weighted average number of outstanding share-based awards not included in the computation of diluted earnings per share as the effect of including such share-based awards in the computation would be anti-dilutive (in thousands): Year Ended December 31, 2015 2014 2013 Weighted average shares subject to anti-dilutive share-based awards 1,058 1,241 1,765 Share-based awards will have a dilutive effect under the treasury method only when the respective period’s average market value of the Company’s common stock exceeds the exercise proceeds.

Comprehensive Income

Comprehensive Income	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Comprehensive Income	22. Comprehensive Income Below is a summary of the components of AOCI (in thousands): Foreign Currency Translation Marketable Securities Derivative Instruments Defined Benefit Plans Income Taxes Total Balance at December 31, 2012 $ 19,312 $ 467 $ (33,542 ) $ (8,235 ) $ 29,693 $ 7,695 Other comprehensive (loss) income before reclassifications (25,141 ) 5,241 (393 ) 2,147 1,331 (16,815 ) Reclassification adjustments — — 13,080 1,044 (5,380 ) 8,744 Balance at December 31, 2013 (5,829 ) 5,708 (20,855 ) (5,044 ) 25,644 (376 ) Other comprehensive (loss) income before reclassifications (49,911 ) (976 ) (6,834 ) (10,218 ) 7,225 (60,714 ) Reclassification adjustments — (5,004 ) 8,630 743 (2,370 ) 1,999 Balance at December 31, 2014 (55,740 ) (272 ) (19,059 ) (14,519 ) 30,499 (59,091 ) Other comprehensive (loss) income before reclassifications (61,090 ) (436 ) (13,202 ) 282 9,110 (65,336 ) Reclassification adjustments — — 18,269 973 (6,181 ) 13,061 Balance at December 31, 2015 $ (116,830 ) $ (708 ) $ (13,992 ) $ (13,264 ) $ 33,428 $ (111,366 ) Below is a summary of the (gains) losses reclassified from AOCI into the consolidated statements of income and the affected financial statement line item (in thousands): Affected Financial Statement Year Ended December 31, Reclassification Adjustments Line Item 2015 2014 2013 Marketable securities Other expense (income), net $ — $ (5,004 ) $ — Total before income taxes — (5,004 ) — Income tax expense — (1,927 ) — Total net of income taxes $ — $ (3,077 ) $ — Derivative instruments: Interest rate swaps Interest expense $ 12,333 $ 12,424 $ 12,582 Foreign exchange forward contracts Service revenues 5,936 (3,794 ) 498 Total before income taxes 18,269 8,630 13,080 Income tax benefit 5,826 4,022 4,991 Total net of income taxes $ 12,443 $ 4,608 $ 8,089 Defined benefit plans: Amortization of prior service costs See Note 17 $ — $ 107 $ 336 Amortization of actuarial losses See Note 17 973 636 708 Total before income taxes 973 743 1,044 Income tax benefit 355 275 389 Total net of income taxes $ 618 $ 468 $ 655

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	23. Supplemental Cash Flow Information The following table presents the Company’s supplemental cash flow information (in thousands): Year Ended December 31, 2015 2014 2013 Supplemental Cash Flow Information: Interest paid $ 82,333 $ 93,912 $ 115,494 Income taxes paid, net of refunds 120,804 138,931 70,983 Non-cash Investing Activities: Acquisition of property and equipment utilizing capital leases $ 4,238 $ 2,476 $ 3,761 Fair value of contingent consideration payable in connection with acquisitions — — 14,300 Fair value of consideration transferred in connection with the Q 2 423,268 — —

Quarterly Financial Data (Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (Unaudited)	24. Quarterly Financial Data (Unaudited) The following table summarizes the Company’s unaudited quarterly results of operations (in thousands, except per share data): 2015 First Quarter Second Quarter Third Quarter Fourth Quarter Service revenues $ 1,029,974 $ 1,074,366 $ 1,093,480 $ 1,128,599 Income from operations 143,217 158,389 167,023 177,983 Net income 86,431 84,947 108,839 108,087 Net (income) loss attributable to noncontrolling interests (33 ) 4 2,447 (3,517 ) Net income attributable to Quintiles Transnational Holdings Inc. $ 86,398 $ 84,951 $ 111,286 $ 104,570 Basic earnings per share (1) $ 0.69 $ 0.69 $ 0.91 $ 0.86 Diluted earnings per share (1) $ 0.68 $ 0.67 $ 0.89 $ 0.85 2014 First Quarter Second Quarter Third Quarter Fourth Quarter Service revenues $ 1,005,288 $ 1,035,476 $ 1,061,013 $ 1,064,045 Income from operations 141,316 141,000 149,142 158,932 Net income 90,214 85,110 92,733 88,444 Net (income) loss attributable to noncontrolling interests (31 ) 10 (79 ) (18 ) Net income attributable to Quintiles Transnational Holdings Inc. $ 90,183 $ 85,120 $ 92,654 $ 88,426 Basic earnings per share (1) $ 0.69 $ 0.66 $ 0.73 $ 0.70 Diluted earnings per share (1) $ 0.68 $ 0.64 $ 0.71 $ 0.69 (1) The sum of the quarterly per share amounts may not equal per share amounts reported for year-to-date periods. This is due to changes in the number of weighted average shares outstanding and the effects of rounding for each period.

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Event	25. Subsequent Event In February 2016, the Board approved a restructuring plan for approximately $22 million, primarily for severance and other exit costs, to align its resources and reduce overcapacity. Some of these actions are subject to certain legal and regulatory requirements. These actions, if implemented, are expected to occur in 2016.

Schedule I - Condensed Financia

Schedule I - Condensed Financial Information of Registrant	12 Months Ended
	Dec. 31, 2015
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Schedule I - Condensed Financial Information of Registrant	(2) Financial Statement Schedules Schedule I—Condensed Financial Information of Registrant QUINTILES TRANSNATIONAL HOLDINGS INC. (PARENT COMPANY ONLY) CONDENSED STATEMENTS OF INCOME Year Ended December 31, 2015 2014 2013 (in thousands) Selling, general and administrative $ 715 $ 1,509 $ 2 Loss from operations (715 ) (1,509 ) (2 ) Interest income (24 ) (52 ) (6 ) Interest expense — — 9,242 Loss on extinguishment of debt — — 15,501 Other expense, net 7 8 — Loss before income taxes and equity in earnings of subsidiary (698 ) (1,465 ) (24,739 ) Income tax benefit (530 ) (810 ) (9,347 ) Loss before equity in earnings of subsidiary (168 ) (655 ) (15,392 ) Equity in earnings of subsidiary 387,373 357,038 241,983 Net income $ 387,205 $ 356,383 $ 226,591 QUINTILES TRANSNATIONAL HOLDINGS INC. (PARENT COMPANY ONLY) CONDENSED STATEMENTS OF COMPREHENSIVE INCOME Year Ended December 31, 2015 2014 2013 (in thousands) Net income $ 387,205 $ 356,383 $ 226,591 Comprehensive income adjustments: Unrealized (losses) gains on marketable securities, net of income taxes of ($168), ($376) and $2,016 (268 ) (600 ) 3,225 Unrealized (losses) gains on derivative instruments, net of income taxes of ($3,679), ($1,767) and ($751) (9,523 ) (5,067 ) 358 Defined benefit plan adjustments, net of income taxes of $318, ($2,981) and ($131) (36 ) (7,237 ) 2,278 Foreign currency translation, net of income taxes of ($5,581), ($2,101) and ($2,465) (55,509 ) (47,810 ) (22,676 ) Reclassification adjustments: Gains on marketable securities included in net income, net of income taxes of ($1,927) — (3,077 ) — Losses on derivative instruments included in net income, net of income taxes of $5,826, $4,022 and $4,991 12,443 4,608 8,089 Amortization of prior service costs and losses included in net income, net of income taxes of $355, $275 and $389 618 468 655 Comprehensive income $ 334,930 $ 297,668 $ 218,520 QUINTILES TRANSNATIONAL HOLDINGS INC. (PARENT COMPANY ONLY) CONDENSED BALANCE SHEETS December 31, 2015 2014 (in thousands, except per share data) ASSETS Current assets: Cash and cash equivalents $ 4,791 $ 11,635 Income taxes receivable 128 546 Other current assets and receivables 16 114 Total current assets 4,935 12,295 Deferred income taxes — 7 Total assets $ 4,935 $ 12,302 LIABILITIES AND SHAREHOLDERS’ DEFICIT Current liabilities: Accounts payable $ 7 $ 21 Accrued expenses — 84 Total current liabilities 7 105 Investment in subsidiary 568,785 716,148 Payable to subsidiary 360 110 Total liabilities 569,152 716,363 Commitments and contingencies Shareholders’ deficit: Common stock and additional paid-in capital, 300,000 shares authorized, $0.01 par value, 119,378 and 124,129 shares issued and outstanding at December 31, 2015 and 2014, respectively 8,784 143,828 Accumulated deficit (461,635 ) (788,798 ) Accumulated other comprehensive loss (111,366 ) (59,091 ) Total shareholders’ deficit (564,217 ) (704,061 ) Total liabilities and shareholders’ deficit $ 4,935 $ 12,302 QUINTILES TRANSNATIONAL HOLDINGS INC. (PARENT COMPANY ONLY) CONDENSED STATEMENTS OF CASH FLOWS Year Ended December 31, 2015 2014 2013 (in thousands) Operating activities: Net income $ 387,205 $ 356,383 $ 226,591 Adjustments to reconcile net income to cash provided by operating activities: Amortization of debt issuance costs and discount — — 10,346 Subsidiary loss (income) 56,627 (27,623 ) (119,998 ) (Benefit from) provision for deferred income taxes (335 ) 37 304 Change in operating assets and liabilities: Accounts receivable and unbilled services — 2,994 (2,995 ) Prepaid expenses and other assets — — (21 ) Accounts payable and accrued expenses (69 ) 65 (62 ) Income taxes payable and other liabilities (195 ) (847 ) (9,651 ) Net cash provided by operating activities 443,233 331,009 104,514 Investing activities: Investments in subsidiary, net of payments received — — (179,847 ) Net cash used in investing activities — — (179,847 ) Financing activities: Repayment of debt — — (300,000 ) Issuance of common stock — — 525,000 Payment of common stock issuance costs — (105 ) (35,439 ) Stock issued under employee stock purchase and option plans 64,297 35,228 12,539 Repurchase of common stock (515,010 ) (415,131 ) (6,434 ) Repurchase of stock options — (8,415 ) (50,649 ) Intercompany with subsidiary 636 (2,893 ) (153 ) Net cash (used in) provided by financing activities (450,077 ) (391,316 ) 144,864 (Decrease) increase in cash and cash equivalents (6,844 ) (60,307 ) 69,531 Cash and cash equivalents at beginning of period 11,635 71,942 2,411 Cash and cash equivalents at end of period $ 4,791 $ 11,635 $ 71,942 QUINTILES TRANSNATIONAL HOLDINGS INC. (PARENT COMPANY ONLY) NOTES TO CONDENSED FINANCIAL STATEMENTS The condensed parent company financial statements have been prepared in accordance with Rule 12-04, Schedule I of Regulation S-X as the restricted net assets of Quintiles Transnational Holdings Inc.’s (the “Company”) wholly-owned subsidiary, Quintiles Transnational Corp. (“Quintiles Transnational”) exceed 25% of the consolidated net assets of the Company. The ability of Quintiles Transnational to pay dividends may be limited due to the restrictive covenants in the agreements governing its credit arrangements. These condensed parent company financial statements include the accounts of Quintiles Transnational Holdings, Inc. on a standalone basis (the “Parent”) and the equity method of accounting is used to reflect ownership interest in its subsidiary. Refer to the consolidated financial statements and notes presented elsewhere herein for additional information and disclosures with respect to these financial statements. Since the Parent is part of a group that files a consolidated income tax return, in accordance with ASC 740, a portion of the consolidated amount of current and deferred income tax expense of the Company has been allocated to the Parent. The income tax benefit of $530,000, $810,000 and $9.3 million in 2015, 2014 and 2013, respectively, represents the income tax benefit that will be or were already utilized in the Company’s consolidated United States federal and state income tax returns. If the Parent was not part of these consolidated income tax returns, it would not be able to recognize any income tax benefit, as it generates no revenue against which the losses could be used on a separate filer basis. Below is a summary of the dividends paid to the Parent by Quintiles Transnational in 2015, 2014 and 2013 (in thousands): Amount Paid in December 2015 $ 1,000 Paid in November 2015 223,000 Paid in May 2015 220,000 Total paid in 2015 $ 444,000 Paid in November 2014 $ 234,000 Paid in May 2014 87,000 Paid in January 2014 8,415 Total paid in 2014 $ 329,415 Paid in November and December 2013 $ 116,585 Paid in February 2013 5,400 Total paid in 2013 $ 121,985

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Valuation And Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	Schedule II—Valuation and Qualifying Accounts Deferred Tax Asset Valuation Allowance Information presented below is in thousands: Balance at Additions Beginning Charged to Balance at of Year Expenses Deductions (a) End of Year December 31, 2015 $ 24,695 $ 1,762 $ (4,295 ) $ 22,162 December 31, 2014 $ 29,501 $ 11,084 $ (15,890 ) $ 24,695 December 31, 2013 $ 32,344 $ 3,611 $ (6,454 ) $ 29,501 (a) – Impact of reductions recorded to expense and translation adjustments.

Summary of Significant Accoun37

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Reclassifications	Reclassifications Certain immaterial prior period amounts have been reclassified to conform to the current presentation including the reclassification of debt issuance costs related to non-revolving debt from deposits and other assets to a direct reduction to the carrying amount of the long-term debt on the balance sheet. These changes had no effect on previously reported total revenues, net income, comprehensive income, shareholders’ deficit or cash flows.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts and operations of the Company and its subsidiaries. Amounts pertaining to the noncontrolling ownership interests held in third parties in the operating results and financial position of the Company’s majority-owned subsidiaries are reported as noncontrolling interests. Intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. These estimates are based on historical experience and various other assumptions believed reasonable under the circumstances. The Company evaluates its estimates on an ongoing basis and makes changes to the estimates and related disclosures as experience develops or new information becomes known. Actual results may differ from those estimates.
Foreign Currencies	Foreign Currencies The Company’s financial statements are reported in United States dollars and, accordingly, the Company’s results of operations are impacted by fluctuations in exchange rates that affect the translation of its revenues and expenses denominated in foreign currencies into United States dollars for purposes of reporting its consolidated financial results. Assets and liabilities recorded in foreign currencies on the books of foreign subsidiaries are translated at the exchange rate on the balance sheet date. Revenues, costs and expenses are translated at average rates of exchange during the year. Translation adjustments resulting from this process are charged or credited to the accumulated other comprehensive income (loss) (“AOCI”) component of shareholders’ deficit. The Company is subject to foreign currency transaction risk for fluctuations in exchange rates during the period of time between the consummation and cash settlement of a transaction. The Company earns revenue from its service contracts over a period of several months and, in some cases, over a period of several years. Accordingly, exchange rate fluctuations during this period may affect the Company’s profitability with respect to such contracts. Other expense (income), net includes foreign currency net (gains) losses for 2015, 2014 and 2013 of approximately ($4.6) million, $4.9 million and $4.0 million, respectively.
Cash Equivalents, Restricted Cash and Investments	Cash Equivalents, Restricted Cash and Investments The Company considers all highly liquid investments with an initial maturity of three months or less when purchased to be cash equivalents. The Company’s restricted cash primarily consisted of amounts collateralizing standby letters of credit issued in favor of certain suppliers and health insurance funds. Investments in marketable equity securities are classified as available-for-sale and measured at fair market value with net unrealized gains and losses recorded in the AOCI component of shareholders’ deficit until realized. The fair market value is based on the closing price as quoted by the respective stock exchange. In addition, the Company has investments in equity securities of companies for which there are not readily available market values and for which the Company does not exercise significant influence or control; such investments are accounted for using the cost method. Any gains or losses from the sales of investments or other-than-temporary declines in fair value are computed by specific identification.
Equity Method Investments	Equity Method Investments The Company’s investments in and advances to unconsolidated affiliates are accounted for under the equity method if the Company exercises significant influence or has an investment in a limited partnership that is considered to be greater than minor. These investments and advances are classified as investments in and advances to unconsolidated affiliates on the accompanying consolidated balance sheets. The Company records its pro rata share of the earnings, adjusted for accretion of basis difference, of these investments in equity in earnings of unconsolidated affiliates on the accompanying consolidated statements of income. The Company reviews its investments in and advances to unconsolidated affiliates for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable.
Derivatives	Derivatives The Company uses derivative instruments to manage exposures to interest rates and foreign currencies. Derivatives are recorded on the balance sheet at fair value at each balance sheet date utilizing pricing models for non-exchange-traded contracts. At inception, the Company designates whether or not the derivative instrument is an effective hedge of an asset, liability or firm commitment which is then classified as either a cash flow hedge or a fair value hedge. If determined to be an effective cash flow hedge, changes in the fair value of the derivative instrument are recorded as a component of AOCI until realized. We include the impact from these hedges in the same line item as the hedged item on the consolidated statements of cash flows. Changes in fair value of effective fair value hedges are recorded in earnings as an offset to the changes in the fair value of the related hedged item. Hedge ineffectiveness, if any, is immediately recognized in earnings. Changes in the fair values of derivative instruments that are not an effective hedge are recognized in earnings. The Company has entered, and may in the future enter, into derivative contracts (swaps, forwards, calls or puts, warrants, for example) related to its debt, investments in marketable equity securities and forecasted foreign currency transactions.
Billed and Unbilled Services and Unearned Income	Billed and Unbilled Services and Unearned Income In general, prerequisites for billings and payments are established by contractual provisions including predetermined payment schedules, which may or may not correspond to the timing of the performance of services under the contract. Unbilled services arise when services have been rendered for which revenue has been recognized but the customers have not been billed. In some cases, payments received are in excess of revenue recognized. Payments received in advance of services being provided are deferred as unearned income on the consolidated balance sheet. As the contracted services are subsequently performed and the associated revenue is recognized, the unearned income balance is reduced by the amount of the revenue recognized during the period.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts The Company’s allowance for doubtful accounts is determined based on a variety of factors that affect the potential collectability of the related receivables, including length of time the receivables are past due, customer credit ratings, financial stability of the customer, specific one-time events and past customer history. In addition, in circumstances where the Company is made aware of a specific customer’s inability to meet its financial obligations, a specific allowance is established. The accounts are individually evaluated on a regular basis and appropriate reserves are established as deemed appropriate based on the above criteria.
Receivables Financing Facility	Receivables Financing Facility Advances received under the Company’s receivables financing facility are accounted for as borrowings secured by the receivables and included in net cash provided by financing activities. The Company services the collateralized accounts receivable and the cash flows for the underlying receivables are included in cash provided by operating activities. The collateralized accounts receivable are included in trade accounts receivable and unbilled services, net.
Business Combinations	Business Combinations Business combinations are accounted for using the acquisition method, and accordingly, the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree are recorded at their estimated fair values on the date of the acquisition. Goodwill represents the excess of the purchase price over the estimated fair value of the net assets acquired, including the amount assigned to identifiable intangible assets. When a business combination involves contingent consideration, the Company recognizes a liability equal to the estimated fair value of the contingent consideration obligation at the date of the acquisition. Subsequent changes in the estimated fair value of the contingent consideration are recognized in earnings in the period of the change.
Long-Lived Assets	Long-Lived Assets Property and equipment are stated at cost and are depreciated using the straight-line method over the shorter of the asset’s estimated useful life or the lease term, if related to leased property, as follows: Buildings and leasehold improvements 3 - 40 years Equipment 3 - 10 years Furniture and fixtures 5 - 10 years Motor vehicles 3 - 5 years Definite-lived identifiable intangible assets are amortized primarily using an accelerated method that reflects the pattern in which the Company expects to benefit from the use of the asset over its estimated remaining useful life as follows: Trademarks and trade names 2 - 6 years Non-compete agreements 3 years Contract backlog and customer relationships 1 - 10 years Software and related assets 2 - 9 years Goodwill and indefinite-lived identifiable intangible assets, which consist of certain trade names, are not amortized but evaluated for impairment annually, or more frequently if events or changes in circumstances indicate an impairment. Included in software and related items is the capitalized cost of internal-use software used in supporting the Company’s business. Qualifying costs incurred during the application development stage are capitalized and amortized over their estimated useful lives. The Company recognized $37.7 million, $33.1 million and $32.2 million of amortization expense in 2015, 2014 and 2013, respectively, related to software and related assets. The carrying values of property, equipment and intangible and other long-lived assets are reviewed for recoverability if the facts and circumstances suggest that a potential impairment may have occurred. If this review indicates that carrying values will not be recoverable, as determined based on undiscounted cash flow projections, the Company will record an impairment charge to reduce carrying values to estimated fair value. During 2015, the Company recognized a $2.5 million impairment charge for long-lived assets related to a facility closure in Japan. There were no events, facts or circumstances in 2014 and 2013 that resulted in any impairment charges to the Company’s property, equipment, intangible or other long-lived assets.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when all of the following conditions are satisfied: (1) there is persuasive evidence of an arrangement; (2) the service offering has been delivered to the customer; (3) the collection of the fees is probable; and (4) the arrangement consideration is fixed or determinable. The Company’s arrangements are primarily service contracts that range in duration from a few months to several years. Most contracts may be terminated upon 30 to 90 days notice by the customer, however, in the event of termination, contract provisions typically require payment for services rendered through the date of termination, as well as for subsequent services rendered to close out the contract. In some cases, contracts provide for consideration that is contingent upon the occurrence of uncertain future events. The Company recognizes contingent revenue when the contingency has been resolved and all other criteria for revenue recognition have been met. The Company treats cash payments to customers as incentives to induce the customers to enter into such a service agreement with the Company. The related asset is amortized as a reduction of revenue over the period the services are performed. The Company records revenues net of any tax assessments by governmental authorities, such as value added taxes, that are imposed on and concurrent with specific revenue generating transactions. The Company does not recognize revenue with respect to start-up activities including contract and scope negotiation, feasibility analysis and conflict of interest review associated with contracts. The costs for these activities are expensed as incurred. For the arrangements that include multiple elements, arrangement consideration is allocated to units of accounting based on the relative selling price. The best evidence of selling price of a unit of accounting is vendor-specific objective evidence (“VSOE”), which is the price the Company charges when the deliverable is sold separately. When VSOE is not available to determine selling price, management uses relevant third-party evidence (“TPE”) of selling price, if available. When neither VSOE nor TPE of selling price exists, management uses its best estimate of selling price considering all relevant information that is available without undue cost and effort. The majority of the Company’s contracts within the Product Development segment are service contracts for clinical research that represent a single unit of accounting. The Company recognizes revenue on its clinical research services contracts as services are performed primarily on a proportional performance basis, generally using output measures that are specific to the service provided. Examples of output measures include among others, number of investigators enrolled, number of site initiation visits and number of monitoring visits completed. Revenue is determined by dividing the actual units of work completed by the total units of work required under the contract and multiplying that ratio by the total contract value. The total contract value, or total contractual payments, represents the aggregate contracted price for each of the agreed upon services to be provided. Changes in the scope of work are common, especially under long-term contracts, and generally result in a change in contract value. Once the customer has agreed to the changes in scope and renegotiated pricing terms, the contract value is amended and revenue is recognized, as described above. To the extent that contracts involve multiple elements, the Company follows the allocation methodology described above and recognizes revenue for each unit of accounting on a proportional performance basis. The Company derives the majority of its revenues in its Integrated Healthcare Services segment from providing commercialization services on a fee-for-service basis to customers within the biopharmaceutical industry. Fees on these arrangements are billed based on a contractual per-diem or hourly rate basis. The Company recognizes revenue on commercialization services contracts primarily on a time and materials basis. Some of the Company’s commercialization contracts are multiple element arrangements, with elements including recruiting, training and deployment of sales representatives. The nature of the terms of these multiple element arrangements will vary based on the customized needs of the Company’s customers. For contracts that have multiple elements, the Company follows the allocation methodology described above and recognizes revenue for each unit of accounting on a time and materials basis. The Company’s commercialization contracts sometimes include variable fees that are based on a percentage of product sales (royalty payments). The Company recognizes revenue on royalty payments when the variable components become fixed or determinable and all other revenue recognition criteria have been met, which generally only occurs upon the sale of the underlying product(s) and upon the Company’s receipt of information necessary to make a reasonable estimate.
Reimbursed Expenses	Reimbursed Expenses The Company includes reimbursed expenses in total revenues and costs of revenue as the Company is deemed to be the primary obligor in the applicable arrangements. These costs include such items as payments to investigators and travel expenses for the Company’s clinical monitors and sales representatives.
Expenses	Expenses Costs of revenue include reimbursed expenses, compensation and benefits for billable employees, depreciation of assets used in generating revenue and other expenses directly related to service contracts such as courier fees and laboratory supplies for the Company’s laboratory services, professional services and travel expenses. Selling, general and administrative expenses primarily include costs related to administrative functions such as compensation and benefits, travel, professional services, training and expenses for advertising, information technology, facilities and depreciation and amortization.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. Investment policies have been implemented that limit purchases of marketable securities to investment grade securities. Substantially all service revenues for Product Development and Integrated Healthcare Services are earned by performing services under contracts with various pharmaceutical, biotechnology, medical device and healthcare companies. The concentration of credit risk is equal to the outstanding accounts receivable and unbilled services balances, less the unearned income related thereto, and such risk is subject to the financial and industry conditions of the Company’s customers. The Company does not require collateral or other securities to support customer receivables. Credit losses have been immaterial and reasonably within management’s expectations. No customer accounted for 10.0% or more of consolidated service revenues in 2015, 2014 or 2013.
Research and Development Costs	Research and Development Costs Research and development costs consist primarily of employee compensation and related expenses and information technology contract services and are charged to expense as incurred. The following is a summary of the research and development expenses (in thousands): Year Ended December 31, 2015 2014 2013 Internally developed software applications and computer technology $ 3,198 $ 4,980 $ 3,955 Funding of customer's research and development activity 139 811 1,000 $ 3,337 $ 5,791 $ 4,955
Advertising Costs	Advertising Costs Advertising costs, which include the development and production of advertising materials and the communication of these materials, are charged to expense as incurred. The Company incurred approximately $12.8 million, $16.0 million and $14.8 million in advertising expense in 2015, 2014 and 2013, respectively.
Restructuring Costs	Restructuring Costs Restructuring costs, which primarily include termination benefits and facility closure costs, are recorded at estimated fair value. Key assumptions in determining the restructuring costs include the terms and payments that may be negotiated to terminate certain contractual obligations and the timing of employees leaving the Company.
Contingencies	Contingencies The Company records accruals for claims, suits, investigations and proceedings when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company reviews claims, suits, investigations and proceedings at least quarterly and records or adjusts accruals related to such matters to reflect the impact and status of any settlements, rulings, advice of counsel or other information pertinent to a particular matter. Legal costs associated with contingencies are charged to expense as incurred. The Company is party to legal proceedings incidental to its business. While the outcome of these matters could differ from management’s expectations, the Company does not believe the resolution of these matters has a reasonable possibility of having a material adverse effect to the Company’s financial statements.
Income Taxes	Income Taxes Income tax expense includes United States federal, state and international income taxes. Certain items of income and expense are not reported in income tax returns and financial statements in the same year. The income tax effects of these differences are reported as deferred income taxes. Valuation allowances are provided to reduce the related deferred income tax assets to an amount which will, more likely than not, be realized. Beginning in 2013, the undistributed earnings of most of the Company’s foreign subsidiaries are considered to be indefinitely reinvested outside of the United States. Accordingly, a deferred income tax liability has not been provided related to those undistributed earnings. Interest and penalties related to unrecognized income tax benefits are recognized as a component of income tax expense as discussed further in Note 16.
Employee Stock Compensation	Employee Stock Compensation The Company accounts for share-based compensation for stock options and stock appreciation rights (“SARs”) under the fair value method and uses the Black-Scholes-Merton model to estimate the value of such share-based awards granted to its employees and non-executive directors. Expected volatility is based upon the historical volatility of a peer group for a period equal to the expected term, as the Company does not have adequate history to calculate its own volatility and believes the expected volatility will approximate the historical volatility of the peer group. Prior to the completion of the Company’s initial public offering (“IPO”) on May 14, 2013, the expected dividends were based on the historical dividends paid by the Company, excluding dividends that resulted from activities that the Company deemed to be one-time in nature. Following the IPO, the Company does not currently anticipate paying dividends. The expected term represents the period of time the grants are expected to be outstanding. The risk-free interest rate is based on the United States Treasury yield curve in effect at the time of the grant. The Company accounts for its share-based compensation for restricted stock units (“RSUs”) and performance awards based on the closing market price of the Company’s common stock on the date of grant. The Company recognized share-based compensation expense of $37.8 million, $30.0 million and $22.8 million in 2015, 2014 and 2013, respectively. Share-based compensation expense is included in selling, general and administrative expenses on the accompanying consolidated statements of income which is consistent with the classification of all other compensation costs incurred for the employees who were granted the share-based awards. The associated future income tax benefit recognized was $8.9 million, $7.6 million and $8.1 million in 2015, 2014 and 2013, respectively. As of December 31, 2015, there was approximately $38.8 million of total unrecognized share-based compensation expense related to outstanding non-vested share-based compensation arrangements, which the Company expects to recognize over a weighted average period of 1.3 years.
Earnings Per Share	Earnings Per Share The calculation of earnings per share is based on the weighted average number of common shares or common stock equivalents outstanding during the applicable period. The dilutive effect of common stock equivalents is excluded from basic earnings per share and is included in the calculation of diluted earnings per share. Potentially dilutive securities include outstanding stock options, shares to be purchased under the Company’s employee stock purchase plan (see Note 17) and unvested RSUs.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In November 2015, the FASB issued new accounting guidance which requires entities to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. The new standard will be effective for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The Company expects to early adopt this new accounting guidance on January 1, 2016. As of December 31, 2015, the Company had approximately $101.0 million and $148,000 of current deferred income tax assets and current deferred income tax liabilities, respectively. In September 2015, the FASB issued new guidance that will change the requirements for reporting measurement period adjustments to provisional amounts initially recognized in connection with a business combination. Currently, an acquiring entity is required to retrospectively adjust, in prior period financial statements, the provisional amounts to reflect new information obtained during the measurement period. Under the new guidance, adjustments to the provisional amounts will be reflected in the financial statements for the reporting period in which the adjustments are determined, including by recognizing in current period earnings the full effect of changes in depreciation, amortization or other income effects. The new guidance requires that the acquiring entity either present separately on the face of the current period income statement or disclose in the notes to the current period financial statements, by line item, the amount of the adjustments made during the current period. The Company will adopt the new guidance on January 1, 2016, as required. The adoption is not expected to have a material impact on the Company’s financial statements. In February 2015, the FASB issued new accounting guidance which changes the analysis in determining whether an entity is considered a variable interest entity (“VIE”) and the identification of the primary beneficiary of the VIE to determine whether the VIE should be included in an entity’s consolidated financial statements. The Company will adopt the new accounting guidance on January 1, 2016, as required. The adoption of the new accounting guidance is not expected to have a material effect on the Company’s financial statements. In May 2014, the FASB and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with customers. The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also will require expanded disclosures on revenue recognition including information about changes in assets and liabilities that result from contracts with customers. Companies have an option to use either a retrospective approach or a cumulative effect adjustment approach to implement the new guidance. The new standard will be effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted for annual reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact of this new standard on its consolidated financial statements, the date of adoption, and the transition approach to implement the new guidance.

Summary of Significant Accoun38

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Property and Equipment at Cost Using Straight-Line Method	Property and equipment are stated at cost and are depreciated using the straight-line method over the shorter of the asset’s estimated useful life or the lease term, if related to leased property, as follows: Buildings and leasehold improvements 3 - 40 years Equipment 3 - 10 years Furniture and fixtures 5 - 10 years Motor vehicles 3 - 5 years
Definite-Lived Identifiable Intangible Assets Amortized	Definite-lived identifiable intangible assets are amortized primarily using an accelerated method that reflects the pattern in which the Company expects to benefit from the use of the asset over its estimated remaining useful life as follows: Trademarks and trade names 2 - 6 years Non-compete agreements 3 years Contract backlog and customer relationships 1 - 10 years Software and related assets 2 - 9 years
Summary of Research and Development Expenses	The following is a summary of the research and development expenses (in thousands): Year Ended December 31, 2015 2014 2013 Internally developed software applications and computer technology $ 3,198 $ 4,980 $ 3,955 Funding of customer's research and development activity 139 811 1,000 $ 3,337 $ 5,791 $ 4,955

Accounts Receivable and Unbil39

Accounts Receivable and Unbilled Services (Tables)	12 Months Ended
	Dec. 31, 2015
Receivables [Abstract]
Accounts Receivable and Unbilled Services	Accounts receivable and unbilled services consist of the following (in thousands): December 31, 2015 2014 Trade: Billed $ 553,652 $ 444,941 Unbilled services 614,381 532,312 1,168,033 977,253 Allowance for doubtful accounts (2,284 ) (1,998 ) $ 1,165,749 $ 975,255
Percentage of Accounts Receivable and Unbilled Services by Region	The percentage of accounts receivable and unbilled services by region is as follows: December 31, 2015 2014 Americas: United States 58 % 55 % Other 1 2 Americas 59 57 Europe and Africa: United Kingdom 23 23 Other 10 11 Europe and Africa 33 34 Asia-Pacific: Japan 3 4 Other 5 5 Asia-Pacific 8 9 100 % 100 %

Investments-Debt, Equity and 40

Investments-Debt, Equity and Other Securities (Tables)	12 Months Ended
	Dec. 31, 2015
Investments Debt And Equity Securities [Abstract]
Summary of the Company's Debt, Equity and Other Securities	The following is a summary of the Company’s debt, equity and other securities (in thousands): December 31, 2015 2014 Marketable securities $ 395 $ 831 Cost method 32,516 33,672 $ 32,911 $ 34,503
Summary of Available-for-Sale Securities	The following is a summary of available-for-sale securities (in thousands): December 31, 2015 December 31, 2014 Gross Gross Amortized Unrealized Market Amortized Unrealized Market Cost Loss Value Cost Loss Value Marketable equity $ 1,103 $ (708 ) $ 395 $ 1,103 $ (272 ) $ 831
Summary of the Company's Portfolio of Cost Method Investments	Below is a summary of the Company’s portfolio of cost method investments (in thousands): December 31, 2015 2014 Equity investments $ 32,516 $ 32,516 Convertible notes — 1,156 $ 32,516 $ 33,672

Investments in and Advances t41

Investments in and Advances to Unconsolidated Affiliates (Tables)	12 Months Ended
	Dec. 31, 2015
Investments In And Advances To Affiliates Schedule Of Investments [Abstract]
Investments in and Advances to Unconsolidated Affiliates	The following is a summary of the Company’s investments in and advances to unconsolidated affiliates (in thousands): December 31, 2015 2014 NovaQuest Pharma Opportunities Fund III, L.P. $ 39,785 $ 22,633 NovaQuest Pharma Opportunities Fund IV, L.P. 2,524 — Cenduit TM 9,478 8,271 Other 595 604 $ 52,382 $ 31,508

Derivatives (Tables)

Derivatives (Tables)	12 Months Ended
	Dec. 31, 2015
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Summary of Fair Values of Derivative Instruments Designated as Hedges	The fair values of the Company’s derivative instruments designated as hedging instruments and the line items on the accompanying consolidated balance sheets to which they were recorded are summarized in the following table (in thousands): December 31, Balance Sheet Classification 2015 2014 Foreign exchange forward contracts Other current liabilities $ 5,194 $ 4,635 Interest rate swaps Other current liabilities $ 5,698 $ 14,424
Effect of Cash Flow Hedging Instruments on Other Comprehensive Income (Loss)	The effect of the Company’s cash flow hedging instruments on other comprehensive income (loss) is summarized in the following table (in thousands): Year Ended December 31, 2015 2014 2013 Foreign exchange forward contracts $ (559 ) $ (8,585 ) $ 3,485 Interest rate swaps 5,626 10,381 9,202 Total $ 5,067 $ 1,796 $ 12,687

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of December 31, 2015 (in thousands): Level 1 Level 2 Level 3 Total Assets: Marketable equity securities $ 395 $ — $ — $ 395 Total $ 395 $ — $ — $ 395 Liabilities: Foreign exchange forward contracts $ — $ 5,194 $ — $ 5,194 Interest rate swaps — 5,698 — 5,698 Contingent consideration — — 4,374 4,374 Total $ — $ 10,892 $ 4,374 $ 15,266 The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of December 31, 2014 (in thousands): Level 1 Level 2 Level 3 Total Assets: Marketable equity securities $ 831 $ — $ — $ 831 Total $ 831 $ — $ — $ 831 Liabilities: Foreign exchange forward contracts $ — $ 4,635 $ — $ 4,635 Interest rate swaps — 14,424 — 14,424 Contingent consideration — — 1,452 1,452 Total $ — $ 19,059 $ 1,452 $ 20,511
Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the year ended December 31 (in thousands): Contingent Consideration – Accrued Expenses and Other Liabilities 2015 2014 2013 Balance as of January 1 $ 1,452 $ 13,014 $ 3,521 Initial estimate of contingent consideration — — 14,300 Contingent consideration paid (3,000 ) (3,000 ) — Revaluations included in earnings 5,922 (8,562 ) (4,807 ) Balance as of December 31 $ 4,374 $ 1,452 $ 13,014

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Summary of Major Classes of Property and Equipment	The major classes of property and equipment were as follows (in thousands): December 31, 2015 2014 Land, buildings and leasehold improvements $ 187,405 $ 185,940 Equipment 257,119 240,227 Furniture and fixtures 52,840 54,615 Motor vehicles 13,348 15,443 510,712 496,225 Less accumulated depreciation (322,319 ) (305,928 ) $ 188,393 $ 190,297

Goodwill and Identifiable Int45

Goodwill and Identifiable Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization Expense Associated with Identifiable Definite-Lived Intangible Assets	Amortization expense associated with identifiable definite-lived intangible assets was as follows (in thousands) Year Ended December 31, 2015 2014 2013 Amortization expense $ 66,545 $ 58,457 $ 51,450
Summary of Identifiable Intangible Assets	The following is a summary of identifiable intangible assets (in thousands): As of December 31, 2015 As of December 31, 2014 Gross Accumulated Net Gross Accumulated Net Amount Amortization Amount Amount Amortization Amount Definite-lived identifiable intangible assets: Product licensing and distribution rights and customer relationships $ 224,149 $ (75,606 ) $ 148,543 $ 123,227 $ (54,413 ) $ 68,814 Trademarks, trade names and other 14,620 (6,081 ) 8,539 18,571 (6,399 ) 12,172 Software and related assets 279,266 (196,489 ) 82,777 260,052 (170,471 ) 89,581 $ 518,035 $ (278,176 ) $ 239,859 $ 401,850 $ (231,283 ) $ 170,567 Indefinite-lived identifiable intangible assets: Trade names $ 128,247 $ — $ 128,247 $ 109,676 $ — $ 109,676
Summary of Goodwill by Segment	The following is a summary of goodwill by segment for the years ended December 31, 2015 and 2014 (in thousands): Integrated Product Healthcare Development Services Consolidated Balance as of December 31, 2013 $ 351,144 $ 58,482 $ 409,626 Business combinations — 62,778 62,778 Impact of foreign currency fluctuations and other (4,536 ) (3,434 ) (7,970 ) Balance as of December 31, 2014 346,608 117,826 464,434 Business combinations 262,377 — 262,377 Impact of foreign currency fluctuations and other (6,879 ) (192 ) (7,071 ) Balance as of December 31, 2015 $ 602,106 $ 117,634 $ 719,740

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2015
Payables And Accruals [Abstract]
Accrued Expenses	Accrued expenses consist of the following (in thousands): December 31, 2015 2014 Compensation, including bonuses, fringe benefits and payroll taxes $ 400,748 $ 403,250 Restructuring 13,564 6,083 Interest 5,115 274 Contract related 271,076 255,530 Other 70,254 68,507 $ 760,757 $ 733,644

Credit Arrangements (Tables)

Credit Arrangements (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Summary of Company's Credit Facilities	The following is a summary of the Company’s revolving credit facilities at December 31, 2015: Facility Interest Rates $500.0 million (revolving credit facility) London Interbank Offer Rate (“LIBOR”) (0.61% at December 31, 2015) plus 1.75% $25.0 million (receivables financing facility) LIBOR Market Index Rate (0.43% at December 31, 2015) plus 0.85% to 1.35% depending upon the Company’s debt rating £10.0 million (approximately $14.8 million) general banking facility with a European headquartered bank Bank’s base rate (0.5% at December 31, 2015) plus 1%
Schedule of Long-term Debt	Long-term debt consists of the following (in thousands): December 31, 2015 2014 4.875% Senior Notes due 2023 $ 800,000 $ — Term Loan A due 2020 (LIBOR plus 1.75%, or 2.36% at December 31, 2015) 828,750 — Term Loan B due 2022 (the greater of LIBOR or 0.75% plus 2.50%, or 3.25% at December 31, 2015) 597,000 — Term Loan B-3 due 2018 (the greater of three month LIBOR or 1.25% plus 2.50%, or 3.75% at December 31, 2014) — 2,030,606 Receivables financing facility due 2018 (LIBOR plus 1.05%, or 1.48% at December 31, 2015) 275,000 275,000 2,500,750 2,305,606 Less: unamortized discount (24,020 ) (12,379 ) Less: unamortized debt issuance costs (8,955 ) (9,879 ) Less: current portion (48,500 ) (750 ) $ 2,419,275 $ 2,282,598
Contractual Maturities of Long-term Debt	Contractual maturities of long-term debt at December 31, 2015 are as follows (in thousands): 2016 $ 48,500 2017 48,500 2018 323,500 2019 48,500 2020 664,750 Thereafter 1,367,000 $ 2,500,750

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2015
Leases [Abstract]
Summary of Future Minimum Lease Payments Under Capital and Operating Leases	The following is a summary of future minimum payments under capital and operating leases that have initial or remaining non-cancelable lease terms in excess of one year at December 31, 2015 (in thousands): Capital Operating Leases Leases 2016 $ 15 $ 84,747 2017 18 62,485 2018 — 41,907 2019 — 29,201 2020 — 25,713 Thereafter — 111,267 Total minimum lease payments 33 $ 355,320 Amounts representing interest (2 ) Present value of net minimum payments 31 Current portion (13 ) Long-term capital lease obligations $ 18

Shareholder's Deficit (Tables)

Shareholder's Deficit (Tables)	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Summary of Share Repurchases Made Under Repurchase Program	Below is a summary of the share repurchases made under the Repurchase Program (in thousands except share data): Year Ended December 31, 2015 2014 2013 Number of shares repurchased 7,855,796 300 153,223 Aggregate purchase price $ 515,010 $ 14 $ 6,434 Average price per share $ 65.56 $ 47.51 $ 42.01

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Summary of Estimated Fair Value of Net Assets Acquired at the Date of Acquisitions	The following table summarizes the estimated fair value of the net assets acquired at the date of the acquisitions (in thousands): Quest Encore Novella Assets acquired: Cash and cash equivalents $ 31,783 $ 2,223 $ 26,190 Accounts receivable and unbilled services 6,186 17,714 28,644 Prepaid expenses 1,185 — — Other current assets 4,426 443 1,441 Property and equipment 16,422 289 9,616 Goodwill 261,710 62,778 116,542 Other identifiable intangibles 125,900 14,150 42,740 Deferred income tax asset – long-term — 396 — Other long-term assets 266 — 2,203 Liabilities assumed: Accounts payable and accrued expenses (12,790 ) (4,206 ) (12,716 ) Unearned income — (31 ) (7,782 ) Other current liabilities — — (132 ) Deferred income tax liability – long-term (10,412 ) — (18,364 ) Other long-term liabilities (1,408 ) — (1,334 ) Net assets acquired $ 423,268 $ 93,756 $ 187,048
Summary Of Identifiable Intangible Assets	The other identifiable intangible assets consisted of the following (in thousands): Quest Encore Novella Customer relationships $ 74,000 $ 8,800 $ 20,800 Backlog 32,900 800 14,000 Trade names 19,000 1,100 7,500 Non-compete agreements — 450 440 Software — 3,000 — Total other identifiable intangibles $ 125,900 $ 14,150 $ 42,740 Amortized over a weighted average useful life (in years) 9 8 7

Restructuring (Tables)

Restructuring (Tables)	12 Months Ended
	Dec. 31, 2015
Restructuring And Related Activities [Abstract]
Summary of Amounts Recorded for Restructuring Plans	The following amounts were recorded for the restructuring plans (in thousands): Severance and Related Costs Exit Costs Total Balance at December 31, 2013 $ 5,276 $ 198 $ 5,474 Expense, net of reversals 8,421 567 8,988 Payments (7,998 ) (160 ) (8,158 ) Foreign currency translation (221 ) — (221 ) Balance at December 31, 2014 5,478 605 6,083 Expense, net of reversals 29,843 909 30,752 Payments (22,943 ) (723 ) (23,666 ) Foreign currency translation and other (199 ) 594 395 Balance at December 31, 2015 $ 12,179 $ 1,385 $ 13,564

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Components of Income Before Income Taxes and Equity in Earnings of Unconsolidated Affiliates	The components of income before income taxes and equity in earnings of unconsolidated affiliates are as follows (in thousands): Year Ended December 31, 2015 2014 2013 Domestic $ 68,455 $ 96,917 $ 68,425 Foreign 470,540 405,272 254,691 $ 538,995 $ 502,189 $ 323,116
Components of Income Tax Expense Attributable to Continuing Operations	The components of income tax expense attributable to continuing operations are as follows (in thousands): Year Ended December 31, 2015 2014 2013 Current expense (benefit): Federal $ 47,311 $ 58,403 $ 38,573 State 3,559 4,618 (4,309 ) Foreign 109,273 95,010 83,744 160,143 158,031 118,008 Deferred (benefit) expense: Federal and state 4,613 (4,549 ) (15,807 ) Foreign (5,767 ) (3,426 ) (6,236 ) (1,154 ) (7,975 ) (22,043 ) $ 158,989 $ 150,056 $ 95,965
Effective Income Tax Rate Reconciliation	The differences between the Company’s consolidated income tax expense attributable to continuing operations and the expense computed at the 35% United States statutory income tax rate were as follows (in thousands): Year Ended December 31, 2015 2014 2013 Federal income tax expense at statutory rate $ 188,648 $ 175,766 $ 113,091 State and local income taxes, net of federal benefit 1,682 2,312 (1,088 ) Research and development (12,634 ) (16,765 ) (12,788 ) Foreign nontaxable interest income (9,351 ) (10,217 ) (9,751 ) Gain on note settlement — — 10,794 United States taxes recorded on foreign earnings 38,246 18,631 (1,616 ) Foreign rate differential (49,288 ) (30,734 ) (10,753 ) Tax contingencies (8,304 ) 4,043 (1,012 ) Other 9,990 7,020 9,088 $ 158,989 $ 150,056 $ 95,965
Income Tax Effects of Temporary Differences from Continuing Operations that Give Rise to Significant Portions of Deferred Income Tax (Liabilities) Assets	The income tax effects of temporary differences from continuing operations that give rise to significant portions of deferred income tax (liabilities) assets are presented below (in thousands): December 31, 2015 2014 Deferred income tax liabilities: Undistributed foreign earnings $ (36,624 ) $ (27,717 ) Depreciation and amortization (53,171 ) (65,614 ) Other (11,830 ) (15,346 ) Total deferred income tax liabilities (101,625 ) (108,677 ) Deferred income tax assets: Net operating loss, capital loss and tax credit carryforwards 41,707 43,535 Accrued expenses and unearned income 23,315 34,048 Employee benefits 123,775 130,217 Other 12,801 17,784 201,598 225,584 Valuation allowance for deferred income tax assets (22,162 ) (24,695 ) Total deferred income tax assets 179,436 200,889 Net deferred income tax assets $ 77,811 $ 92,212
Reconciliation of Beginning and Ending Amount of Gross Unrecognized Income Tax Benefits	A reconciliation of the beginning and ending amount of gross unrecognized income tax benefits is presented below (in thousands): Year Ended December 31, 2015 2014 2013 Balance at January 1 $ 40,821 $ 54,936 $ 43,393 Additions based on tax positions related to the current year 2,068 2,807 4,493 Additions for income tax positions of prior years 8,838 1,588 12,854 Impact of changes in exchange rates (608 ) (376 ) (71 ) Settlements with tax authorities (121 ) (135 ) (1,052 ) Reductions for income tax positions of prior years (1,945 ) (6,023 ) (3,520 ) Reductions due to the lapse of the applicable statute of limitations (19,387 ) (11,976 ) (1,161 ) Balance at December 31 $ 29,666 $ 40,821 $ 54,936
Summary of Tax Years Open for Examination	The following table summarizes the tax years that remain open for examination by tax authorities in the most significant jurisdictions in which the Company operates: United States 2012-2014 India 2006-2015 Japan 2010-2014 United Kingdom 2014

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2015
Compensation And Retirement Disclosure [Abstract]
Summary of Components of Pension Expenses Related to Defined Benefit Plans	The following table summarizes the components of pension expense related to these defined benefit plans (in thousands): Year Ended December 31, 2015 2014 2013 Service cost $ 15,486 $ 12,944 $ 13,227 Interest cost 3,453 3,821 3,684 Expected return on plan assets (3,555 ) (4,277 ) (3,442 ) Amortization of prior service costs — 107 336 Amortization of actuarial losses 973 636 708 $ 16,357 $ 13,231 $ 14,513
Weighted Average Assumptions Used in Determining Pension Expense	The weighted average assumptions used in determining pension expense were as follows: Year Ended December 31, 2015 2014 2013 Discount rate 2.46 % 3.01 % 3.06 % Rate of compensation increases 4.32 % 4.36 % 4.74 % Expected return on plan assets 4.05 % 5.21 % 5.33 %
Financial Information About Defined Benefit Plans	The following table summarizes financial information about the Company’s defined benefit plans (in thousands): December 31, 2015 2014 Projected benefit obligation January 1 $ 147,127 $ 135,110 Service costs 15,486 12,944 Interest cost 3,453 3,821 Expected return on plan assets (3,555 ) (4,277 ) Actuarial (gains) losses (2,306 ) 16,396 Business combination 1,746 — Benefits paid (6,325 ) (7,409 ) Foreign currency fluctuations and other (1,732 ) (9,458 ) Projected benefit obligation December 31 $ 153,894 $ 147,127 Plan assets at fair value, January 1 $ 88,420 $ 82,787 Actual return on plan assets 1,312 10,004 Contributions 5,982 8,594 Business combination 1,966 — Benefits paid (6,325 ) (7,409 ) Foreign currency fluctuations and other (4,212 ) (5,556 ) Plan assets at fair value, December 31 $ 87,143 $ 88,420 Unfunded balance $ 66,751 $ 58,707
Summary of Amounts Recognized in Consolidated Balance Sheets	The following table summarizes the amounts recognized in the consolidated balance sheets related to the defined benefit plans (in thousands): December 31, 2015 2014 Deposits and other assets $ 19,185 $ 18,690 Accrued expenses 4,520 6,075 Other long-term liabilities 81,410 71,322 AOCI $ (13,264 ) $ (14,519 )
Summary of Amounts Recognized in Accumulated Other Comprehensive Income	The following table summarizes the amounts recognized in AOCI related to the defined benefit plans (in thousands): Prior Actuarial Deferred Service Net Income Costs (Gain) Loss Taxes Total Balance as of December 31, 2013 $ (107 ) $ (4,937 ) $ 2,956 $ (2,088 ) Reclassification adjustments included in pension expense: Amortization 107 636 (275 ) 468 Amounts arising during the period: Actuarial changes in benefit obligation — (10,218 ) 2,981 (7,237 ) Balance as of December 31, 2014 — (14,519 ) 5,662 (8,857 ) Reclassification adjustments included in pension expense: Amortization — 973 (355 ) 618 Amounts arising during the period: Actuarial changes in benefit obligation — 282 (318 ) (36 ) Balance as of December 31, 2015 $ — $ (13,264 ) $ 4,989 $ (8,275 )
Weighted Average Assumptions Used in Determining Pension Obligations	The following table summarizes the weighted average assumptions used in determining the pension obligations: December 31, 2015 2014 Discount rate 2.50 % 2.46 % Rate of compensation increases 4.37 % 4.32 %
Schedule of Fair Value Measurement	The following table summarizes the fair value of the Company’s defined benefit plans assets (in thousands): December 31, 2015 2014 Funds that hold debt investments primarily government bonds $ 49,355 $ 47,473 Funds that hold United Kingdom equity investments 15,700 19,547 Funds that hold global equity investments 6,277 8,255 Diversified growth fund 15,248 12,569 Other 563 576 Total $ 87,143 $ 88,420
Schedule of Expected Benefit Payments Under the Defined Benefit Plans	The following table summarizes the Company’s expected benefit payments under the defined benefit plans for each of the next five years and the aggregate of the five years thereafter (in thousands): 2016 $ 6,684 2017 6,615 2018 7,096 2019 7,802 2020 9,092 Years 2021 through 2025 66,117 $ 103,406
Estimated Fair Value of Stock Options and SARs	The following assumptions were used to estimate the fair value of stock options and SARs: Year Ended December 31, 2015 2014 2013 Expected volatility 26 – 41% 26 – 43% 18 – 47% Weighted average expected volatility 34% 36% 40% Expected dividends 0.0% 0.0% 0.0 - 5.45% Expected term (in years) 3.7 – 6.7 1.5 – 6.7 0.25 – 6.4 Risk-free interest rate 1.06 – 2.04% 0.28 – 2.21% 0.04 – 2.24%
Summary of Stock Option Activity	The Company’s stock option activity in 2015 is as follows: Weighted Number Average Aggregate of Exercise Intrinsic Options Price Value (in thousands) Outstanding at December 31, 2014 9,124,954 $ 29.15 $ 271,216 Granted 993,600 $ 65.05 Exercised (3,013,190 ) $ 19.41 Canceled (457,365 ) $ 42.08 Outstanding at December 31, 2015 6,647,999 $ 38.04 $ 203,679
Schedule of Stock Options Outstanding and Exercisable	Selected information regarding the Company’s stock options as of December 31, 2015 is as follows: Options Outstanding Options Exercisable Weighted Weighted Average Weighted Number Exercise Average Remaining Number Average of Price Exercise Life of Exercise Options Range Price (in Years) Options Price 1,063,999 $ 5.76 - $ 21.69 $ 17.58 4.19 947,799 $ 17.14 1,069,630 $ 22.01 - $ 23.83 $ 23.79 6.32 661,630 $ 23.79 867,197 $ 24.59 - $ 30.07 $ 25.07 6.30 545,947 $ 24.97 1,241,087 $ 40.00 - $ 40.00 $ 40.00 7.10 421,837 $ 40.00 1,208,586 $ 42.74 - $ 53.26 $ 50.76 8.00 261,334 $ 50.30 1,197,500 $ 57.00 - $ 77.11 $ 63.44 8.87 58,375 $ 57.43
Schedule of Stock Appreciation Rights Activity	The Company’s SAR activity in 2015 is as follows: Weighted Number Average Aggregate of Grant Intrinsic SARs Price Value (in thousands) Outstanding at December 31, 2014 418,801 $ 43.55 $ 6,417 Granted 176,200 $ 64.93 Exercised (33,262 ) $ 39.61 Canceled (31,038 ) $ 51.00 Outstanding at December 31, 2015 530,701 $ 50.46 $ 9,659
Schedule of Restricted Stock Units Activity	The Company’s RSU activity in 2015 is as follows: Weighted Average Number Grant-Date of Fair RSUs Value Non-vested at December 31, 2014 93,667 $ 45.89 Granted 276,922 $ 65.61 Vested (918 ) $ 47.87 Canceled (10,118 ) $ 62.77 Non-vested at December 31, 2015 359,553 $ 60.60
Summary of Performance Units Activity	The Company’s performance units activity in 2015 is as follows: Weighted Number Average of Grant-Date Performance Fair Units Value Non-vested at December 31, 2014 — $ — Granted 51,977 $ 64.93 Canceled (2,310 ) $ 64.93 Non-vested at December 31, 2015 49,667 $ 64.93
Summary of Severance Associated with Cost Reduction Programs	The following amounts were recorded for the severance associated with cost reduction programs (in thousands): Balance at December 31, 2014 $ 6,274 Expense, net of reversals (1,042 ) Payments (1,873 ) Foreign currency translation (22 ) Balance at December 31, 2015 $ 3,337

Operations by Geographic Loca54

Operations by Geographic Location (Tables)	12 Months Ended
	Dec. 31, 2015
Operations By Geographic Location [Abstract]
Operations within Geographic Region	The table below presents the Company’s operations by geographical location. The Company attributes revenues to geographical locations based upon where the services are performed. The Company’s operations within each geographical region are further broken down to show each country which accounts for 10% or more of the totals (in thousands): Year Ended December 31, 2015 2014 2013 Service revenues: Americas: United States $ 1,787,918 $ 1,589,402 $ 1,351,160 Other 185,583 194,597 181,814 Americas 1,973,501 1,783,999 1,532,974 Europe and Africa: United Kingdom 409,920 402,184 362,242 Other 1,050,070 1,121,354 1,139,262 Europe and Africa 1,459,990 1,523,538 1,501,504 Asia-Pacific: Japan 442,957 471,831 438,882 Other 449,971 386,454 334,980 Asia-Pacific 892,928 858,285 773,862 Total service revenues 4,326,419 4,165,822 3,808,340 Reimbursed expenses 1,411,200 1,294,176 1,291,205 Total revenues $ 5,737,619 $ 5,459,998 $ 5,099,545
Long Lived Assets	As of December 31, 2015 2014 Property, equipment and software, net: Americas: United States $ 169,674 $ 167,890 Other 1,204 1,774 Americas 170,878 169,664 Europe and Africa: United Kingdom 46,042 48,409 Other 16,615 15,782 Europe and Africa 62,657 64,191 Asia-Pacific: Japan 12,660 20,752 Other 24,975 25,271 Asia-Pacific 37,635 46,023 Total property, equipment and software, net $ 271,170 $ 279,878

Segments (Tables)

Segments (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Reconciliation of Revenues and Income from Segments to Consolidated	Information presented below is in thousands: Year Ended December 31, 2015 2014 2013 Service revenues Product Development $ 3,191,630 $ 3,097,831 $ 2,919,730 Integrated Healthcare Services 1,134,789 1,067,991 888,610 Total service revenues 4,326,419 4,165,822 3,808,340 Costs of revenue, service costs Product Development 1,828,734 1,820,937 1,752,800 Integrated Healthcare Services 896,852 863,169 718,626 Total costs of revenue, service costs 2,725,586 2,684,106 2,471,426 Selling, general and administrative Product Development 648,297 631,678 604,663 Integrated Healthcare Services 153,896 140,019 127,860 General corporate and unallocated 118,792 110,641 127,987 Total selling, general and administrative 920,985 882,338 860,510 Income from operations Product Development 714,599 645,216 562,267 Integrated Healthcare Services 84,041 64,803 42,124 General corporate and unallocated (118,792 ) (110,641 ) (127,987 ) Restructuring costs (30,752 ) (8,988 ) (14,071 ) Impairment charges (2,484 ) — — Total income from operations $ 646,612 $ 590,390 $ 462,333
Reconciliation of Assets from Segment to Consolidated	As of December 31, 2015 2014 2013 Assets Product Development $ 3,343,502 $ 2,786,692 $ 2,571,502 Integrated Healthcare Services 405,411 330,689 299,284 General corporate and unallocated 177,403 178,572 183,437 Total assets $ 3,926,316 $ 3,295,953 $ 3,054,223
Reconciliation of Other Significant Reconciling Items from Segments to Consolidated	Year Ended December 31, 2015 2014 2013 Expenditures to acquire long-lived assets Product Development $ 67,660 $ 68,187 $ 69,375 Integrated Healthcare Services 8,667 8,279 17,398 General corporate and unallocated 2,064 6,184 1,574 Total expenditures to acquire long-lived assets $ 78,391 $ 82,650 $ 88,347
Depreciation and Amortization Expense	Year Ended December 31, 2015 2014 2013 Depreciation and amortization expense Product Development $ 100,913 $ 95,168 $ 82,047 Integrated Healthcare Services 21,961 20,821 20,475 General corporate and unallocated 4,868 5,024 4,982 Total depreciation and amortization expense $ 127,742 $ 121,013 $ 107,504

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Reconciles the Basic to Diluted Weighted Average Shares Outstanding	The following table reconciles the basic to diluted weighted average shares outstanding (in thousands): Year Ended December 31, 2015 2014 2013 Basic weighted average common shares outstanding 123,038 127,994 124,147 Effect of dilutive stock options and share awards 2,592 3,089 3,715 Diluted weighted average common shares outstanding 125,630 131,083 127,862
Summary of Weighted-Average Outstanding Stock Options Excluded from Computation of Diluted Earnings Per Share	The following table shows the weighted average number of outstanding share-based awards not included in the computation of diluted earnings per share as the effect of including such share-based awards in the computation would be anti-dilutive (in thousands): Year Ended December 31, 2015 2014 2013 Weighted average shares subject to anti-dilutive share-based awards 1,058 1,241 1,765

Comprehensive Income (Tables)

Comprehensive Income (Tables)	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Summary of Components of AOCI	Below is a summary of the components of AOCI (in thousands): Foreign Currency Translation Marketable Securities Derivative Instruments Defined Benefit Plans Income Taxes Total Balance at December 31, 2012 $ 19,312 $ 467 $ (33,542 ) $ (8,235 ) $ 29,693 $ 7,695 Other comprehensive (loss) income before reclassifications (25,141 ) 5,241 (393 ) 2,147 1,331 (16,815 ) Reclassification adjustments — — 13,080 1,044 (5,380 ) 8,744 Balance at December 31, 2013 (5,829 ) 5,708 (20,855 ) (5,044 ) 25,644 (376 ) Other comprehensive (loss) income before reclassifications (49,911 ) (976 ) (6,834 ) (10,218 ) 7,225 (60,714 ) Reclassification adjustments — (5,004 ) 8,630 743 (2,370 ) 1,999 Balance at December 31, 2014 (55,740 ) (272 ) (19,059 ) (14,519 ) 30,499 (59,091 ) Other comprehensive (loss) income before reclassifications (61,090 ) (436 ) (13,202 ) 282 9,110 (65,336 ) Reclassification adjustments — — 18,269 973 (6,181 ) 13,061 Balance at December 31, 2015 $ (116,830 ) $ (708 ) $ (13,992 ) $ (13,264 ) $ 33,428 $ (111,366 )
Summary of (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item	Below is a summary of the (gains) losses reclassified from AOCI into the consolidated statements of income and the affected financial statement line item (in thousands): Affected Financial Statement Year Ended December 31, Reclassification Adjustments Line Item 2015 2014 2013 Marketable securities Other expense (income), net $ — $ (5,004 ) $ — Total before income taxes — (5,004 ) — Income tax expense — (1,927 ) — Total net of income taxes $ — $ (3,077 ) $ — Derivative instruments: Interest rate swaps Interest expense $ 12,333 $ 12,424 $ 12,582 Foreign exchange forward contracts Service revenues 5,936 (3,794 ) 498 Total before income taxes 18,269 8,630 13,080 Income tax benefit 5,826 4,022 4,991 Total net of income taxes $ 12,443 $ 4,608 $ 8,089 Defined benefit plans: Amortization of prior service costs See Note 17 $ — $ 107 $ 336 Amortization of actuarial losses See Note 17 973 636 708 Total before income taxes 973 743 1,044 Income tax benefit 355 275 389 Total net of income taxes $ 618 $ 468 $ 655

Supplemental Cash Flow Inform58

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	The following table presents the Company’s supplemental cash flow information (in thousands): Year Ended December 31, 2015 2014 2013 Supplemental Cash Flow Information: Interest paid $ 82,333 $ 93,912 $ 115,494 Income taxes paid, net of refunds 120,804 138,931 70,983 Non-cash Investing Activities: Acquisition of property and equipment utilizing capital leases $ 4,238 $ 2,476 $ 3,761 Fair value of contingent consideration payable in connection with acquisitions — — 14,300 Fair value of consideration transferred in connection with the Q 2 423,268 — —

Quarterly Financial Data (Una59

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Unaudited Quarterly Results of Operations	The following table summarizes the Company’s unaudited quarterly results of operations (in thousands, except per share data): 2015 First Quarter Second Quarter Third Quarter Fourth Quarter Service revenues $ 1,029,974 $ 1,074,366 $ 1,093,480 $ 1,128,599 Income from operations 143,217 158,389 167,023 177,983 Net income 86,431 84,947 108,839 108,087 Net (income) loss attributable to noncontrolling interests (33 ) 4 2,447 (3,517 ) Net income attributable to Quintiles Transnational Holdings Inc. $ 86,398 $ 84,951 $ 111,286 $ 104,570 Basic earnings per share (1) $ 0.69 $ 0.69 $ 0.91 $ 0.86 Diluted earnings per share (1) $ 0.68 $ 0.67 $ 0.89 $ 0.85 2014 First Quarter Second Quarter Third Quarter Fourth Quarter Service revenues $ 1,005,288 $ 1,035,476 $ 1,061,013 $ 1,064,045 Income from operations 141,316 141,000 149,142 158,932 Net income 90,214 85,110 92,733 88,444 Net (income) loss attributable to noncontrolling interests (31 ) 10 (79 ) (18 ) Net income attributable to Quintiles Transnational Holdings Inc. $ 90,183 $ 85,120 $ 92,654 $ 88,426 Basic earnings per share (1) $ 0.69 $ 0.66 $ 0.73 $ 0.70 Diluted earnings per share (1) $ 0.68 $ 0.64 $ 0.71 $ 0.69 (1) The sum of the quarterly per share amounts may not equal per share amounts reported for year-to-date periods. This is due to changes in the number of weighted average shares outstanding and the effects of rounding for each period.

Summary of Significant Accoun60

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015USD ($)EmployeeCountryCustomer	Dec. 31, 2014USD ($)Customer	Dec. 31, 2013USD ($)Customer
Summary Of Significant Accounting Policies [Line Items]
Number of countries | Country	100
Number of employees | Employee	36,100
Foreign currency net losses	$ (4,600,000)	$ 4,900,000	$ 4,000,000
Capitalized and amortized expense related to software and related assets	37,700,000	33,100,000	32,200,000
Impairment charges	$ 2,484,000	0	0
Contract termination period	Most contracts may be terminated upon 30 to 90 days notice by the customer, however, in the event of termination, contract provisions typically require payment for services rendered through the date of termination, as well as for subsequent services rendered to close out the contract.
Advertising expense	$ 12,800,000	16,000,000	14,800,000
Share-based compensation expense	37,758,000	30,001,000	22,826,000
Recognized future income tax benefit	8,900,000	7,600,000	$ 8,100,000
Unrecognized non-vested share-based compensation	$ 38,800,000
Weighted average period of share-based compensation	1 year 3 months 18 days
Deferred income tax assets current	$ 100,978,000	$ 118,515,000
Deferred income tax liabilities, current	$ 148,000
Customer Concentration Risk [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of customers served | Customer	0	0	0

Summary of Significant Accoun61

Summary of Significant Accounting Policies - Property and Equipment at Cost Using Straight-Line Method (Detail)	12 Months Ended
	Dec. 31, 2015
Minimum [Member] | Buildings and leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life, Years	3 years
Minimum [Member] | Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life, Years	3 years
Minimum [Member] | Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life, Years	5 years
Minimum [Member] | Motor vehicles [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life, Years	3 years
Maximum [Member] | Buildings and leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life, Years	40 years
Maximum [Member] | Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life, Years	10 years
Maximum [Member] | Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life, Years	10 years
Maximum [Member] | Motor vehicles [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life, Years	5 years

Summary of Significant Accoun62

Summary of Significant Accounting Policies - Definite-lived identifiable intangible assets amortized (Detail)	12 Months Ended
	Dec. 31, 2015
Trademarks and trade names [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life, Years	2 years
Trademarks and trade names [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life, Years	6 years
Non-compete agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life, Years	3 years
Contract backlog and customer relationships [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life, Years	1 year
Contract backlog and customer relationships [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life, Years	10 years
Software and related assets [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life, Years	2 years
Software and related assets [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life, Years	9 years

Summary of Significant Accoun63

Summary of Significant Accounting Policies - Summary of Research and Development Expenses (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Research And Development [Line Items]
Research and development expenses	$ 3,337	$ 5,791	$ 4,955
Software and related assets [Member]
Schedule Of Research And Development [Line Items]
Research and development expenses	3,198	4,980	3,955
Research and development activity [Member]
Schedule Of Research And Development [Line Items]
Research and development expenses	$ 139	$ 811	$ 1,000

Accounts Receivable and Unbil64

Accounts Receivable and Unbilled Services - Accounts Receivable and Unbilled Services (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Trade:
Billed	$ 553,652	$ 444,941
Unbilled services	614,381	532,312
Trade accounts receivable and unbilled services, gross	1,168,033	977,253
Allowance for doubtful accounts	(2,284)	(1,998)
Trade accounts receivable and unbilled services, net	$ 1,165,749	$ 975,255

Accounts Receivable and Unbil65

Accounts Receivable and Unbilled Services - Percentage of Accounts Receivable and Unbilled Services by Region (Detail)	Dec. 31, 2015	Dec. 31, 2014
Accounts Receivable [Line Items]
Percentage of accounts receivables	100.00%	100.00%
United States [Member]
Accounts Receivable [Line Items]
Percentage of accounts receivables	58.00%	55.00%
Other [Member]
Accounts Receivable [Line Items]
Percentage of accounts receivables	1.00%	2.00%
Americas [Member]
Accounts Receivable [Line Items]
Percentage of accounts receivables	59.00%	57.00%
United Kingdom [Member]
Accounts Receivable [Line Items]
Percentage of accounts receivables	23.00%	23.00%
Other [Member]
Accounts Receivable [Line Items]
Percentage of accounts receivables	10.00%	11.00%
Europe and Africa [Member]
Accounts Receivable [Line Items]
Percentage of accounts receivables	33.00%	34.00%
Japan [Member]
Accounts Receivable [Line Items]
Percentage of accounts receivables	3.00%	4.00%
Other [Member]
Accounts Receivable [Line Items]
Percentage of accounts receivables	5.00%	5.00%
Asia-Pacific [Member]
Accounts Receivable [Line Items]
Percentage of accounts receivables	8.00%	9.00%

Investments - Debt, Equity and

Investments - Debt, Equity and Other Securities - Summary of the Company's Debt, Equity and Other Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Investments Debt And Equity Securities [Abstract]
Marketable securities	$ 395	$ 831
Cost method	32,516	33,672
Total	$ 32,911	$ 34,503

Investments - Debt, Equity an67

Investments - Debt, Equity and Other Securities - Summary of Available-for-Sale Securities (Detail) - Marketable Equity Securities [Member] - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 1,103	$ 1,103
Gross Unrealized Loss	(708)	(272)
Market Value	$ 395	$ 831

Investments - Debt, Equity an68

Investments - Debt, Equity and Other Securities - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Feb. 25, 2011
Investments Debt And Equity Securities [Abstract]
Gains or losses from the sale of marketable equity securities	$ 0	$ 5,000,000	$ 0
Net of tax adjustment to unrealized gain (loss) on available-for-sale securities	(438,000)	(170,000)	3,500,000
Loss on sale of marketable equity securities	$ 0	$ 0	$ 0
Investment in joint venture				$ 30,000,000
Non controlling interest percentage in exchange of investment in joint venture	2.20%	3.00%
Customer incentive	$ 12,500,000
Preferred stock acquired from Intarcia	5,000,000
Total customer incentive	2,500,000	$ 7,100,000
Preferred stock investment	$ 5,000,000

Investments - Debt, Equity an69

Investments - Debt, Equity and Other Securities - Summary of the Company's Portfolio of Cost Method Investments (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Schedule Of Cost Method Investments [Line Items]
Cost of investments	$ 32,516	$ 33,672
Equity investments [Member]
Schedule Of Cost Method Investments [Line Items]
Cost of investments	$ 32,516	32,516
Convertible notes [Member]
Schedule Of Cost Method Investments [Line Items]
Cost of investments		$ 1,156

Investments in and Advances t70

Investments in and Advances to Unconsolidated Affiliates - Investments in and Advances to Unconsolidated Affiliates (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Investments in and Advances to Affiliates [Line Items]
Investments in and Advances to Affiliates	$ 52,382	$ 31,508
NovaQuest Pharma Opportunities Fund lll, L.P [Member]
Investments in and Advances to Affiliates [Line Items]
Investments in and Advances to Affiliates	39,785	22,633
NovaQuest Pharma Opportunities Fund lV, L.P [Member]
Investments in and Advances to Affiliates [Line Items]
Investments in and Advances to Affiliates	2,524
Cenduit TM [Member]
Investments in and Advances to Affiliates [Line Items]
Investments in and Advances to Affiliates	9,478	8,271
Other [Member]
Investments in and Advances to Affiliates [Line Items]
Investments in and Advances to Affiliates	$ 595	$ 604

Investments in and Advances t71

Investments in and Advances to Unconsolidated Affiliates - Additional Information (Detail) $ in Thousands	Dec. 31, 2015USD ($)	Feb. 28, 2015USD ($)	Dec. 31, 2014	Feb. 25, 2011USD ($)	May. 31, 2007USD ($)Location
Schedule of Investments [Line Items]
Amount of initial capital				$ 30,000
NovaQuest Pharma Opportunities Fund lll, L.P [Member]
Schedule of Investments [Line Items]
Committed to invest fund	$ 50,000
Commitment funded	34,700
Funding commitments	$ 15,300
Beneficial ownership in common stock	10.90%		10.90%
NovaQuest Pharma Opportunities Fund lV, L.P [Member]
Schedule of Investments [Line Items]
Committed to invest fund		$ 20,000
Commitment funded	$ 2,700
Funding commitments	$ 17,300
Beneficial ownership in common stock	2.30%
Cenduit TM [Member]
Schedule of Investments [Line Items]
Ownership interest					50.00%
Number of locations | Location					3
Cenduit TM [Member] | United Kingdom [Member]
Schedule of Investments [Line Items]
Amount of initial capital					$ 3,500
Cenduit TM [Member] | United States [Member]
Schedule of Investments [Line Items]
Amount of initial capital					3,500
Cenduit TM [Member] | Switzerland [Member]
Schedule of Investments [Line Items]
Amount of initial capital					$ 3,500

Derivatives - Additional Inform

Derivatives - Additional Information (Detail)	1 Months Ended	12 Months Ended
	May. 31, 2015USD ($)	Dec. 31, 2015USD ($)Derivative	Dec. 31, 2014USD ($)Derivative	Jun. 03, 2015USD ($)Agreement	Jun. 09, 2011Agreement
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of foreign exchange forward contracts | Agreement				7	6
Notional amount				$ 440,000,000
Payment to terminate hedge accounting	$ 12,400,000
Interest rate cash flow hedge loss to be reclassified during next nine months, net		$ (3,100,000)
Interest swaps accrual beginning date		Jun. 30, 2016
Derivative fixed interest rate		2.10%
Interest rate cash flow hedge loss to be reclassified during next 12 months, net		$ (3,200,000)
Senior Notes [Member] | Variable Rate Debt [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps effectively converted percent		50.00%
Senior Notes [Member] | Fixed Rate Debt [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps effectively converted percent		50.00%
Accrued Interest [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Payment to terminate hedge accounting	$ 1,400,000
Foreign Exchange Forward Contracts [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of foreign exchange forward contracts | Derivative		15	13
Notional amount		$ 117,500,000	$ 76,000,000
Losses related to these foreign exchange forward contracts		$ 5,200,000	$ 4,600,000
Expiration year of hedge instruments		2,016	2,015
Six Interest Rate Swaps [Member] | Minimum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps expiry date		Sep. 30, 2013
Six Interest Rate Swaps [Member] | Maximum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps expiry date		Mar. 31, 2016
Seven Interest Rate Swaps [Member] | Minimum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps expiry date		Mar. 31, 2017
Seven Interest Rate Swaps [Member] | Maximum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps expiry date		Mar. 31, 2020

Derivatives - Summary of Fair V

Derivatives - Summary of Fair Values of Derivative Instruments Designated as Hedges (Detail) - Designated as Hedging Instrument [Member] - Other Current Liabilities [Member] - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Foreign Exchange Forward Contracts [Member]
Derivatives Fair Value [Line Items]
Derivative liability fair value	$ 5,194	$ 4,635
Interest Rate Swaps [Member]
Derivatives Fair Value [Line Items]
Derivative liability fair value	$ 5,698	$ 14,424

Derivatives - Effect of Cash Fl

Derivatives - Effect of Cash Flow Hedging Instruments on Other Comprehensive Income (Loss) (Detail) - Derivatives Designated As Cash Flow Hedges [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	$ 5,067	$ 1,796	$ 12,687
Foreign Exchange Forward Contracts [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	(559)	(8,585)	3,485
Interest Rate Swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	$ 5,626	$ 10,381	$ 9,202

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Detail) - Recurring Fair Value Measurements [Member] - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	$ 395	$ 831
Fair value of liabilities	15,266	20,511
Foreign Exchange Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	5,194	4,635
Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	5,698	14,424
Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	4,374	1,452
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	395	831
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	10,892	19,059
Level 2 [Member] | Foreign Exchange Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	5,194	4,635
Level 2 [Member] | Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	5,698	14,424
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	4,374	1,452
Level 3 [Member] | Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	4,374	1,452
Marketable Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	395	831
Marketable Equity Securities [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	$ 395	$ 831

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis (Detail) - Accounts Payable and Accrued Expenses and Other Liabilities [Member] - Contingent Consideration [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance, Contingent Consideration	$ 1,452	$ 13,014	$ 3,521
Initial estimate of contingent consideration			14,300
Contingent consideration paid	(3,000)	(3,000)
Revaluations included in earnings	5,922	(8,562)	(4,807)
Ending Balance, Contingent Consideration	$ 4,374	$ 1,452	$ 13,014

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other identifiable intangibles, net	$ 368,106	$ 280,243
Non-recurring Fair Value Measurements [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	1,172,700
Cost and equity method investments	84,900
Goodwill	719,700
Other identifiable intangibles, net	$ 368,100

Property and Equipment - Summar

Property and Equipment - Summary of Major Classes of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	$ 510,712	$ 496,225
Less accumulated depreciation	(322,319)	(305,928)
Property and Equipment, Net	188,393	190,297
Land, buildings and leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	187,405	185,940
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	257,119	240,227
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	52,840	54,615
Motor vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	$ 13,348	$ 15,443

Goodwill and Identifiable Int79

Goodwill and Identifiable Intangible Assets - Additional Information (Detail) $ in Millions	Dec. 31, 2015USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Identifiable intangible assets	$ 368.1
Identifiable intangible assets related to trade name	128.2
Estimated amortization expense, 2015	61.7
Estimated amortization expense, 2016	50.2
Estimated amortization expense, 2017	39.2
Estimated amortization expense, 2018	32.5
Estimated amortization expense, 2019	$ 20.8

Goodwill and Identifiable Int80

Goodwill and Identifiable Intangible Assets - Summary of Amortization Expense Associated with Identifiable Definite-Lived Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization expense	$ 66,545	$ 58,457	$ 51,450

Goodwill and Identifiable Int81

Goodwill and Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Identifiable Intangible Assets [Line Items]
Gross Amount	$ 518,035	$ 401,850
Accumulated Amortization	(278,176)	(231,283)
Net Amount	239,859	170,567
Product licensing and distribution rights and customer relationships [Member]
Identifiable Intangible Assets [Line Items]
Gross Amount	224,149	123,227
Accumulated Amortization	(75,606)	(54,413)
Net Amount	148,543	68,814
Software and related assets [Member]
Identifiable Intangible Assets [Line Items]
Gross Amount	279,266	260,052
Accumulated Amortization	(196,489)	(170,471)
Net Amount	82,777	89,581
Trademarks and trade names [Member]
Identifiable Intangible Assets [Line Items]
Gross Amount	14,620	18,571
Accumulated Amortization	(6,081)	(6,399)
Net Amount	8,539	12,172
Trade names [Member]
Identifiable Intangible Assets [Line Items]
Gross Amount	$ 128,247	$ 109,676

Goodwill and Identifiable Int82

Goodwill and Identifiable Intangible Assets - Summary of Goodwill by Segment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Goodwill [Line Items]
Beginning Balance	$ 464,434	$ 409,626
Business combinations	262,377	62,778
Impact of foreign currency fluctuations and other	(7,071)	(7,970)
Ending Balance	719,740	464,434
Product Development [Member]
Goodwill [Line Items]
Beginning Balance	346,608	351,144
Business combinations	262,377
Impact of foreign currency fluctuations and other	(6,879)	(4,536)
Ending Balance	602,106	346,608
Integrated Healthcare Services [Member]
Goodwill [Line Items]
Beginning Balance	117,826	58,482
Business combinations		62,778
Impact of foreign currency fluctuations and other	(192)	(3,434)
Ending Balance	$ 117,634	$ 117,826

Accrued Expenses - Accrued Expe

Accrued Expenses - Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Compensation, including bonuses, fringe benefits and payroll taxes	$ 400,748	$ 403,250
Restructuring	13,564	6,083
Interest	5,115	274
Contract related	271,076	255,530
Other	70,254	68,507
Total	$ 760,757	$ 733,644

Credit Arrangements - Summary o

Credit Arrangements - Summary of Credit Facilities (Detail)	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2015GBP (£)
Revolving credit facility [Member]
Line Of Credit Facility [Line Items]
Facility	$ 500,000,000
Interest Rate Description	London Interbank Offer Rate (“LIBOR”) (0.61% at December 31, 2015) plus 1.75%
LIBOR [Member] | Revolving credit facility [Member]
Line Of Credit Facility [Line Items]
Rate	0.61%	0.61%
Interest Rate spread on base rate	1.75%
Receivables Financing Facility [Member]
Line Of Credit Facility [Line Items]
Facility	$ 25,000,000
Interest Rate Description	LIBOR Market Index Rate (0.43% at December 31, 2015) plus 0.85% to 1.35% depending upon the Company’s debt rating
Rate	0.43%	0.43%
Receivables Financing Facility [Member] | LIBOR [Member]
Line Of Credit Facility [Line Items]
Rate	1.48%	1.48%
Interest Rate spread on base rate	1.05%
Receivables Financing Facility [Member] | LIBOR [Member] | Minimum [Member]
Line Of Credit Facility [Line Items]
Interest Rate spread on base rate	0.85%
Receivables Financing Facility [Member] | LIBOR [Member] | Maximum [Member]
Line Of Credit Facility [Line Items]
Interest Rate spread on base rate	1.35%
General Banking Facility [Member]
Line Of Credit Facility [Line Items]
Facility	$ 14,800,000	£ 10,000,000
Interest Rate Description	Bank’s base rate (0.5% at December 31, 2015) plus 1%
General Banking Facility [Member] | Base Rate
Line Of Credit Facility [Line Items]
Rate	0.50%	0.50%
Interest Rate spread on base rate	1.00%

Credit Arrangements - Additiona

Credit Arrangements - Additional Information (Detail) £ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2015GBP (£)	Dec. 31, 2014USD ($)
Line Of Credit Facility [Line Items]
Outstanding borrowings	$ 0		$ 0
Revolving Credit Facility
Line Of Credit Facility [Line Items]
Credit facility repaid			$ 150,000,000
Outstanding borrowings	150,000,000
General Banking Facility [Member]
Line Of Credit Facility [Line Items]
Bank guarantees	$ 5,800,000	£ 3.9
Term Loan A [Member] | Revolving Credit Facility
Line Of Credit Facility [Line Items]
Debt instrument restrictive covenants, description	The credit agreement also contains one financial covenant, which is a total leverage ratio that provides for a maximum ratio of consolidated total debt to consolidated EBITDA, as defined in the credit agreement, for any period of four consecutive fiscal quarters, measured as of the end of such period, of 5.75 to 1.00, and applies at any time that the Term Loan A or New Revolver commitments remain outstanding.	The credit agreement also contains one financial covenant, which is a total leverage ratio that provides for a maximum ratio of consolidated total debt to consolidated EBITDA, as defined in the credit agreement, for any period of four consecutive fiscal quarters, measured as of the end of such period, of 5.75 to 1.00, and applies at any time that the Term Loan A or New Revolver commitments remain outstanding.
Term Loan A [Member] | Revolving Credit Facility | Maximum [Member]
Line Of Credit Facility [Line Items]
Total debt to consolidated EBITDA	575.00%	575.00%

Credit Arrangements - Schedule

Credit Arrangements - Schedule of Long-term Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term debt	$ 2,500,750	$ 2,305,606
Less: unamortized discount	(24,020)	(12,379)
Less: unamortized debt issuance costs	(8,955)	(9,879)
Less: current portion	(48,500)	(750)
Long term debt, total	2,419,275	2,282,598
4.875% Senior Notes [Member] | Due in 2023 [Member]
Debt Instrument [Line Items]
Long-term debt	800,000
Term Loan A [Member] | Due in 2020 [Member]
Debt Instrument [Line Items]
Long-term debt	828,750
Term Loan B [Member] | Due in 2022 [Member]
Debt Instrument [Line Items]
Long-term debt	597,000
Term Loan B-3 [Member] | Due in 2018 [Member]
Debt Instrument [Line Items]
Long-term debt		2,030,606
Receivables Financing Facility [Member]
Debt Instrument [Line Items]
Long-term debt	$ 275,000	$ 275,000

Credit Arrangements - Schedul87

Credit Arrangements - Schedule of Long-term Debt (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2015	May. 12, 2015
4.875% Senior Notes [Member] | Due in 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	4.875%	4.875%
Debt maturity year	2,023
Term Loan A [Member] | Due in 2020 [Member]
Debt Instrument [Line Items]
Debt maturity year	2,020
Debt instrument interest rate terms, Description	LIBOR plus 1.75%, or 2.36% at December 31, 2015
Term Loan B [Member] | Due in 2022 [Member]
Debt Instrument [Line Items]
Debt maturity year	2,022
Debt instrument interest rate terms, Description	The greater of LIBOR or 0.75% plus 2.50%, or 3.25% at December 31, 2015
Term Loan B-3 [Member] | Due in 2018 [Member]
Debt Instrument [Line Items]
Debt maturity year	2,018
Debt instrument interest rate terms, Description	The greater of three month LIBOR or 1.25% plus 2.50%, or 3.75% at December 31, 2014
Receivables Financing Facility [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	0.43%
Debt maturity year	2,018
Debt instrument interest rate terms, Description	LIBOR plus 1.05%, or 1.48% at December 31, 2015
LIBOR [Member] | Term Loan A [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	2.36%
Interest Rate spread on base rate	1.75%
LIBOR [Member] | Term Loan B [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	3.25%
LIBOR [Member] | Term Loan B-3 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	3.75%
LIBOR [Member] | Receivables Financing Facility [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	1.48%
Interest Rate spread on base rate	1.05%
LIBOR [Member] | Minimum [Member] | Term Loan B [Member]
Debt Instrument [Line Items]
Interest Rate spread on base rate	0.75%
LIBOR [Member] | Minimum [Member] | Term Loan B-3 [Member]
Debt Instrument [Line Items]
Interest Rate spread on base rate	1.25%
LIBOR [Member] | Minimum [Member] | Receivables Financing Facility [Member]
Debt Instrument [Line Items]
Interest Rate spread on base rate	0.85%
LIBOR [Member] | Maximum [Member] | Term Loan B [Member]
Debt Instrument [Line Items]
Interest Rate spread on base rate	2.50%
LIBOR [Member] | Maximum [Member] | Term Loan B-3 [Member]
Debt Instrument [Line Items]
Interest Rate spread on base rate	2.50%
LIBOR [Member] | Maximum [Member] | Receivables Financing Facility [Member]
Debt Instrument [Line Items]
Interest Rate spread on base rate	1.35%

Credit Arrangements - Contractu

Credit Arrangements - Contractual Maturities of Long-term Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
2,016	$ 48,500
2,017	48,500
2,018	323,500
2,019	48,500
2,020	664,750
Thereafter	1,367,000
Long-term debt	$ 2,500,750	$ 2,305,606

Credit Arrangements - Senior Se

Credit Arrangements - Senior Secured Credit Agreement - Additional Information (Detail) - USD ($)	May. 12, 2015	Nov. 07, 2014	Dec. 20, 2013	Dec. 31, 2015	Dec. 31, 2014
Line Of Credit Facility [Line Items]
Outstanding borrowings				$ 0	$ 0
Senior Notes [Member]
Line Of Credit Facility [Line Items]
Debt Instrument payment frequency				Interest on the Senior Notes is paid semiannually on May 15 and November 15 of each year until maturity.
Revolving Credit Facility
Line Of Credit Facility [Line Items]
Aggregate maximum principal amount				$ 500,000,000
Outstanding borrowings				$ 150,000,000
Revolving Credit Facility | Minimum [Member] | 2014 Revolving Credit Facility Amendment [Member]
Line Of Credit Facility [Line Items]
Outstanding borrowings		$ 300,000,000
Revolving Credit Facility | Maximum [Member] | 2014 Revolving Credit Facility Amendment [Member]
Line Of Credit Facility [Line Items]
Credit facility arrangement amended date		Nov. 7, 2014
Outstanding borrowings		$ 400,000,000
Senior secured credit facilities [Member]
Line Of Credit Facility [Line Items]
Aggregate maximum principal amount	$ 1,950,000,000
Percentage of excess cash flow for loan repayment	25.00%
Percentage of repayment from cash proceeds of asset disposition	100.00%
Percentage of equity interest of domestic subsidiaries pledged as collateral	100.00%
Percentage of equity interest of foreign subsidiaries pledged as collateral	65.00%
Senior secured credit facilities [Member] | Minimum [Member]
Line Of Credit Facility [Line Items]
Percentage of excess cash flow for loan repayment	0.00%
Senior secured credit facilities [Member] | Term Loans [Member]
Line Of Credit Facility [Line Items]
Aggregate maximum principal amount	$ 1,450,000,000
Senior secured credit facilities [Member] | Revolving Credit Facility
Line Of Credit Facility [Line Items]
Aggregate maximum principal amount	$ 500,000,000
Credit facility maturity period				5 years
Term Loan A [Member]
Line Of Credit Facility [Line Items]
Annual Maturities Percentage	5.00%
Term Loan A [Member] | Term Loans [Member]
Line Of Credit Facility [Line Items]
Aggregate maximum principal amount	$ 850,000,000
Debt maturity year				2,020
Term Loan B [Member]
Line Of Credit Facility [Line Items]
Annual Maturities Percentage	1.00%
Term Loan B [Member] | Term Loans [Member]
Line Of Credit Facility [Line Items]
Aggregate maximum principal amount	$ 600,000,000
Debt maturity year				2,022
4.875% Senior Notes [Member] | Due in 2023 [Member]
Line Of Credit Facility [Line Items]
Debt maturity year				2,023
Notes issued in private placement, amount	$ 800,000,000
Debt instrument interest rate stated percentage	4.875%			4.875%
Term Loan A and B [Member]
Line Of Credit Facility [Line Items]
Term loan maturity dates, description				Annual maturities on the New Term Loan A and the New Term Loan B are 5% and 1%, respectively, of the respective original principal amount with the remaining balance to be repaid on their respective maturity dates
Percentage of excess cash flow for loan repayment	50.00%
Term Loan B-3 [Member] | Due in 2018 [Member]
Line Of Credit Facility [Line Items]
Debt maturity year				2,018
Termination of interest rate swaps				$ 11,000,000
Term Loan B-3 [Member] | Due 2018 [Member]
Line Of Credit Facility [Line Items]
Aggregate maximum principal amount			$ 2,061,000,000
Credit facility due			2,018

Credit Arrangements - Additio90

Credit Arrangements - Additional Information - Detail (Detail) - USD ($)	1 Months Ended	12 Months Ended
	May. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 20, 2013
Line Of Credit Facility [Line Items]
Outstanding borrowings		$ 0	$ 0
Loss on extinguishment of debt		(7,780,000)		$ (19,831,000)
Unamortized debt issuance cost		8,955,000	9,879,000
Unamortized discount		24,020,000	12,379,000
Cash paid to pay down debt		2,056,780,000	$ 30,157,000	2,444,600,000
Revolving Credit Facility
Line Of Credit Facility [Line Items]
Aggregate maximum principal amount		500,000,000
Outstanding borrowings		$ 150,000,000
Term Loans [Member]
Line Of Credit Facility [Line Items]
Loss on extinguishment of debt	$ 15,500,000
Unamortized debt issuance cost	4,700,000
Unamortized discount	4,700,000
Fees and expenses	6,100,000
Cash paid to pay down debt	308,900,000
Term Loan B-1 [Member] | Due 2018 [Member]
Line Of Credit Facility [Line Items]
Loss on extinguishment of debt	(1,000,000)
Unamortized debt issuance cost	930,000,000
Unamortized discount	112,000,000
Cash paid to pay down debt	$ 50,000,000
Receivables Financing Facility [Member]
Line Of Credit Facility [Line Items]
Securitization arrangement initiation date		Dec. 5, 2014
Credit facility maturity period		4 years
Aggregate maximum principal amount		$ 25,000,000
Receivables Financing Facility [Member] | Term Loans [Member]
Line Of Credit Facility [Line Items]
Aggregate maximum principal amount		275,000,000
Receivables Financing Facility [Member] | Revolving Loan Commitment [Member]
Line Of Credit Facility [Line Items]
Aggregate maximum principal amount		25,000,000
Increase in revolving loan commitment		35,000,000
Term Loan B-3 [Member] | Due 2018 [Member]
Line Of Credit Facility [Line Items]
Aggregate maximum principal amount					$ 2,061,000,000
Repayment of term loan		25,000,000
Loss on extinguishment of debt		7,800,000		(3,300,000)
Unamortized debt issuance cost		1,100,000		1,600,000
Unamortized discount		1,300,000		1,600,000
Fees and expenses		$ 5,400,000		$ 25,000,000

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Leases [Abstract]
Rental expenses under agreement	$ 109.4	$ 114.6	$ 125.6
Operating lease year of expiry	2,029

Leases - Summary of Future Mini

Leases - Summary of Future Minimum Lease Payments Under Capital and Operating Leases (Detail) $ in Thousands	Dec. 31, 2015USD ($)
Leases [Abstract]
Capital leases, future minimum payments due, 2016	$ 15
Capital leases, future minimum payments due, 2017	18
Capital leases, total minimum lease payments	33
Capital leases, Amounts representing interest	(2)
Capital leases, Present value of net minimum payments	31
Capital leases, Current portion	(13)
Capital leases, Long-term capital lease obligations	18
Operating leases, future minimum payments due, 2016	84,747
Operating leases, future minimum payments due, 2017	62,485
Operating leases, future minimum payments due, 2018	41,907
Operating leases, future minimum payments due, 2019	29,201
Operating leases, future minimum payments due, 2020	25,713
Operating leases, future minimum payments due, Thereafter	111,267
Operating leases, total minimum lease payments	$ 355,320

Shareholders' Deficit - Additio

Shareholders' Deficit - Additional Information (Detail) - USD ($)	Nov. 10, 2014	May. 28, 2014	May. 27, 2014	May. 14, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2015	Oct. 30, 2013
Class Of Stock [Line Items]
Common stock issued					119,378,000	124,129,000		119,378,000
Proceeds from issue of common stock through IPO							$ 525,000,000
Preferred stock, authorized					1,000,000			1,000,000
Preferred stock, par value					$ 0.01			$ 0.01
Preferred stock, shares issued					0	0		0
Preferred stock, shares outstanding					0	0		0
Repurchase of common stock, value					$ 515,010,000	$ 415,131,000	$ 6,434,000	$ 995,600,000
Equity repurchase program authorized amount									$ 125,000,000
Repurchase of common stock, Shares					7,855,796	7,591,175	153,223
Q2 Solutions
Class Of Stock [Line Items]
Percentage of Quest’s noncontrolling interest in Q2 Solutions					40.00%			40.00%
Quest’s noncontrolling interest in Q2 Solutions					$ 231,900,000
Equity Repurchase Program [Member]
Class Of Stock [Line Items]
Repurchase of common stock, value					515,010,000	$ 14,000	$ 6,434,000
Equity repurchase program authorized amount					725,000,000			$ 725,000,000
Equity repurchase program increase in authorized amount					600,000,000
Equity available for repurchase under the repurchase program					$ 144,500,000			$ 144,500,000
Repurchase of common stock, Shares					7,855,796	300	153,223
Other Equity Repurchases [Member]
Class Of Stock [Line Items]
Repurchase of common stock, value	$ 250,000,000	$ 165,100,000
Repurchase of common stock, Shares	4,303,666	3,287,209
Repurchase of common stock, share price	$ 58.09	$ 50.23	$ 51.26
Repurchase price per share percentage			98.00%
Other Equity Repurchases [Member] | Revolving credit facility [Member]
Class Of Stock [Line Items]
Credit facility amount used to fund repurchase	$ 150,000,000
IPO [Member]
Class Of Stock [Line Items]
Common stock price				$ 40
Common stock issued				13,125,000
Proceeds from issue of common stock through IPO				$ 489,500,000
Selling Shareholders [Member] | IPO [Member]
Class Of Stock [Line Items]
Sale of common stock				14,111,841
Proceeds from issue of common stock through IPO				$ 0
Selling Shareholders [Member] | IPO [Member] | Underwriters Option [Member]
Class Of Stock [Line Items]
Shares offered and sold by selling shareholders pursuant to the full exercise of the underwriters' option to purchase additional shares				3,552,631
Stock Options [Member]
Class Of Stock [Line Items]
Equity repurchased -vested in-the-money employee stock options, shares							2,000,000
Equity repurchased -vested in-the-money employee stock options, value							$ 59,100,000
Repurchase vested in-the-money employee stock options, average market price							$ 43.42
Repurchase of vested in-the-money employee stock options, average exercise price per option							$ 13.74

Shareholders' Deficit - Summary

Shareholders' Deficit - Summary of Share Repurchases Made Under Repurchase Program (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended			26 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2015
Class Of Stock [Line Items]
Repurchase of common stock, Shares	7,855,796	7,591,175	153,223
Aggregate purchase price	$ 515,010	$ 415,131	$ 6,434	$ 995,600
Equity Repurchase Program [Member]
Class Of Stock [Line Items]
Repurchase of common stock, Shares	7,855,796	300	153,223
Aggregate purchase price	$ 515,010	$ 14	$ 6,434
Average price per share	$ 65.56	$ 47.51	$ 42.01

Management Fees - Additional In

Management Fees - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2013	Jan. 31, 2008
Management Fees Disclosure [Abstract]
Annual management service fee agreed to pay		$ 5
Termination fee	$ 25
Management service fee	$ 27.7

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands	Jul. 02, 2015	Jul. 02, 2014	Sep. 16, 2013	Dec. 31, 2015
Business Acquisition [Line Items]
Business combination, fair value of consideration transferred				$ 423,268
Quest [Member]
Business Acquisition [Line Items]
Business acquisition, percentage of voting interests acquired	40.00%
Business combination, fair value of consideration transferred	$ 423,300
Encore [Member]
Business Acquisition [Line Items]
Business acquisition through merger		$ 91,500
Date of Acquisition				Jul. 1, 2014
Cash acquired		$ 2,200
Novella [Member]
Business Acquisition [Line Items]
Business acquisition, percentage of voting interests acquired			100.00%
Date of Acquisition				Sep. 16, 2013
Cash acquired			$ 26,200
Outstanding stock value			146,600
Contingent consideration, annual earn out payment			21,000
Liability recognized on acquisition			$ 14,300

Business Combinations - Summary

Business Combinations - Summary of Estimated Fair Value of Net Assets Acquired at the Date of Acquisitions (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Assets acquired:
Goodwill	$ 719,740	$ 464,434	$ 409,626
Quest [Member]
Assets acquired:
Cash and cash equivalents	31,783
Accounts receivable and unbilled services	6,186
Prepaid expenses	1,185
Other current assets	4,426
Property and equipment	16,422
Goodwill	261,710
Other identifiable intangibles	125,900
Other long-term assets	266
Liabilities assumed:
Accounts payable and accrued expenses	(12,790)
Deferred income tax liability – long-term	(10,412)
Other long-term liabilities	(1,408)
Net assets acquired	423,268
Encore [Member]
Assets acquired:
Cash and cash equivalents	2,223
Accounts receivable and unbilled services	17,714
Other current assets	443
Property and equipment	289
Goodwill	62,778
Other identifiable intangibles	14,150
Deferred income tax asset – long-term	396
Liabilities assumed:
Accounts payable and accrued expenses	(4,206)
Unearned income	(31)
Net assets acquired	93,756
Novella [Member]
Assets acquired:
Cash and cash equivalents	26,190
Accounts receivable and unbilled services	28,644
Other current assets	1,441
Property and equipment	9,616
Goodwill	116,542
Other identifiable intangibles	42,740
Other long-term assets	2,203
Liabilities assumed:
Accounts payable and accrued expenses	(12,716)
Unearned income	(7,782)
Other current liabilities	(132)
Deferred income tax liability – long-term	(18,364)
Other long-term liabilities	(1,334)
Net assets acquired	$ 187,048

Business Combinations - Summa98

Business Combinations - Summary Of Identifiable Intangible Assets (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Quest [Member]
Acquired Intangible Assets [Line Items]
Total other identifiable intangibles	$ 125,900
Amortized over a weighted average useful life (in years)	9 years
Quest [Member] | Trade names [Member]
Acquired Intangible Assets [Line Items]
Total other identifiable intangibles	$ 19,000
Quest [Member] | Contract backlog and customer relationships [Member]
Acquired Intangible Assets [Line Items]
Total other identifiable intangibles	74,000
Quest [Member] | Backlog [Member]
Acquired Intangible Assets [Line Items]
Total other identifiable intangibles	32,900
Encore [Member]
Acquired Intangible Assets [Line Items]
Total other identifiable intangibles	$ 14,150
Amortized over a weighted average useful life (in years)	8 years
Encore [Member] | Contract backlog and customer relationships [Member]
Acquired Intangible Assets [Line Items]
Total other identifiable intangibles	$ 8,800
Encore [Member] | Backlog [Member]
Acquired Intangible Assets [Line Items]
Total other identifiable intangibles	800
Encore [Member] | Finite lived trade name [Member]
Acquired Intangible Assets [Line Items]
Total other identifiable intangibles	1,100
Encore [Member] | Non-compete agreements [Member]
Acquired Intangible Assets [Line Items]
Total other identifiable intangibles	450
Encore [Member] | Software and related assets [Member]
Acquired Intangible Assets [Line Items]
Total other identifiable intangibles	3,000
Novella [Member]
Acquired Intangible Assets [Line Items]
Total other identifiable intangibles	$ 42,740
Amortized over a weighted average useful life (in years)	7 years
Novella [Member] | Contract backlog and customer relationships [Member]
Acquired Intangible Assets [Line Items]
Total other identifiable intangibles	$ 20,800
Novella [Member] | Backlog [Member]
Acquired Intangible Assets [Line Items]
Total other identifiable intangibles	14,000
Novella [Member] | Finite lived trade name [Member]
Acquired Intangible Assets [Line Items]
Total other identifiable intangibles	7,500
Novella [Member] | Non-compete agreements [Member]
Acquired Intangible Assets [Line Items]
Total other identifiable intangibles	$ 440

Restructuring - Additional Info

Restructuring - Additional Information (Detail)	1 Months Ended	3 Months Ended	12 Months Ended			24 Months Ended	35 Months Ended
	Feb. 28, 2013USD ($)	Sep. 30, 2015USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2015USD ($)	Feb. 28, 2015USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring costs			$ 30,752,000	$ 8,988,000	$ 14,071,000
Quest [Member]
Restructuring Cost and Reserve [Line Items]
Severance, facility closure and other exit-related costs		$ 14,000,000
2015 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring plan approved								$ 30,000,000
2015 Plan [Member] | Operating Segments [Member] | Product Development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs			11,800,000
2015 Plan [Member] | Operating Segments [Member] | Product Development [Member] | Quest [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs			8,700,000
2015 Plan [Member] | Operating Segments [Member] | Integrated Healthcare Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs			8,900,000
2015 Plan [Member] | Corporate, Non-Segment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs			$ 749,000
2014 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring plan approved				$ 13,000,000
Restructuring costs						$ 11,000,000
Number of positions reduced				250
2014 Plan [Member] | Operating Segments [Member] | Product Development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs						8,000,000
2014 Plan [Member] | Operating Segments [Member] | Integrated Healthcare Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs						$ 3,000,000
2013 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring plan approved	$ 15,000,000
Restructuring costs							$ 13,600,000
Number of positions reduced	400
2013 Plan [Member] | Operating Segments [Member] | Product Development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs							8,400,000
2013 Plan [Member] | Operating Segments [Member] | Integrated Healthcare Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs							4,700,000
2013 Plan [Member] | Corporate, Non-Segment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs							$ 500,000

Restructuring - Summary of Amou

Restructuring - Summary of Amounts Recorded for Restructuring Plans (Detail) - USD ($) $ in Thousands	12 Months Ended			24 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance	$ 6,083	$ 5,474		$ 5,474
Expense, net of reversals	30,752	8,988	$ 14,071
Payments	(23,666)	(8,158)
Foreign currency translation		(221)
Foreign currency translation and other	395
Restructuring reserves, ending balance	13,564	6,083	5,474	13,564
Severance and Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance	5,478	5,276		5,276
Expense, net of reversals	29,843	8,421
Payments	(22,943)	(7,998)
Foreign currency translation		(221)
Foreign currency translation and other	(199)
Restructuring reserves, ending balance	12,179	5,478	5,276	12,179
Exit Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance	605	198		198
Expense, net of reversals	909	567
Payments	(723)	(160)
Foreign currency translation and other	594
Restructuring reserves, ending balance	$ 1,385	$ 605	$ 198	$ 1,385

Income Taxes - Components of In

Income Taxes - Components of Income Before Income Taxes and Equity in Earnings of Unconsolidated Affiliates (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Before Income Taxes [Line Items]
Income before income taxes and equity in earnings (losses) of unconsolidated affiliates	$ 538,995	$ 502,189	$ 323,116
Domestic [Member]
Income Before Income Taxes [Line Items]
Income before income taxes and equity in earnings (losses) of unconsolidated affiliates	68,455	96,917	68,425
Foreign [Member]
Income Before Income Taxes [Line Items]
Income before income taxes and equity in earnings (losses) of unconsolidated affiliates	$ 470,540	$ 405,272	$ 254,691

Income Taxes - Components of102

Income Taxes - Components of Income Tax Expense Attributable to Continuing Operations (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Federal		$ 47,311	$ 58,403	$ 38,573
State		3,559	4,618	(4,309)
Foreign		109,273	95,010	83,744
Current Income Tax Expense (Benefit)		160,143	158,031	118,008
Federal and state		4,613	(4,549)	(15,807)
Foreign		(5,767)	(3,426)	(6,236)
Deferred Income Tax Expense (Benefit)		(1,154)	(7,975)	(22,043)
Income Tax Expense (Benefit)	$ (8,100)	$ 158,989	$ 150,056	$ 95,965

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Examination [Line Items]
Statutory U.S. tax rate		35.00%
Income tax benefit	$ 8,100,000	$ (158,989,000)	$ (150,056,000)	$ (95,965,000)
Undistributed earnings of foreign subsidiaries		862,300,000
Undistributed earnings of foreign subsidiary, taxable upon repatriation		283,900,000
Deferred income tax liability, net of foreign income tax credits upon repatriation		34,900,000
Indefinitely reinvested undistributed earnings of foreign subsidiaries		578,400,000
Additional tax liability on Indefinitely reinvested undistributed earnings of foreign subsidiaries		94,600,000
Net operating loss carryforwards		41,707,000	43,535,000
Decrease in valuation allowances			24,700,000
Unrecognized income tax benefits		29,700,000
Unrecognized benefits		29,300,000
Accrued interest and penalties		2,900,000	4,800,000
(Reduction)/Addition of Interest and penalties recorded		(2,000,000)	1,300,000	843,000
Gross unrecognized income tax benefits		29,666,000	40,821,000	54,936,000	$ 43,393,000
Quintiles East Asia [Member]
Income Tax Examination [Line Items]
Income tax benefit		$ 2,000,000	$ 2,400,000	798,000
Income tax holiday period		Through June 2015
Outcome Europe Sarl [Member]
Income Tax Examination [Line Items]
Income tax benefit				64,000
Earnings per share		$ 0.02	$ 0.02
Minimum [Member]
Income Tax Examination [Line Items]
Decrease in valuation allowances		$ 2,500,000
Maximum [Member]
Income Tax Examination [Line Items]
Decrease in valuation allowances		22,200,000
United Kingdom [Member]
Income Tax Examination [Line Items]
Operating Loss and capital loss carryforwards		44,900,000
Foreign Jurisdictions [Member]
Income Tax Examination [Line Items]
Operating Loss and capital loss carryforwards		40,700,000
United States [Member]
Income Tax Examination [Line Items]
Net operating loss carryforwards		$ 44,000,000
Net operating loss carryforwards expiration year		2,035
Novella, EA And Advion BioSciences, Inc. [Member] | United States [Member]
Income Tax Examination [Line Items]
Net operating loss carryforwards				$ 16,600,000	$ 16,600,000	$ 16,600,000
Net operating loss carryforwards expiration year		2,023
Federal State And Foreign Tax [Member]
Income Tax Examination [Line Items]
Gross unrecognized income tax benefits		$ 8,100,000
Foreign Tax [Member]
Income Tax Examination [Line Items]
Gross unrecognized income tax benefits		$ 160,000

Income Taxes - Effective Income

Income Taxes - Effective Income Tax Rate Reconciliation (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Federal income tax expense at statutory rate		$ 188,648	$ 175,766	$ 113,091
State and local income taxes, net of federal benefit		1,682	2,312	(1,088)
Research and development		(12,634)	(16,765)	(12,788)
Foreign nontaxable interest income		(9,351)	(10,217)	(9,751)
Gain on note settlement				10,794
United States taxes recorded on foreign earnings		38,246	18,631	(1,616)
Foreign rate differential		(49,288)	(30,734)	(10,753)
Tax contingencies		(8,304)	4,043	(1,012)
Other		9,990	7,020	9,088
Income Tax Expense (Benefit)	$ (8,100)	$ 158,989	$ 150,056	$ 95,965

Income Taxes - Income Tax Effec

Income Taxes - Income Tax Effects of Temporary Differences from Continuing Operations that Give Rise to Significant Portions of Deferred Income Tax (Liabilities) Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred income tax liabilities:
Undistributed foreign earnings	$ (36,624)	$ (27,717)
Depreciation and amortization	(53,171)	(65,614)
Other	(11,830)	(15,346)
Total deferred income tax liabilities	(101,625)	(108,677)
Deferred income tax assets:
Net operating loss, capital loss and tax credit carryforwards	41,707	43,535
Accrued expenses and unearned income	23,315	34,048
Employee benefits	123,775	130,217
Other	12,801	17,784
Deferred Tax Assets, Gross	201,598	225,584
Valuation allowance for deferred income tax assets	(22,162)	(24,695)
Total deferred income tax assets	179,436	200,889
Net deferred income tax assets	$ 77,811	$ 92,212

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Beginning and Ending Amount of Gross Unrecognized Income Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Beginning balance	$ 40,821	$ 54,936	$ 43,393
Additions based on tax positions related to the current year	2,068	2,807	4,493
Additions for income tax positions of prior years	8,838	1,588	12,854
Impact of changes in exchange rates	(608)	(376)	(71)
Settlements with tax authorities	(121)	(135)	(1,052)
Reductions for income tax positions of prior years	(1,945)	(6,023)	(3,520)
Reductions due to the lapse of the applicable statute of limitations	(19,387)	(11,976)	(1,161)
Ending balance	$ 29,666	$ 40,821	$ 54,936

Income Taxes - Summary of Tax Y

Income Taxes - Summary of Tax Years Open for Examination (Detail)	12 Months Ended
	Dec. 31, 2015
United States [Member] | Earliest Tax Year [Member]
Schedule Of Income Taxes [Line Items]
Open tax year	2,012
United States [Member] | Latest Tax Year [Member]
Schedule Of Income Taxes [Line Items]
Open tax year	2,014
India [Member] | Earliest Tax Year [Member]
Schedule Of Income Taxes [Line Items]
Open tax year	2,006
India [Member] | Latest Tax Year [Member]
Schedule Of Income Taxes [Line Items]
Open tax year	2,015
Japan [Member] | Earliest Tax Year [Member]
Schedule Of Income Taxes [Line Items]
Open tax year	2,010
Japan [Member] | Latest Tax Year [Member]
Schedule Of Income Taxes [Line Items]
Open tax year	2,014
United Kingdom [Member] | Latest Tax Year [Member]
Schedule Of Income Taxes [Line Items]
Open tax year	2,014

Employee Benefit Plans - Define

Employee Benefit Plans - Defined Contribution Plans And Defined Benefit Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Contribution And Defined Benefit Plans [Line Items]
Expenses related to matching contributions		$ 36,300,000	$ 31,200,000	$ 26,100,000
Amortization of actuarial losses		(973,000)	(636,000)	$ (708,000)
Accumulated benefit obligation		139,100,000	127,900,000
Projected benefit obligation related to unfunded plans		94,600,000	83,400,000
Accumulated benefit obligation related to unfunded plan		$ 82,900,000	$ 66,400,000
Minimum [Member]
Defined Contribution And Defined Benefit Plans [Line Items]
Long term government bonds premium percentage		3.00%
Maximum [Member]
Defined Contribution And Defined Benefit Plans [Line Items]
Long term government bonds premium percentage		5.00%
Scenario, Forecast [Member]
Defined Contribution And Defined Benefit Plans [Line Items]
Amortization of actuarial losses	$ 870,000
Estimated employer contribution to defined benefit plan	$ 5,500,000
Scenario, Forecast [Member] | Bond Investments [Member]
Defined Contribution And Defined Benefit Plans [Line Items]
Defined benefit plan, target allocation percentage, minimum	45.00%
Defined benefit plan, target allocation percentage, maximum	55.00%
Scenario, Forecast [Member] | Equity Investments [Member]
Defined Contribution And Defined Benefit Plans [Line Items]
Defined benefit plan, target allocation percentage, minimum	25.00%
Defined benefit plan, target allocation percentage, maximum	35.00%
Scenario, Forecast [Member] | Diversified Growth Funds [Member]
Defined Contribution And Defined Benefit Plans [Line Items]
Defined benefit plan, target allocation percentage, minimum	15.00%
Defined benefit plan, target allocation percentage, maximum	25.00%

Employee Benefit Plans - Summar

Employee Benefit Plans - Summary of Components of Pension Expenses Related to Defined Benefit Plans (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Compensation And Retirement Disclosure [Abstract]
Service cost	$ 15,486	$ 12,944	$ 13,227
Interest cost	3,453	3,821	3,684
Expected return on plan assets	(3,555)	(4,277)	(3,442)
Amortization of prior service costs		107	336
Amortization of actuarial losses	973	636	708
Total pension expense related to defined benefit plans	$ 16,357	$ 13,231	$ 14,513

Employee Benefit Plans - Weight

Employee Benefit Plans - Weighted Average Assumptions Used in Determining Pension Expense (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Compensation And Retirement Disclosure [Abstract]
Discount rate	2.46%	3.01%	3.06%
Rate of compensation increases	4.32%	4.36%	4.74%
Expected return on plan assets	4.05%	5.21%	5.33%

Employee Benefit Plans - Financ

Employee Benefit Plans - Financial Information About Defined Benefit Plans (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Projected benefit obligation January 1	$ 147,127	$ 135,110
Service costs	15,486	12,944	$ 13,227
Interest cost	3,453	3,821	3,684
Expected return on plan assets	(3,555)	(4,277)	(3,442)
Actuarial (gains) losses	(2,306)	16,396
Business combination	1,746
Benefits paid	(6,325)	(7,409)
Foreign currency fluctuations and other	(1,732)	(9,458)
Projected benefit obligation December 31	153,894	147,127	135,110
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Plan assets at fair value, January 1	88,420	82,787
Actual return on plan assets	1,312	10,004
Contributions	5,982	8,594
Business combination	1,966
Benefits paid	(6,325)	(7,409)
Foreign currency fluctuations and other	(4,212)	(5,556)
Plan assets at fair value, December 31	87,143	88,420	$ 82,787
Unfunded balance	$ 66,751	$ 58,707

Employee Benefit Plans - Sum112

Employee Benefit Plans - Summary of Amounts Recognized in Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Benefit Plan Disclosure [Line Items]
Deposits and other assets	$ 19,185	$ 18,690
Accrued expenses	4,520	6,075
Other long-term liabilities	81,410	71,322
AOCI	(8,275)	(8,857)	$ (2,088)
Actuarial Net (Gain) Loss [Member]
Defined Benefit Plan Disclosure [Line Items]
AOCI	$ (13,264)	$ (14,519)	$ (4,937)

Employee Benefit Plans - Sum113

Employee Benefit Plans - Summary of Amounts Recognized in Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Benefit Plan Disclosure [Line Items]
Beginning balance	$ (8,857)	$ (2,088)
Reclassification adjustments included in pension expense:
Amortization	618	468
Amounts arising during the period:
Actuarial changes in benefit obligation	(36)	(7,237)	$ 2,278
Ending balance	(8,275)	(8,857)	(2,088)
Prior Service Costs [Member]
Defined Benefit Plan Disclosure [Line Items]
Beginning balance		(107)
Reclassification adjustments included in pension expense:
Amortization		107
Amounts arising during the period:
Ending balance			(107)
Actuarial Net (Gain) Loss [Member]
Defined Benefit Plan Disclosure [Line Items]
Beginning balance	(14,519)	(4,937)
Reclassification adjustments included in pension expense:
Amortization	973	636
Amounts arising during the period:
Actuarial changes in benefit obligation	282	(10,218)
Ending balance	(13,264)	(14,519)	(4,937)
Deferred Income Taxes [Member]
Defined Benefit Plan Disclosure [Line Items]
Beginning balance	5,662	2,956
Reclassification adjustments included in pension expense:
Amortization	(355)	(275)
Amounts arising during the period:
Actuarial changes in benefit obligation	(318)	2,981
Ending balance	$ 4,989	$ 5,662	$ 2,956

Employee Benefit Plans - Wei114

Employee Benefit Plans - Weighted Average Assumptions Used in Determining Pension Obligations (Detail)	Dec. 31, 2015	Dec. 31, 2014
Compensation And Retirement Disclosure [Abstract]
Discount rate	2.50%	2.46%
Rate of compensation increases	4.37%	4.32%

Employee Benefit Plans - Schedu

Employee Benefit Plans - Schedule of Fair Value Measurement (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	$ 87,143	$ 88,420	$ 82,787
Funds that hold debt investments primarily government bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	49,355	47,473
Funds that hold United Kingdom equity investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	15,700	19,547
Funds that hold global equity investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	6,277	8,255
Diversified Growth Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	15,248	12,569
Other [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, fair value of plan assets	$ 563	$ 576

Employee Benefit Plans - Sch116

Employee Benefit Plans - Schedule of Expected Benefit Payments Under the Defined Benefit Plans (Detail) $ in Thousands	Dec. 31, 2015USD ($)
Compensation And Retirement Disclosure [Abstract]
2,016	$ 6,684
2,017	6,615
2,018	7,096
2,019	7,802
2,020	9,092
Years 2021 through 2025	66,117
Total	$ 103,406

Employee Benefit Plans - Stock

Employee Benefit Plans - Stock Incentive Plans - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 31, 2012	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry period of options from grant date		10 years
Percentage of options granted per annum	20.00%
Weighted average remaining contractual life of the options outstanding		6 years 10 months 21 days
Weighted average remaining contractual life of the options exercisable		5 years 10 months 24 days
Aggregate intrinsic value of the exercisable stock options and the stock options expected to vest		$ 201,000,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value per share of options granted		$ 21.96	$ 18.72	$ 14.39
Total intrinsic value of options exercised		$ 143,700,000	$ 77,300,000	$ 27,100,000
Proceeds from options exercised		$ 58,500,000	$ 33,100,000	$ 12,500,000
Second Anniversary of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of options granted per annum		25.00%
Third Anniversary Of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of options granted per annum		33.00%
Fourth Anniversary Of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of options granted per annum		67.00%
Vesting Scenario One [Member] | First Anniversary Of Grant Date [Member] | Non Employee Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of options granted per annum		100.00%
Vesting Scenario Two [Member] | Second Anniversary of Grant Date [Member] | Non Employee Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of options granted per annum		33.00%
Vesting Scenario Two [Member] | Third Anniversary Of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of options granted per annum		33.00%
Vesting Scenario Two [Member] | First Anniversary Of Grant Date [Member] | Non Employee Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of options granted per annum		34.00%
Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for future grant		7,372,127
Stock appreciation rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock appreciation rights vesting description		These awards either (i) vest 25% per year or (ii) vest 33% on the third anniversary of the date of grant and 67% on the fourth anniversary of the date of grant.
Fair value of Stock Appreciation Rights granted		$ 29.79	$ 27.17	$ 19.07
Cash paid to settle exercised SARs		$ 967,000	$ 408,000	$ 83,000
Weighted average remaining contractual life of SARs outstanding		8 years 1 month 6 days
Weighted average remaining contractual life of SARs exercisable		7 years 4 months 24 days
Aggregate intrinsic value of exercisable expected to vest		$ 9,500,000
Number of stock units outstanding		530,701	418,801
Intrinsic value of stock units outstanding		$ 9,659,000	$ 6,417,000
Stock appreciation rights (SARs) [Member] | Third Anniversary Of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of options granted per annum		33.00%
Stock appreciation rights (SARs) [Member] | Fourth Anniversary Of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of options granted per annum		67.00%
Stock appreciation rights (SARs) [Member] | 25% per year [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of options granted per annum		25.00%
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of options granted per annum		25.00%
Number of days for stock units to settle in common stock from vesting date		45 days
Number of stock units outstanding		359,553
Intrinsic value of stock units outstanding		$ 24,700,000
Restricted Stock [Member] | Third Anniversary Of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of options granted per annum		33.00%
Restricted Stock [Member] | Fourth Anniversary Of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of options granted per annum		67.00%
Restricted Stock [Member] | Vesting Scenario One [Member] | First Anniversary Of Grant Date [Member] | Non Employee Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of RSU granted per annum		100.00%
Restricted Stock [Member] | Vesting Scenario Two [Member] | Second Anniversary of Grant Date [Member] | Non Employee Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of RSU granted per annum		33.00%
Restricted Stock [Member] | Vesting Scenario Two [Member] | Third Anniversary Of Grant Date [Member] | Non Employee Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of RSU granted per annum		33.00%
Restricted Stock [Member] | Vesting Scenario Two [Member] | First Anniversary Of Grant Date [Member] | Non Employee Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of RSU granted per annum		34.00%
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of Stock Appreciation Rights granted		$ 64.93
Number of stock units outstanding		49,667
Intrinsic value of stock units outstanding		$ 3,400,000

Employee Benefit Plans - Assump

Employee Benefit Plans - Assumptions Used to Estimate Value of Share-Based Compensation for Stock Options and Stock Appreciation Rights Issued (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected volatility, Minimum	26.00%	26.00%	18.00%
Expected volatility, Maximum	41.00%	43.00%	47.00%
Weighted average expected volatility	34.00%	36.00%	40.00%
Expected dividends	0.00%	0.00%
Risk-free interest rate, Minimum	1.06%	0.28%	0.04%
Risk-free interest rate, Maximum	2.04%	2.21%	2.24%
Minimum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected dividends			0.00%
Expected term (in years)	3 years 8 months 12 days	1 year 6 months	3 months
Maximum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected dividends			5.45%
Expected term (in years)	6 years 8 months 12 days	6 years 8 months 12 days	6 years 4 months 24 days

Employee Benefit Plans - Sum119

Employee Benefit Plans - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Compensation And Retirement Disclosure [Abstract]
Number of Options Outstanding at Beginning Balance	9,124,954
Number of Options, Granted	993,600
Number of Options, Exercised	(3,013,190)
Number of Options, Canceled	(457,365)
Number of Options Outstanding at Ending Balance	6,647,999
Weighted Average Exercise Price Outstanding at Beginning Balance	$ 29.15
Weighted Average Exercise Price, Granted	65.05
Weighted Average Exercise Price, Exercised	19.41
Weighted Average Exercise Price, Canceled	42.08
Weighted Average Exercise Price Outstanding at Ending Balance	$ 38.04
Aggregate Intrinsic Value	$ 203,679	$ 271,216

Employee Benefit Plans - Sch120

Employee Benefit Plans - Schedule of Stock Options Outstanding and Exercisable (Detail)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Exercise Price Range $5.76 - $21.69 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding | shares	1,063,999
Exercise Price Lower Range Outstanding	$ 5.76
Exercise Price Upper Range Outstanding	21.69
Weighted Average Exercise Price Outstanding	$ 17.58
Weighted Average Remaining Life Outstanding (in years)	4 years 2 months 9 days
Number of Options Exercisable | shares	947,799
Weighted Average Exercise Price	$ 17.14
Exercise Price Range $22.10 - $23.83 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding | shares	1,069,630
Exercise Price Lower Range Outstanding	$ 22.01
Exercise Price Upper Range Outstanding	23.83
Weighted Average Exercise Price Outstanding	$ 23.79
Weighted Average Remaining Life Outstanding (in years)	6 years 3 months 26 days
Number of Options Exercisable | shares	661,630
Weighted Average Exercise Price	$ 23.79
Exercise Price Range $24.59 - $30.07 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding | shares	867,197
Exercise Price Lower Range Outstanding	$ 24.59
Exercise Price Upper Range Outstanding	30.07
Weighted Average Exercise Price Outstanding	$ 25.07
Weighted Average Remaining Life Outstanding (in years)	6 years 3 months 18 days
Number of Options Exercisable | shares	545,947
Weighted Average Exercise Price	$ 24.97
Exercise Price Range $40.00 - $40.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding | shares	1,241,087
Exercise Price Lower Range Outstanding	$ 40
Exercise Price Upper Range Outstanding	40
Weighted Average Exercise Price Outstanding	$ 40
Weighted Average Remaining Life Outstanding (in years)	7 years 1 month 6 days
Number of Options Exercisable | shares	421,837
Weighted Average Exercise Price	$ 40
Exercise Price Range $42.74 - $53.26 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding | shares	1,208,586
Exercise Price Lower Range Outstanding	$ 42.74
Exercise Price Upper Range Outstanding	53.26
Weighted Average Exercise Price Outstanding	$ 50.76
Weighted Average Remaining Life Outstanding (in years)	8 years
Number of Options Exercisable | shares	261,334
Weighted Average Exercise Price	$ 50.30
Exercise Price Range $57.00 - $77.11 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding | shares	1,197,500
Exercise Price Lower Range Outstanding	$ 57
Exercise Price Upper Range Outstanding	77.11
Weighted Average Exercise Price Outstanding	$ 63.44
Weighted Average Remaining Life Outstanding (in years)	8 years 10 months 13 days
Number of Options Exercisable | shares	58,375
Weighted Average Exercise Price	$ 57.43

Employee Benefit Plans - Sch121

Employee Benefit Plans - Schedule of Stock Appreciation Rights Activity (Detail) - Stock appreciation rights (SARs) [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of SARs Outstanding Beginning Balance	418,801
Number of SARs Granted	176,200
Number of SARs Exercised	(33,262)
Number of SARs Canceled	(31,038)
Number of SARs Outstanding Ending Balance	530,701
Weighted Average Grant Price Outstanding Beginning Balance	$ 43.55
Weighted Average Grant Price Granted	64.93
Weighted Average Grant Price Exercised	39.61
Weighted Average Grant Price Canceled	51
Weighted Average Grant Price Outstanding Ending Balance	$ 50.46
Aggregate Intrinsic Value	$ 9,659	$ 6,417

Employee Benefit Plans - Sum122

Employee Benefit Plans - Summary of Company's RSU Activity (Detail) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Units Non-vested Beginning Balance | shares	93,667
Number of Units Granted | shares	276,922
Number of Units Vested | shares	(918)
Number of Units Canceled | shares	(10,118)
Number of Units Non-vested Ending Balance | shares	359,553
Weighted Average Grant-Date Fair Value Non-vested Beginning Balance | $ / shares	$ 45.89
Weighted Average Grant-Date Fair Value Granted | $ / shares	65.61
Weighted Average Grant-Date Fair Value Vested | $ / shares	47.87
Weighted Average Grant-Date Fair Value Canceled | $ / shares	62.77
Weighted Average Grant-Date Fair Value Non-vested Ending Balance | $ / shares	$ 60.60

Employee Benefit Plans - Sum123

Employee Benefit Plans - Summary of Company's Performance Units Activity (Detail) - Performance Shares [Member]	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Units Granted | shares	51,977
Number of Units Canceled | shares	(2,310)
Number of Units Non-vested Ending Balance | shares	49,667
Weighted Average Grant-Date Fair Value Granted | $ / shares	$ 64.93
Weighted Average Grant-Date Fair Value Canceled | $ / shares	64.93
Weighted Average Grant-Date Fair Value Non-vested Ending Balance | $ / shares	$ 64.93

Employee Benefit Plans - Employ

Employee Benefit Plans - Employee Stock Purchase Plan and Other - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015USD ($)Positionshares	Dec. 31, 2014USD ($)shares
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Severance expenses payable	$ 3,337,000	$ 6,274,000
Number of positions expected to be eliminated | Position	270
Severance expense, net of reversals	$ (1,042,000)
Product Development [Member]
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Severance expense, net of reversals	(837,000)
Integrated Healthcare Services [Member]
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Severance expense, net of reversals	$ (205,000)
Employee Stock Purchase Plan [Member]
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Employee stock purchase plan payroll deductions percent	10.00%
Discount on closing price of share	15.00%
Fair market value of shares under ESPP	$ 25,000
Number of shares issued for purchases under ESPP | shares	90,079	46,032
Employee stock purchase plan amendment, description	Offering periods under the ESPP are six months in duration. The first two offering periods for the ESPP began March 1, 2014 and September 1, 2014, respectively. In November 2014, the ESPP was amended to change the start of the offering periods to begin on April 1 and October 1 of each year, beginning April 1, 2015.
Employee Stock Purchase Plan [Member] | Maximum [Member]
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Aggregate number of shares that may be issued under ESPP | shares	2,500,000

Employee Benefit Plans - Sum125

Employee Benefit Plans - Summary of Severance Associated with Cost Reduction Programs (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Compensation And Retirement Disclosure [Abstract]
Severance expenses payable, opening balance	$ 6,274
Severance expense, net of reversals	(1,042)
Severance payments	(1,873)
Severance foreign currency translation	(22)
Severance expenses payable, ending balance	$ 3,337

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Feb. 28, 2015	Jun. 30, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Board of Directors Chairman [Member]
Related Party Transaction [Line Items]
Business related travel expense			$ 1,300,000	$ 1,800,000	$ 2,700,000
Payment of fee for modification of agreement relating to business usage of airplane		$ 1,500,000
Board of Directors Chairman [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Maximum future annual reimbursements		$ 2,500,000
HUYA Bioscience International, LLC [Member]
Related Party Transaction [Line Items]
Additional consideration agreement			16,500,000
Gain on termination of collaboration agreement	$ 5,000,000
HUYA Bioscience International, LLC [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Related party fund to research and development activity			2,300,000
Affiliated Entity [Member]
Related Party Transaction [Line Items]
Fee for services			6,900,000	2,300,000	772,000
Sublease income				76,000
Affiliated Entity [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Fee for services			$ 31,700,000	$ 416,000	$ 19,200,000

Operations by Geographic Loc127

Operations by Geographic Location - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015
Operations By Geographic Location [Abstract]
Minimum percentage of revenue account for major country	10.00%

Operations by Geographic Loc128

Operations by Geographic Location - Operations Within Geographic Region (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Geographic Information [Line Items]
Sales Revenue Services Net	$ 1,128,599	$ 1,093,480	$ 1,074,366	$ 1,029,974	$ 1,064,045	$ 1,061,013	$ 1,035,476	$ 1,005,288	$ 4,326,419	$ 4,165,822	$ 3,808,340
Reimbursed expenses									1,411,200	1,294,176	1,291,205
Total revenues									5,737,619	5,459,998	5,099,545
Americas [Member]
Geographic Information [Line Items]
Sales Revenue Services Net									1,973,501	1,783,999	1,532,974
Americas [Member] | United States [Member]
Geographic Information [Line Items]
Sales Revenue Services Net									1,787,918	1,589,402	1,351,160
Americas [Member] | Other [Member]
Geographic Information [Line Items]
Sales Revenue Services Net									185,583	194,597	181,814
Europe and Africa [Member]
Geographic Information [Line Items]
Sales Revenue Services Net									1,459,990	1,523,538	1,501,504
Europe and Africa [Member] | Other [Member]
Geographic Information [Line Items]
Sales Revenue Services Net									1,050,070	1,121,354	1,139,262
Europe and Africa [Member] | United Kingdom [Member]
Geographic Information [Line Items]
Sales Revenue Services Net									409,920	402,184	362,242
Asia-Pacific [Member]
Geographic Information [Line Items]
Sales Revenue Services Net									892,928	858,285	773,862
Asia-Pacific [Member] | Other [Member]
Geographic Information [Line Items]
Sales Revenue Services Net									449,971	386,454	334,980
Asia-Pacific [Member] | Japan [Member]
Geographic Information [Line Items]
Sales Revenue Services Net									$ 442,957	$ 471,831	$ 438,882

Operations by Geographic Loc129

Operations by Geographic Location - Long Lived Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Long Lived Assets Geographic [Line Items]
Property, equipment and software, net	$ 271,170	$ 279,878
Americas [Member]
Long Lived Assets Geographic [Line Items]
Property, equipment and software, net	170,878	169,664
Americas [Member] | United States [Member]
Long Lived Assets Geographic [Line Items]
Property, equipment and software, net	169,674	167,890
Americas [Member] | Other [Member]
Long Lived Assets Geographic [Line Items]
Property, equipment and software, net	1,204	1,774
Europe and Africa [Member]
Long Lived Assets Geographic [Line Items]
Property, equipment and software, net	62,657	64,191
Europe and Africa [Member] | Other [Member]
Long Lived Assets Geographic [Line Items]
Property, equipment and software, net	16,615	15,782
Europe and Africa [Member] | United Kingdom [Member]
Long Lived Assets Geographic [Line Items]
Property, equipment and software, net	46,042	48,409
Asia-Pacific [Member]
Long Lived Assets Geographic [Line Items]
Property, equipment and software, net	37,635	46,023
Asia-Pacific [Member] | Other [Member]
Long Lived Assets Geographic [Line Items]
Property, equipment and software, net	24,975	25,271
Asia-Pacific [Member] | Japan [Member]
Long Lived Assets Geographic [Line Items]
Property, equipment and software, net	$ 12,660	$ 20,752

Segments - Additional Informati

Segments - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2015Segment	Dec. 31, 2013USD ($)
Segment Reporting [Abstract]
Number of reportable segments | Segment	2
Management agreement termination fee		$ 25
Agreement modification fee		$ 1.5

Segments - Operations by Report

Segments - Operations by Reportable Segments (Detail) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Service revenues	$ 1,128,599,000	$ 1,093,480,000	$ 1,074,366,000	$ 1,029,974,000	$ 1,064,045,000	$ 1,061,013,000	$ 1,035,476,000	$ 1,005,288,000	$ 4,326,419,000	$ 4,165,822,000	$ 3,808,340,000
Costs of revenue, service costs									2,725,586,000	2,684,106,000	2,471,426,000
Selling, general and administrative									920,985,000	882,338,000	860,510,000
Income from operations	$ 177,983,000	$ 167,023,000	$ 158,389,000	$ 143,217,000	$ 158,932,000	$ 149,142,000	$ 141,000,000	$ 141,316,000	646,612,000	590,390,000	462,333,000
Restructuring costs									(30,752,000)	(8,988,000)	(14,071,000)
Impairment charges									(2,484,000)	0	0
Operating Segments [Member] | Product Development [Member]
Segment Reporting Information [Line Items]
Service revenues									3,191,630,000	3,097,831,000	2,919,730,000
Costs of revenue, service costs									1,828,734,000	1,820,937,000	1,752,800,000
Selling, general and administrative									648,297,000	631,678,000	604,663,000
Income from operations									714,599,000	645,216,000	562,267,000
Operating Segments [Member] | Integrated Healthcare Services [Member]
Segment Reporting Information [Line Items]
Service revenues									1,134,789,000	1,067,991,000	888,610,000
Costs of revenue, service costs									896,852,000	863,169,000	718,626,000
Selling, general and administrative									153,896,000	140,019,000	127,860,000
Income from operations									84,041,000	64,803,000	42,124,000
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative									118,792,000	110,641,000	127,987,000
Income from operations									$ (118,792,000)	$ (110,641,000)	$ (127,987,000)

Segments - Reconciliation of As

Segments - Reconciliation of Assets from Segments to Consolidated (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Assets	$ 3,926,316	$ 3,295,953	$ 3,054,223
Operating Segments [Member] | Product Development [Member]
Segment Reporting Information [Line Items]
Assets	3,343,502	2,786,692	2,571,502
Operating Segments [Member] | Integrated Healthcare Services [Member]
Segment Reporting Information [Line Items]
Assets	405,411	330,689	299,284
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Assets	$ 177,403	$ 178,572	$ 183,437

Segments - Reconciliation of Ot

Segments - Reconciliation of Other Significant Reconciling Items from Segments to Consolidated (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Expenditures to acquire long-lived assets	$ 78,391	$ 82,650	$ 88,347
Operating Segments [Member] | Product Development [Member]
Segment Reporting Information [Line Items]
Expenditures to acquire long-lived assets	67,660	68,187	69,375
Operating Segments [Member] | Integrated Healthcare Services [Member]
Segment Reporting Information [Line Items]
Expenditures to acquire long-lived assets	8,667	8,279	17,398
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Expenditures to acquire long-lived assets	$ 2,064	$ 6,184	$ 1,574

Segments - Depreciation and Amo

Segments - Depreciation and Amortization Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Depreciation and amortization expense	$ 127,742	$ 121,013	$ 107,504
Operating Segments [Member] | Product Development [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	100,913	95,168	82,047
Operating Segments [Member] | Integrated Healthcare Services [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	21,961	20,821	20,475
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	$ 4,868	$ 5,024	$ 4,982

Earnings Per Share - Reconciles

Earnings Per Share - Reconciles the Basic to Diluted Weighted Average Shares Outstanding (Detail) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Basic weighted average common shares outstanding	123,038	127,994	124,147
Effect of dilutive stock options and share awards	2,592	3,089	3,715
Diluted weighted average common shares outstanding	125,630	131,083	127,862

Earnings Per Share - Summary of

Earnings Per Share - Summary of Weighted-Average Outstanding Share-Based Awards Excluded from Computation of Diluted Earnings Per Share (Detail) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Weighted average shares subject to anti-dilutive share-based awards	1,058	1,241	1,765

Comprehensive Income - Summary

Comprehensive Income - Summary of Components of AOCI (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	$ 30,499	$ 25,644	$ 29,693
Other comprehensive (loss) income before reclassifications, tax	9,110	7,225	1,331
Reclassification adjustments, tax	(6,181)	(2,370)	(5,380)
Ending Balance	33,428	30,499	25,644
Beginning Balance	(704,061)
Ending Balance	(564,217)	(704,061)
Foreign Currency Translation [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(55,740)	(5,829)	19,312
Other comprehensive (loss) income before reclassifications, before tax	(61,090)	(49,911)	(25,141)
Ending Balance	(116,830)	(55,740)	(5,829)
Marketable Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(272)	5,708	467
Other comprehensive (loss) income before reclassifications, before tax	(436)	(976)	5,241
Reclassification adjustments, before tax		(5,004)
Ending Balance	(708)	(272)	5,708
Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(19,059)	(20,855)	(33,542)
Other comprehensive (loss) income before reclassifications, before tax	(13,202)	(6,834)	(393)
Reclassification adjustments, before tax	18,269	8,630	13,080
Ending Balance	(13,992)	(19,059)	(20,855)
Defined Benefit Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(14,519)	(5,044)	(8,235)
Other comprehensive (loss) income before reclassifications, before tax	282	(10,218)	2,147
Reclassification adjustments, before tax	973	743	1,044
Ending Balance	(13,264)	(14,519)	(5,044)
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(59,091)	(376)	7,695
Other comprehensive (loss) income before reclassifications, net of tax	(65,336)	(60,714)	(16,815)
Reclassification adjustments, net of tax	13,061	1,999	8,744
Ending Balance	$ (111,366)	$ (59,091)	$ (376)

Comprehensive Income - Summa138

Comprehensive Income - Summary of (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes		$ (5,004)
Income tax expense		(1,927)
Total net of income taxes		(3,077)
Total before income taxes	$ 18,269	8,630	$ 13,080
Income tax benefit	5,826	4,022	4,991
Total net of income taxes	12,443	4,608	8,089
Amortization of prior service costs		107	336
Amortization of actuarial losses	973	636	708
Total before income taxes	973	743	1,044
Income tax benefit	355	275	389
Total net of income taxes	618	468	655
Other Nonoperating Expense (Income), Net [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes		(5,004)
Interest Rate Swaps [Member] | Interest Expense [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes	12,333	12,424	12,582
Foreign Exchange Forward Contracts [Member] | Service Revenues [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes	$ 5,936	$ (3,794)	$ 498

Supplemental Cash Flow Infor139

Supplemental Cash Flow Information - Supplemental Cash Flow Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Supplemental Cash Flow Information:
Interest paid	$ 82,333	$ 93,912	$ 115,494
Income taxes paid, net of refunds	120,804	138,931	70,983
Non-cash Investing Activities:
Acquisition of property and equipment utilizing capital leases	4,238	$ 2,476	3,761
Fair value of contingent consideration payable in connection with acquisitions			$ 14,300
Fair value of consideration transferred in connection with acquisitions	423,268
Q2 Solutions
Non-cash Investing Activities:
Fair value of consideration transferred in connection with acquisitions	$ 423,268

Quarterly Financial Data - Unau

Quarterly Financial Data - Unaudited Quarterly Results of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Service revenues	$ 1,128,599	$ 1,093,480	$ 1,074,366	$ 1,029,974	$ 1,064,045	$ 1,061,013	$ 1,035,476	$ 1,005,288	$ 4,326,419	$ 4,165,822	$ 3,808,340
Income from operations	177,983	167,023	158,389	143,217	158,932	149,142	141,000	141,316	646,612	590,390	462,333
Net income	108,087	108,839	84,947	86,431	88,444	92,733	85,110	90,214	388,304	356,501	226,027
Net (income) loss attributable to noncontrolling interests	(3,517)	2,447	4	(33)	(18)	(79)	10	(31)	(1,099)	(118)	564
Net income attributable to Quintiles Transnational Holdings Inc.	$ 104,570	$ 111,286	$ 84,951	$ 86,398	$ 88,426	$ 92,654	$ 85,120	$ 90,183	$ 387,205	$ 356,383	$ 226,591
Basic earnings per share	$ 0.86	$ 0.91	$ 0.69	$ 0.69	$ 0.70	$ 0.73	$ 0.66	$ 0.69	$ 3.15	$ 2.78	$ 1.83
Diluted earnings per share	$ 0.85	$ 0.89	$ 0.67	$ 0.68	$ 0.69	$ 0.71	$ 0.64	$ 0.68	$ 3.08	$ 2.72	$ 1.77

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) $ in Millions	Feb. 29, 2016USD ($)
Subsequent Event [Member]
Subsequent Event [Line Items]
Restructuring plan approved	$ 22

Schedule I - Condensed Statemen

Schedule I - Condensed Statements of Income (Detail) - USD ($) $ in Thousands	3 Months Ended									12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Condensed Income Statements, Captions [Line Items]
Selling, general and administrative										$ 920,985	$ 882,338	$ 860,510
Loss from operations	$ 177,983	$ 167,023	$ 158,389	$ 143,217	$ 158,932	$ 149,142	$ 141,000	$ 141,316		646,612	590,390	462,333
Interest income										(4,317)	(3,410)	(3,937)
Interest expense										101,792	100,589	123,508
Loss on extinguishment of debt										7,780		19,831
Other expense, net										2,362	(8,978)	(185)
Income before income taxes and equity in earnings (losses) of unconsolidated affiliates										538,995	502,189	323,116
Income tax expense									$ (8,100)	158,989	150,056	95,965
Net income attributable to Quintiles Transnational Holdings Inc.	$ 104,570	$ 111,286	$ 84,951	$ 86,398	$ 88,426	$ 92,654	$ 85,120	$ 90,183		387,205	356,383	226,591
Parent Company [Member]
Condensed Income Statements, Captions [Line Items]
Selling, general and administrative										715	1,509	2
Loss from operations										(715)	(1,509)	(2)
Interest income										(24)	(52)	(6)
Interest expense												9,242
Loss on extinguishment of debt												15,501
Other expense, net										7	8
Income before income taxes and equity in earnings (losses) of unconsolidated affiliates										(698)	(1,465)	(24,739)
Income tax expense										(530)	(810)	(9,347)
Loss before equity in earnings of subsidiary										(168)	(655)	(15,392)
Equity in earnings of subsidiary										387,373	357,038	241,983
Net income attributable to Quintiles Transnational Holdings Inc.										$ 387,205	$ 356,383	$ 226,591

Schedule I - Condensed State143

Schedule I - Condensed Statements of Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Condensed Income Statements, Captions [Line Items]
Net income	$ 108,087	$ 108,839	$ 84,947	$ 86,431	$ 88,444	$ 92,733	$ 85,110	$ 90,214	$ 388,304	$ 356,501	$ 226,027
Comprehensive income adjustments:
Unrealized gain (loss) on marketable securities, net of tax									(268)	(600)	3,225
Unrealized gain (loss) on derivative instruments, net of tax									(9,523)	(5,067)	358
Defined benefit plan adjustments, net of income taxes of $318, ($2,981) and ($131)									36	7,237	(2,278)
Foreign currency translation, net of income taxes of ($5,581), ($2,101) and ($2,465)									(60,024)	(47,807)	(22,663)
Reclassification adjustments:
Gains on marketable securities included in net income, net of income taxes of ($1,927)										(3,077)
Losses on derivative instruments included in net income, net of income taxes of $5,826, $4,022 and $4,991									12,443	4,608	8,089
Amortization of prior service costs and losses included in net income, net of income taxes of $355, $275 and $389									(618)	(468)
Comprehensive income attributable to Quintiles Transnational Holdings Inc.									334,930	297,668	218,520
Parent Company [Member]
Condensed Income Statements, Captions [Line Items]
Net income									387,205	356,383	226,591
Comprehensive income adjustments:
Unrealized gain (loss) on marketable securities, net of tax									(268)	(600)	3,225
Unrealized gain (loss) on derivative instruments, net of tax									(9,523)	(5,067)	358
Defined benefit plan adjustments, net of income taxes of $318, ($2,981) and ($131)									(36)	(7,237)	2,278
Foreign currency translation, net of income taxes of ($5,581), ($2,101) and ($2,465)									(55,509)	(47,810)	(22,676)
Reclassification adjustments:
Gains on marketable securities included in net income, net of income taxes of ($1,927)										(3,077)
Losses on derivative instruments included in net income, net of income taxes of $5,826, $4,022 and $4,991									12,443	4,608	8,089
Amortization of prior service costs and losses included in net income, net of income taxes of $355, $275 and $389									618	468	655
Comprehensive income attributable to Quintiles Transnational Holdings Inc.									$ 334,930	$ 297,668	$ 218,520

Schedule I - Condensed State144

Schedule I - Condensed Statements of Comprehensive Income (Parenthetical) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Condensed Income Statements, Captions [Line Items]
Unrealized (losses) gains on marketable securities, income taxes	$ (168)	$ (376)	$ 2,016
Unrealized (losses) gains on derivative instruments, income taxes	(3,679)	(1,767)	(751)
Defined benefit plan adjustment, income taxes	318	(2,981)	(131)
Foreign currency translation, income taxes	(5,581)	(2,101)	(2,465)
Gains on marketable securities included in net income, net of income taxes		1,927
Losses on derivative instruments included in net income, income taxes	5,826	4,022	4,991
Amortization of prior service costs and losses included in net income, income taxes	355	275	389
Parent Company [Member]
Condensed Income Statements, Captions [Line Items]
Unrealized (losses) gains on marketable securities, income taxes	(168)	(376)	2,016
Unrealized (losses) gains on derivative instruments, income taxes	(3,679)	(1,767)	(751)
Defined benefit plan adjustment, income taxes	318	(2,981)	(131)
Foreign currency translation, income taxes	(5,581)	(2,101)	(2,465)
Gains on marketable securities included in net income, net of income taxes		(1,927)
Losses on derivative instruments included in net income, income taxes	5,826	4,022	4,991
Amortization of prior service costs and losses included in net income, income taxes	$ 355	$ 275	$ 389

Schedule I - Condensed Balance

Schedule I - Condensed Balance Sheets (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 977,151	$ 867,358	$ 778,143	$ 567,728
Income taxes receivable	34,089	45,357
Other current assets and receivables	80,916	92,088
Total current assets	2,411,985	2,146,083
Deferred income taxes	42,684	35,972
Total assets	3,926,316	3,295,953	3,054,223
Current liabilities:
Accounts payable	145,484	108,743
Accrued expenses	760,757	733,644
Total current liabilities	1,594,176	1,471,900
Total liabilities	$ 4,261,997	$ 3,999,965
Commitments and contingencies (Note 1)
Shareholders’ deficit:
Common stock and additional paid-in capital, 300,000 shares authorized, $0.01 par value, 119,378 and 124,129 shares issued and outstanding at December 31, 2015 and 2014, respectively	$ 8,784	$ 143,828
Accumulated deficit	(461,635)	(788,798)
Accumulated other comprehensive loss	(111,366)	(59,091)
Deficit attributable to Quintiles Transnational Holdings Inc.’s shareholders	(564,217)	(704,061)
Total liabilities and shareholders’ deficit	3,926,316	3,295,953
Parent Company [Member]
Current assets:
Cash and cash equivalents	4,791	11,635	$ 71,942	$ 2,411
Income taxes receivable	128	546
Other current assets and receivables	16	114
Total current assets	4,935	12,295
Deferred income taxes		7
Total assets	4,935	12,302
Current liabilities:
Accounts payable	7	21
Accrued expenses		84
Total current liabilities	7	105
Investment in subsidiary	568,785	716,148
Payable to subsidiary	360	110
Total liabilities	$ 569,152	$ 716,363
Commitments and contingencies (Note 1)
Shareholders’ deficit:
Common stock and additional paid-in capital, 300,000 shares authorized, $0.01 par value, 119,378 and 124,129 shares issued and outstanding at December 31, 2015 and 2014, respectively	$ 8,784	$ 143,828
Accumulated deficit	(461,635)	(788,798)
Accumulated other comprehensive loss	(111,366)	(59,091)
Deficit attributable to Quintiles Transnational Holdings Inc.’s shareholders	(564,217)	(704,061)
Total liabilities and shareholders’ deficit	$ 4,935	$ 12,302

Schedule I - Condensed Balan146

Schedule I - Condensed Balance Sheets (Parenthetical) (Detail) - $ / shares	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Condensed Balance Sheet Statements Captions [Line Items]
Common stock, shares authorized	300,000,000	300,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares issued	119,378,000	124,129,000
Common stock, shares outstanding	119,377,731	124,129,340	129,651,907	115,763,510
Parent Company [Member]
Condensed Balance Sheet Statements Captions [Line Items]
Common stock, shares authorized	300,000,000	300,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares issued	119,378,000	124,129,000
Common stock, shares outstanding	119,378,000	124,129,000

Schedule I - Condensed State147

Schedule I - Condensed Statements of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating activities:
Net income	$ 108,087	$ 108,839	$ 84,947	$ 86,431	$ 88,444	$ 92,733	$ 85,110	$ 90,214	$ 388,304	$ 356,501	$ 226,027
Adjustments to reconcile net income to cash provided by operating activities:
Amortization of debt issuance costs and discount									9,170	6,688	21,825
(Benefit from) provision for deferred income taxes									18,351	(6,168)	(24,236)
Changes in operating assets and liabilities:
Accounts receivable and unbilled services									(246,028)	(78,630)	(151,681)
Accounts payable and accrued expenses									104,350	45,804	107,047
Investing activities:
Investments in subsidiary, net of payments received									(12,350)	(4,472)	(7,353)
Net cash used in investing activities									(66,955)	(173,114)	(236,176)
Financing activities:
Repayment of debt									(2,056,780)	(30,157)	(2,444,600)
Issuance of common stock											525,000
Payment of common stock issuance costs										(105)	(35,439)
Stock issued under employee stock purchase and option plans									64,297	35,228	12,539
Repurchase of common stock									(515,010)	(415,131)	(6,434)
Repurchase of stock options										(8,415)	(50,649)
Net cash (used in) provided by financing activities									(249,246)	(130,344)	70,957
Increase (decrease) in cash and cash equivalents									109,793	89,215	210,415
Cash and cash equivalents at beginning of period				867,358				778,143	867,358	778,143	567,728
Cash and cash equivalents at end of period	977,151				867,358				977,151	867,358	778,143
Parent Company [Member]
Operating activities:
Net income									387,205	356,383	226,591
Adjustments to reconcile net income to cash provided by operating activities:
Amortization of debt issuance costs and discount											10,346
Subsidiary loss (income)									56,627	(27,623)	(119,998)
(Benefit from) provision for deferred income taxes									(335)	37	304
Changes in operating assets and liabilities:
Accounts receivable and unbilled services										2,994	(2,995)
Prepaid expenses and other assets											(21)
Accounts payable and accrued expenses									(69)	65	(62)
Income taxes payable and other liabilities									(195)	(847)	(9,651)
Net cash provided by operating activities									443,233	331,009	104,514
Investing activities:
Investments in subsidiary, net of payments received											(179,847)
Net cash used in investing activities											(179,847)
Financing activities:
Repayment of debt											(300,000)
Issuance of common stock											525,000
Payment of common stock issuance costs										(105)	(35,439)
Stock issued under employee stock purchase and option plans									64,297	35,228	12,539
Repurchase of common stock									(515,010)	(415,131)	(6,434)
Repurchase of stock options										(8,415)	(50,649)
Intercompany with subsidiary									636	(2,893)	(153)
Net cash (used in) provided by financing activities									(450,077)	(391,316)	144,864
Increase (decrease) in cash and cash equivalents									(6,844)	(60,307)	69,531
Cash and cash equivalents at beginning of period				$ 11,635				$ 71,942	11,635	71,942	2,411
Cash and cash equivalents at end of period	$ 4,791				$ 11,635				$ 4,791	$ 11,635	$ 71,942

Schedule I - Additional Informa

Schedule I - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Condensed Financial Statements, Captions [Line Items]
Income tax benefit	$ 8,100	$ (158,989)	$ (150,056)	$ (95,965)
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Minimum percentage of restricted net assets of consolidated subsidiaries of consolidated net assets		25.00%
Income tax benefit		$ 530	$ 810	$ 9,347

Schedule I - Dividends Paid (De

Schedule I - Dividends Paid (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Dividends Payable [Line Items]
Cash dividend paid to parent company	$ 444,000	$ 329,415	$ 121,985
Paid in December 2015 [Member]
Dividends Payable [Line Items]
Cash dividend paid to parent company	1,000
Paid in November 2015 [Member]
Dividends Payable [Line Items]
Cash dividend paid to parent company	223,000
Paid in May 2015 [Member]
Dividends Payable [Line Items]
Cash dividend paid to parent company	$ 220,000
Paid in November 2014 [Member]
Dividends Payable [Line Items]
Cash dividend paid to parent company		234,000
Paid in May 2014 [Member]
Dividends Payable [Line Items]
Cash dividend paid to parent company		87,000
Paid in January 2014 [Member]
Dividends Payable [Line Items]
Cash dividend paid to parent company		$ 8,415
Paid in November and December 2013 [Member]
Dividends Payable [Line Items]
Cash dividend paid to parent company			116,585
Paid in February 2013 [Member]
Dividends Payable [Line Items]
Cash dividend paid to parent company			$ 5,400

Schedule II - Valuation and 150

Schedule II - Valuation and Qualifying Accounts (Detail) - Valuation Allowance of Deferred Tax Assets [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	$ 24,695	$ 29,501	$ 32,344
Addition Charged to Expenses	1,762	11,084	3,611
Deductions	(4,295)	(15,890)	(6,454)
Balance at End of Year	$ 22,162	$ 24,695	$ 29,501